0001654954-20-008596.txt : 20200806 0001654954-20-008596.hdr.sgml : 20200806 20200806161822 ACCESSION NUMBER: 0001654954-20-008596 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ChromaDex Corp. CENTRAL INDEX KEY: 0001386570 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 262940963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37752 FILM NUMBER: 201081930 BUSINESS ADDRESS: STREET 1: 10900 WILSHIRE BLVD STREET 2: SUITE 600 CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: 310-388-6706 MAIL ADDRESS: STREET 1: 10900 WILSHIRE BLVD STREET 2: SUITE 600 CITY: LOS ANGELES STATE: CA ZIP: 90024 FORMER COMPANY: FORMER CONFORMED NAME: CODY RESOURCES, INC. DATE OF NAME CHANGE: 20070112 10-Q 1 cdxc_10q.htm QUARTERLY REPORT cdxc_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2020

 

Commission File Number: 001-37752

 

CHROMADEX CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

26-2940963

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

10900 Wilshire Blvd. Suite 600,

Los Angeles, California

 

90024

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant's telephone number, including area code: (310) 388-6706

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of Each exchange on which registered

Common Stock, $0.001 par value per share

CDXC

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒    No ☐  

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, non-accelerated filer,  smaller reporting company or emerging growth company. See definition of “large accelerated filer, accelerated filer, smaller reporting company and emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

 ☐

Accelerated filer

 ☒

Non-accelerated filer

 ☐

Smaller reporting company

 

 

 

Emerging growth company

 ☐

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes   No ☒

 

As of August 5, 2020 there were 61,624,426 shares of the registrant’s common stock issued and outstanding.

 

 

 

CHROMADEX CORPORATION
 QUARTERLY REPORT ON FORM 10-Q

 

TABLE OF CONTENTS

 

PART I  – 

FINANCIAL INFORMATION (UNAUDITED)

 

 

 

 

ITEM 1

FINANCIAL STATEMENTS (UNAUDITED):

 3

 

Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

 3

 

Condensed Consolidated Statements of Operations for the three and the six months ended June 30, 2020 and June 30, 2019

 4

 

Condensed Consolidated Statements of Stockholders Equity for the three and the six months ended June 30, 2020 and June 30, 2019

 5

 

Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and June 30, 2019

 7

 

Notes to Condensed Consolidated Financial Statements

 8

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 24

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 32

ITEM 4

CONTROLS AND PROCEDURES

 32

 

 

 

PART II  –  

OTHER INFORMATION

 

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

 34

ITEM 1A

RISK FACTORS

 34

ITEM 2

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 51

ITEM 3

DEFAULTS UPON SENIOR SECURITIES

 51

ITEM 4

MINE SAFETY DISCLOSURES

 51

ITEM 5

OTHER INFORMATION

 51

ITEM 6

EXHIBITS

 52

 

SIGNATURES

 53

 

 
2

Table of Contents

  

PART I – FINANCIAL INFORMATION (UNAUDITED)

 

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

 

ChromaDex Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

June 30, 2020 and December 31, 2019

(In thousands, except per share data)

 

 

 

Jun. 30, 2020

 

 

Dec. 31, 2019

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash, including restricted cash of $0.2 million and $0.2 million, respectively

 

$18,890

 

 

$18,812

 

Trade receivables, net of allowances of $0.0 million and $2.8 million, respectively;

 

 

 

 

 

 

 

 

Receivables from Related Party: $1.1 million and $0.8 million, respectively

 

 

3,954

 

 

 

2,175

 

Inventories

 

 

12,338

 

 

 

11,535

 

Prepaid expenses and other assets

 

 

584

 

 

 

996

 

Total current assets

 

 

35,766

 

 

 

33,518

 

 

 

 

 

 

 

 

 

 

Leasehold Improvements and Equipment, net

 

 

3,487

 

 

 

3,765

 

Intangible Assets, net

 

 

1,189

 

 

 

1,311

 

Right of Use Assets

 

 

705

 

 

 

891

 

Other Long-term Assets

 

 

845

 

 

 

762

 

 

 

 

 

 

 

 

 

 

Total assets

 

$41,992

 

 

$40,247

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$9,780

 

 

$9,626

 

Accrued expenses

 

 

5,246

 

 

 

4,415

 

Current maturities of operating lease obligations

 

 

632

 

 

 

595

 

Current maturities of finance lease obligations

 

 

134

 

 

 

258

 

Customer deposits

 

 

250

 

 

 

169

 

Total current liabilities

 

 

16,042

 

 

 

15,063

 

 

 

 

 

 

 

 

 

 

Deferred Revenue

 

 

3,820

 

 

 

3,873

 

Operating Lease Obligations, Less Current Maturities

 

 

522

 

 

 

848

 

Finance Lease Obligations, Less Current Maturities

 

 

27

 

 

 

18

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

20,411

 

 

 

19,802

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

 

 

 

Common stock, $.001 par value; authorized 150,000 shares;

 

 

 

 

 

 

 

 

   issued and outstanding June 30, 2020 61,421 shares and

 

 

 

 

 

 

 

 

   December 31, 2019 59,562 shares

 

 

61

 

 

 

60

 

Additional paid-in capital

 

 

153,036

 

 

 

142,285

 

Accumulated deficit

 

 

(131,513)

 

 

(121,900)

Cumulative translation adjustments

 

 

(3)

 

 

-

 

Total stockholders' equity

 

 

21,581

 

 

 

20,445

 

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' equity

 

$41,992

 

 

$40,247

 

 

See Notes to Consolidated Financial Statements.

 

 
3

Table of Contents

   

ChromaDex Corporation and Subsidiaries

Condensed Consolidated Statements of Operations

For the Three and the Six Month Periods Ended June 30, 2020 and June 30, 2019

(In thousands, except per share data)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales, net

 

$15,287

 

 

$11,101

 

 

$29,632

 

 

$21,149

 

Cost of sales

 

 

6,199

 

 

 

4,847

 

 

 

12,233

 

 

 

9,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

9,088

 

 

 

6,254

 

 

 

17,399

 

 

 

11,555

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,959

 

 

 

4,308

 

 

 

9,406

 

 

 

8,482

 

Research and development

 

 

942

 

 

 

1,069

 

 

 

1,861

 

 

 

2,237

 

General and administrative

 

 

6,874

 

 

 

7,932

 

 

 

15,709

 

 

 

16,263

 

Other

 

 

-

 

 

 

125

 

 

 

-

 

 

 

125

 

Operating expenses

 

 

12,775

 

 

 

13,434

 

 

 

26,976

 

 

 

27,107

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(3,687)

 

 

(7,180)

 

 

(9,577)

 

 

(15,552)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nonoperating expense:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(24)

 

 

(575)

 

 

(36)

 

 

(540)

Nonoperating expense

 

 

(24)

 

 

(575)

 

 

(36)

 

 

(540)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(3,711)

 

$(7,755)

 

$(9,613)

 

$(16,092)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$(0.06)

 

$(0.14)

 

$(0.16)

 

$(0.29)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted weighted average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    common shares outstanding

 

 

60,906

 

 

 

55,539

 

 

 

60,344

 

 

 

55,433

 

 

See Notes to Consolidated Financial Statements.

 
4

Table of Contents

  

ChromaDex Corporation and Subsidiaries

Condensed Consolidated Statement of Stockholders' Equity

For the Three Month Periods Ended June 30, 2020 and June 30, 2019

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Cumulative

Translation

 

 

Total

Stockholders'

 

 

 

Shares

 

 

 Amount

 

 

 Capital

 

 

 Deficit

 

 

 Adjustments

 

 

 Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2020

 

 

59,605

 

 

 

60

 

 

 

144,290

 

 

 

(127,802)

 

 

-

 

 

 

16,548

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    net of offering costs of $0.1 million

 

 

1,225

 

 

 

1

 

 

 

4,855

 

 

 

-

 

 

 

-

 

 

 

4,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

591

 

 

 

-

 

 

 

2,180

 

 

 

-

 

 

 

-

 

 

 

2,180

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

-

 

 

 

-

 

 

 

1,711

 

 

 

-

 

 

 

-

 

 

 

1,711

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3)

 

 

(3)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,711)

 

 

-

 

 

 

(3,711)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2020

 

 

61,421

 

 

$61

 

 

$153,036

 

 

$(131,513)

 

$(3)

 

$21,581

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Cumulative

Translation

 

 

Total

Stockholders'

 

 

 

 

Shares

 

 

 

 Amount

 

 

 Capital

 

 

Deficit

 

 

Adjustments

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2019

 

 

55,321

 

 

$55

 

 

$119,012

 

 

$(98,090)

 

$-

 

 

$20,977

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

63

 

 

 

-

 

 

 

164

 

 

 

-

 

 

 

-

 

 

 

164

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

-

 

 

 

-

 

 

 

1,759

 

 

 

-

 

 

 

-

 

 

 

1,759

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7,755)

 

 

-

 

 

 

(7,755)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2019

 

 

55,384

 

 

$55

 

 

$120,935

 

 

$(105,845)

 

$-

 

 

$15,145

 

   

See Notes to Consolidated Financial Statements.

 
5

Table of Contents

  

ChromaDex Corporation and Subsidiaries

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Statement of Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Six Month Periods Ended June 30, 2020 and June 30, 2019

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Cumulative

Translation

 

 

Total

Stockholders'

 

 

 

Shares

 

 

 Amount

 

 

 Capital

 

 

 Deficit

 

 

 Adjustments

 

 

 Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2019

 

 

59,562

 

 

$60

 

 

$142,285

 

 

$(121,900)

 

$-

 

 

$20,445

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    net of offering costs of $0.1 million

 

 

1,225

 

 

 

1

 

 

 

4,855

 

 

 

-

 

 

 

-

 

 

 

4,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

634

 

 

 

-

 

 

 

2,312

 

 

 

-

 

 

 

-

 

 

 

2,312

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

-

 

 

 

-

 

 

 

3,584

 

 

 

-

 

 

 

-

 

 

 

3,584

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3)

 

 

(3)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(9,613)

 

 

-

 

 

 

(9,613)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2020

 

 

61,421

 

 

$61

 

 

$153,036

 

 

$(131,513)

 

$(3)

 

$21,581

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Cumulative

Translation

 

 

Total

Stockholders'

 

 

 

Shares

 

 

 Amount

 

 

 Capital

 

 

 Deficit

 

 

 Adjustments

 

 

 Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2018

 

 

55,089

 

 

$55

 

 

$116,876

 

 

$(89,753)

 

$-

 

 

$27,178

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of stock options

 

 

128

 

 

 

-

 

 

 

271

 

 

 

-

 

 

 

-

 

 

 

271

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

167

 

 

 

-

 

 

 

3,788

 

 

 

-

 

 

 

-

 

 

 

3,788

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(16,092)

 

 

-

 

 

 

(16,092)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2019

 

 

55,384

 

 

$55

 

 

$120,935

 

 

$(105,845)

 

$-

 

 

$15,145

 

 

See Notes to Consolidated Financial Statements.

 

 
6

Table of Contents

 

ChromaDex Corporation and Subsidiaries

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows

 

 

 

 

 

 

For the Six Month Periods Ended June 30, 2020 and June 30, 2019

 

 

 

 

 

 

(In thousands)

 

 

 

 

 

 

 

 

June 30, 2020

 

 

June 30, 2019

 

 

 

 

 

 

 

 

Cash Flows From Operating Activities

 

 

 

 

 

 

  Net loss

 

$(9,613)

 

$(16,092)

  Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

    Depreciation of leasehold improvements and equipment

 

 

432

 

 

 

363

 

    Amortization of intangibles

 

 

122

 

 

 

122

 

    Amortization of right of use assets

 

 

187

 

 

 

279

 

    Share-based compensation expense

 

 

3,584

 

 

 

3,788

 

    Allowance for doubtful trade receivables

 

 

(2,730)

 

 

(8)

    Amortization of convertible notes issuance costs

 

 

-

 

 

 

552

 

    Non-cash financing costs

 

 

51

 

 

 

-

 

  Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

    Trade receivables

 

 

952

 

 

 

(1,373)

    Contract assets

 

 

-

 

 

 

4

 

    Inventories

 

 

(804)

 

 

(2,465)

    Prepaid expenses and other assets

 

 

322

 

 

 

50

 

    Accounts payable 

 

 

154

 

 

 

(224)

    Accrued expenses

 

 

830

 

 

 

(671)

    Deferred revenue

 

 

(53)

 

 

3,873

 

    Customer deposits and other

 

 

78

 

 

 

18

 

    Principal payments on operating leases

 

 

(289)

 

 

(285)

Net cash used in operating activities

 

 

(6,777)

 

 

(12,069)

 

 

 

 

 

 

 

 

 

Cash Flows From Investing Activities

 

 

 

 

 

 

 

 

  Purchases of leasehold improvements and equipment

 

 

(107)

 

 

(308)

  Purchases of intangible assets

 

 

-

 

 

 

(10)

  Investment in other long-term assets

 

 

(15)

 

 

(47)

Net cash used in investing activities

 

 

(122)

 

 

(365)

 

 

 

 

 

 

 

 

 

Cash Flows From Financing Activities

 

 

 

 

 

 

 

 

  Proceeds from issuance of common stock, net

 

 

4,856

 

 

 

-

 

  Proceeds from sale of convertible notes

 

 

-

 

 

 

10,000

 

  Payment of convertible notes issuance costs

 

 

-

 

 

 

(565)

  Proceeds from exercise of stock options

 

 

2,312

 

 

 

271

 

  Payment of debt issuance costs

 

 

(30)

 

 

-

 

  Principal payments on finance leases

 

 

(161)

 

 

(128)

Net cash provided by financing activities

 

 

6,977

 

 

 

9,578

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash

 

 

78

 

 

 

(2,856)

 

 

 

 

 

 

 

 

 

Cash Beginning of Period, including restricted cash of $0.2 million for both 2020 and 2019

 

 

18,812

 

 

 

22,616

 

 

 

 

 

 

 

 

 

 

Cash Ending of Period, including restricted cash $0.2 million for both 2020 and 2019

 

$18,890

 

 

$19,760

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosures of Cash Flow Information

 

 

 

 

 

 

 

 

  Cash payments for interest on finance leases

 

$9

 

 

$17

 

 

 

 

 

 

 

 

 

 

Supplemental Schedule of Noncash Operating Activity

 

 

 

 

 

 

 

 

  Financing lease obligation incurred for prepayment of licensing fees

 

$-

 

 

$99

 

 

 

 

 

 

 

 

 

 

Supplemental Schedule of Noncash Investing Activity

 

 

 

 

 

 

 

 

  Financing lease obligation incurred for purchase of computer equipment and software

 

$47

 

 

$143

 

  Operating lease obligation incurred for tenant improvement credit received

 

$-

 

 

$64

 

  

See Notes to Consolidated Financial Statements.

 

 
7

Table of Contents

 

Note 1. Interim Financial Statements

 

The accompanying financial statements of ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., Healthspan Research, LLC, ChromaDex Analytics, Inc. and ChromaDex Asia Limited (collectively referred to herein as “ChromaDex” or the “Company” or, in the first person as “we”, “us” and “our”) include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and results of operations and cash flows for the three and the six months ended June 30, 2020 and June 30, 2019. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2019 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 10, 2020, as amended on May 18, 2020. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results to be achieved for the full year ending on December 31, 2020.The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

 

The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

 

Note 2. Nature of Business

  

ChromaDex is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide and its impact on human health.Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive intellectual property protection.The Company also has analytical reference standards and services segment, which focuses on natural product fine chemicals (known as “phytochemicals”) and related chemistry services.

 

Note 3. Liquidity

 

The Company's net cash outflow from operating activities was approximately $6.8 million for the six-month period ended June 30, 2020.As of June 30, 2020, cash and cash equivalents totaled approximately $18.9 million, which includes restricted cash of approximately $0.2 million.

 

The Company anticipates that its current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet its projected operating plans through at least the next twelve months from the issuance date of this report. The Company may, however, seek additional capital within the next twelve months, both to meet its projected operating plans within the next twelve months and/or to fund its longer-term strategic objectives.

  

Note 4. Significant Accounting Policies

 

Basis of presentation:The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on December 31.

 

 
8

Table of Contents

 

Recent accounting standards: In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit loss impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company can elect to defer compliance effective for fiscal years beginning after December 15, 2022. We are currently evaluating the impact of our pending adoption of ASU 2016-13 on our consolidated financial statements.

  

Note 5. Earnings Per Share Applicable to Common Stockholders

 

The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and the six months ended June 30, 2020 and June 30, 2019:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands, except per share data)

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(3,711)

 

$(7,755)

 

$(9,613)

 

$(16,092)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$(0.06)

 

$(0.14)

 

$(0.16)

 

$(0.29)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted weighted average common shares outstanding (1):

 

 

60,906

 

 

 

55,539

 

 

 

60,344

 

 

 

55,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potentially dilutive securities (2):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Stock options

 

 

11,457

 

 

 

10,174

 

 

 

11,457

 

 

 

10,174

 

  Warrants

 

 

-

 

 

 

140

 

 

 

-

 

 

 

140

 

  Convertible notes

 

 

-

 

 

 

2,192

 

 

 

-

 

 

 

2,192

 

____________________________

(1) Includes approximately 0.2 million and 0.2 million nonvested restricted stock for the periods ending June 30, 2020and June 30, 2019, respectively, which are participating securities that feature voting and dividend rights.

(2) Excluded from the computation of loss per share as their impact is antidilutive.

 

 
9

Table of Contents

   

Note 6. Related Party Transactions

 

Sale of consumer products

  

 

Net sales
Three months ended
Jun. 30, 2020

Net sales
Three months ended
Jun. 30, 2019

Net sales
Six months ended
Jun. 30, 2020

Net sales
Six months ended
Jun. 30, 2019

Trade receivable at
Jun. 30, 2020

Trade receivable at
Dec. 31, 2019

A.S. Watson Group

$1.3 million

$1.9 million

$3.1 million

$3.2 million

$1.0 million

$0.8 million

Horizon Ventures(1)

$1.6 million

-

$1.6 million

-

$0.1million

-

Total

$2.9 million

$1.9 million

$4.7 million

$3.2 million

$1.1 million

$0.8 million

 

*A.S. Watson Group and Horizon Ventures are related parties through common ownership of an enterprise that beneficially owns more than 10% of the common stock of the Company.

(1) For the three and six months ended June 30, 2020, Horizon Ventures made purchases to donate to the healthcare workers in Hong Kong hospitals.

 

   

Note 7. Inventories

 

The amounts of major classes of inventory as of June 30, 2020 and December 31, 2019 are as follows:

 

(In thousands)

 

Jun. 30, 2020

 

 

Dec. 31, 2019

 

Consumer Products - Finished Goods

 

$

7,994

 

 

 

4,877

 

Consumer Products - Work in Process

 

 

2,996

 

 

 

4,659

 

Bulk ingredients

 

 

684

 

 

$

1,364

 

Reference standards

 

 

664

 

 

 

635

 

 

 

$

12,338

 

 

$

11,535

 

  

Note 8. Stock Issuance

 

On April 27, 2020, the Company entered into a Securities Purchase Agreement with related parties pursuant to which the Company agreed to sell and issue approximately 1.2 million shares for $5.0 million, or $4.08 per share. The selling price was determined by the average closing price over the ten trading days immediately preceding the date of Securities Purchase Agreement (the “Financing”).On May 7, 2020, the Company closed the Financing and received proceeds of $4.9 million, net of offering costs.

 

 
10

Table of Contents

 

Note 9. Leases

 

Operating Leases

 

As of June 30, 2020, the Company had operating lease assets in right of use assets of approximately $0.7 million and corresponding operating lease liabilities of approximately $1.2 million.For the three and the six months ended June 30, 2020 and June 30, 2019, the following were expenses incurred in connection with our operating leases:

 

 

 

For the Three Months Ended Jun. 30, 2020

 

 

For the Three Months Ended Jun. 30, 2019

 

 

For the Six Months Ended Jun. 30, 2020

 

 

For the Six Months Ended Jun. 30, 2019

 

(In thousands)

 

 

 

 

Operating leases

 

 

 

 

 

 

 

 

 

 

 

 

   Operating lease expense

 

$120

 

 

$180

 

 

$240

 

 

$360

 

   Variable lease expense

 

 

65

 

 

 

66

 

 

 

134

 

 

 

121

 

Operating lease expense

 

 

185

 

 

 

246

 

 

 

374

 

 

 

481

 

Short-term lease rent expense

 

 

64

 

 

 

1

 

 

 

127

 

 

 

3

 

Total expense

 

$249

 

 

$247

 

 

$501

 

 

$484

 

  

 

Weighted-average remaining lease term (years) – operating leases

 

1.6

 

Weighted-average discount rate – operating leases

 

 

8.0%

 

Minimum future lease payments under operating leases as of June 30, 2020 are as follows:

  

 

 

 

 

Six months ending December 31, 2020

 

$347

 

Year Ending December 31, 2021

 

 

614

 

Year Ending December 31, 2022

 

 

138

 

Year Ending December 31, 2023

 

 

143

 

Year Ending December 31, 2024

 

 

25

 

Total

 

 

1,267

 

Less present value discount

 

 

113

 

Operating lease liabilities

 

 

1,154

 

Long-term obligations under operating leases

 

$522

 

 

 
11

Table of Contents

 

Finance Leases

 

As of June 30, 2020, the Company had finance lease assets in equipment assets of approximately $0.4 million and corresponding finance lease liabilities of approximately $0.2 million.For the three and the six months ended June 30, 2020 and June 30, 2019, the following were expenses incurred in connection with our finance leases:

 

 

 

For the Three Months Ended Jun. 30, 2020

 

 

For the Three Months Ended Jun. 30, 2019

 

 

For the Six Months Ended Jun. 30, 2020

 

 

For the Six Months Ended Jun. 30, 2019

 

(In thousands)

 

 

 

 

 

 

 

 

Finance leases

 

 

 

 

 

 

 

 

 

 

 

 

   Amortization of equipment assets

 

$29

 

 

$15

 

 

$57

 

 

$37

 

   Interest on lease liabilities

 

 

3

 

 

 

10

 

 

 

9

 

 

 

17

 

Total expenses

 

$32

 

 

$25

 

 

$66

 

 

$54

 

 

 

 

At Jun. 30, 2020

 

Weighted-average remaining lease term (years) finance leases

 

 

1.1

 

Weighted-average discount rate finance leases

 

 

7.9%

 

Minimum future lease payments under finance leases as of June 30, 2020 are as follows: 

 

(In thousands)

 

 

 

Six Months Ending December 31, 2020

 

$115

 

Year Ending December 31, 2021

 

 

32

 

Year Ending December 31, 2022

 

 

21

 

Total

 

 

168

 

Less present value discount

 

 

7

 

Finance lease liabilities

 

 

161

 

Less current portion

 

 

134

 

Long-term obligations under finance leases

 

$27

 

   

Note 10. Share-Based Compensation

 

Equity Plans

 

On June 20, 2017, the stockholders of the Company approved the ChromaDex Corporation 2017 Equity Incentive Plan (the "2017 Plan"). The Company's Board of Directors amended the 2017 Plan in January 2018 and the stockholders of the Company approved amendments to the 2017 Plan in June 2018 and June 2020. The 2017 Plan is the successor to the ChromaDex Corporation Second Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan"). As of June 30, 2020, under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the 2007 Plan, (iii) any returning shares from the 2007 Plan or the 2017 Plan, such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 6.9 million shares at June 30, 2020.

 

 
12

Table of Contents

 

General Vesting Conditions

 

The stock option awards generally vest ratably over a three-year period following grant date after a passage of time. However, some stock option awards are market or performance based and vest based on certain triggering events established by the Compensation Committee of the Board of Directors.

 

The fair value of the Company’s stock options that are not market based was estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted during the six months ended June 30, 2020.

 

Six months Ended June 30, 2020

 

 

Expected term

 

6 years

 

Expected volatility

 

 

66%

Risk-free rate

 

 

1%

Expected dividends

 

 

0%

 

Service Period Based Stock Options

 

The following table summarizes activity of service period-based stock options at June 30, 2020 and changes during the six months then ended (in thousands except per-share data and remaining contractual term):

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Fair

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

 

Value

 

Outstanding at Dec. 31, 2019

 

 

9,509

 

 

$3.86

 

 

 

6.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

2,133

 

 

 

3.62

 

 

 

10.0

 

 

$2.13

 

 

 

 

Options Exercised

 

 

(592)

 

 

3.77

 

 

 

 

 

 

 

 

 

 

$719

 

Options Expired

 

 

(239)

 

 

4.70

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Forfeited

 

 

(518)

 

 

3.44

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at Jun. 30, 2020

 

 

10,293

 

 

$3.82

 

 

 

7.1

 

 

 

 

 

 

$9,322*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at Jun. 30, 2020

 

 

6,126

 

 

$3.76

 

 

 

5.7

 

 

 

 

 

 

$6,252*

______________

*The aggregate intrinsic values in the table above are based on the Company’s stock price of $4.59, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2020.

  

Performance Based Stock Options

 

The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee of the Board of Directors. If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.

 

 
13

Table of Contents

 

The following table summarizes performance based stock options activity at June 30, 2020 and changes during the six months then ended (in thousands except per share data and remaining contractual term):

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Fair

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

 

Value

 

Outstanding at Dec. 31, 2019

 

 

42

 

 

$1.89

 

 

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

164

 

 

 

4.34

 

 

 

4.0

 

 

$2.26

 

 

 

 

Options Exercised

 

 

(42)

 

 

1.89

 

 

 

 

 

 

 

 

 

 

$100

 

Options Forfeited

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at Jun. 30, 2020

 

 

164

 

 

$4.34

 

 

 

3.6

 

 

 

 

 

 

$41*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at Jun. 30, 2020

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

_________________

*The aggregate intrinsic values in the table above are based on the Company’s stock price of $4.59, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2020.

  

Total Remaining Unamortized Compensation for Stock Options

 

As of June 30, 2020, there was approximately $8.4 million of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options.That cost is expected to be recognized over a weighted average period of 2 years.

  

Share-Based Compensation

 

Share-based compensation expenses were as follows: 

 

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

Share-based compensation expense

 

 

 

 

 

 

 

 

 

 

  Cost of sales

 

$42

 

 

$34

 

 

$75

 

 

$60

 

  Sales and marketing

 

 

242

 

 

 

144

 

 

 

474

 

 

 

263

 

  Research and development

 

 

134

 

 

 

127

 

 

 

272

 

 

 

250

 

  General and administrative

 

 

1,293

 

 

 

1,454

 

 

 

2,763

 

 

 

3,215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total

 

$1,711

 

 

$1,759

 

 

$3,584

 

 

$3,788

 

  

 
14

Table of Contents

 

Note 11. Business Segments

 

The Company has the following three reportable segments for the three- and six-month periods ended June 30, 2020:

 

 

·

Consumer products segment: provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers as well as to distributors.

 

 

 

 

·

Ingredients segment: develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

 

 

 

 

·

Analytical reference standards and services segment: includes supply of phytochemical reference standards and other research and development services.

  

The “Corporate and other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.  

 

Three months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$11,720

 

 

$2,850

 

 

$717

 

 

$-

 

 

$15,287

 

Cost of sales

 

 

4,339

 

 

 

1,135

 

 

 

725

 

 

 

-

 

 

 

6,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

7,381

 

 

 

1,715

 

 

 

(8)

 

 

-

 

 

 

9,088

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,743

 

 

 

76

 

 

 

140

 

 

 

-

 

 

 

4,959

 

Research and development

 

 

805

 

 

 

137

 

 

 

-

 

 

 

-

 

 

 

942

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6,874

 

 

 

6,874

 

Operating expenses

 

 

5,548

 

 

 

213

 

 

 

140

 

 

 

6,874

 

 

 

12,775

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$1,833

 

 

$1,502

 

 

$(148)

 

$(6,874)

 

$(3,687)

  

Three months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$8,744

 

 

$1,387

 

 

$970

 

 

$-

 

 

$11,101

 

Cost of sales

 

 

3,519

 

 

 

641

 

 

 

687

 

 

 

-

 

 

 

4,847

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

5,225

 

 

 

746

 

 

 

283

 

 

 

-

 

 

 

6,254

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,072

 

 

 

79

 

 

 

157

 

 

 

-

 

 

 

4,308

 

Research and development

 

 

875

 

 

 

194

 

 

 

-

 

 

 

-

 

 

 

1,069

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

7,932

 

 

 

7,932

 

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

125

 

 

 

125

 

Operating expenses

 

 

4,947

 

 

 

273

 

 

 

157

 

 

 

8,057

 

 

 

13,434

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$278

 

 

$473

 

 

$126

 

 

$(8,057)

 

$(7,180)

  

 
15

Table of Contents

 

Six months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$22,864

 

 

$5,325

 

 

$1,443

 

 

$-

 

 

$29,632

 

Cost of sales

 

 

8,641

 

 

 

2,191

 

 

 

1,401

 

 

 

-

 

 

 

12,233

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

14,223

 

 

 

3,134

 

 

 

42

 

 

 

-

 

 

 

17,399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

9,152

 

 

 

(8)

 

 

262

 

 

 

-

 

 

 

9,406

 

Research and development

 

 

1,587

 

 

 

274

 

 

 

-

 

 

 

-

 

 

 

1,861

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

15,709

 

 

 

15,709

 

Operating expenses

 

 

10,739

 

 

 

266

 

 

 

262

 

 

 

15,709

 

 

 

26,976

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$3,484

 

 

$2,868

 

 

$(220)

 

$(15,709)

 

$(9,577)

  

Six months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$16,198

 

 

$2,881

 

 

$2,070

 

 

$-

 

 

$21,149

 

Cost of sales

 

 

6,590

 

 

 

1,454

 

 

 

1,550

 

 

 

-

 

 

 

9,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

9,608

 

 

 

1,427

 

 

 

520

 

 

 

-

 

 

 

11,555

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

7,989

 

 

 

191

 

 

 

302

 

 

 

-

 

 

 

8,482

 

Research and development

 

 

1,844

 

 

 

393

 

 

 

-

 

 

 

-

 

 

 

2,237

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

16,263

 

 

 

16,263

 

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

125

 

 

 

125

 

Operating expenses

 

 

9,833

 

 

 

584

 

 

 

302

 

 

 

16,388

 

 

 

27,107

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$(225)

 

$843

 

 

$218

 

 

$(16,388)

 

$(15,552)

  

 
16

Table of Contents

 

 

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

At June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$14,392

 

 

$2,280

 

 

$950

 

 

$24,370

 

 

$41,992

 

  

 

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

At December 31, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$12,137

 

 

$2,135

 

 

$918

 

 

$25,057

 

 

$40,247

 

 

Disaggregation of Revenue

 

We disaggregate our revenue from contracts with customers by type of goods or services for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. See details in the tables below.

 

Three Months Ended June 30, 2020
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$11,720

 

 

$-

 

 

$-

 

 

$11,720

 

NIAGEN® Ingredient

 

 

-

 

 

 

1,995

 

 

 

-

 

 

 

1,995

 

Subtotal NIAGEN Related

 

$11,720

 

 

$1,995

 

 

$-

 

 

$13,715

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

855

 

 

 

-

 

 

 

855

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

686

 

 

 

686

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

31

 

 

 

31

 

Subtotal Other Goods and Services

 

$-

 

 

$855

 

 

$717

 

 

$1,572

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$11,720

 

 

$2,850

 

 

$717

 

 

$15,287

 

 

 
17

Table of Contents

   

Three Months Ended June 30, 2019
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN , Consumer Product

 

$8,744

 

 

$-

 

 

$-

 

 

$8,744

 

NIAGEN Ingredient

 

 

-

 

 

 

1,080

 

 

 

-

 

 

 

1,080

 

Subtotal NIAGEN Related

 

$8,744

 

 

$1,080

 

 

$-

 

 

$9,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

307

 

 

 

-

 

 

 

307

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

717

 

 

 

717

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

253

 

 

 

253

 

Subtotal Other Goods and Services

 

$-

 

 

$307

 

 

$970

 

 

$1,277

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$8,744

 

 

$1,387

 

 

$970

 

 

$11,101

 

 

Six Months Ended June 30, 2020
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$22,864

 

 

$-

 

 

$-

 

 

$22,864

 

NIAGEN® Ingredient

 

 

-

 

 

 

3,956

 

 

 

-

 

 

 

3,956

 

Subtotal NIAGEN Related

 

$22,864

 

 

$3,956

 

 

$-

 

 

$26,820

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

1,369

 

 

 

-

 

 

 

1,369

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

1,359

 

 

 

1,359

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

84

 

 

 

84

 

Subtotal Other Goods and Services

 

$-

 

 

$1,369

 

 

$1,443

 

 

$2,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$22,864

 

 

$5,325

 

 

$1,443

 

 

$29,632

 

  

 
18

Table of Contents

 

 

Six Months Ended June 30, 2019
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$16,198

 

 

$-

 

 

$-

 

 

$16,198

 

NIAGEN® Ingredient

 

 

-

 

 

 

2,190

 

 

 

-

 

 

 

2,190

 

Subtotal NIAGEN Related

 

$16,198

 

 

$2,190

 

 

$-

 

 

$18,388

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

691

 

 

 

-

 

 

 

691

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

1,547

 

 

 

1,547

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

523

 

 

 

523

 

Subtotal Other Goods and Services

 

$-

 

 

$691

 

 

$2,070

 

 

$2,761

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$16,198

 

 

$2,881

 

 

$2,070

 

 

$21,149

 

  

Disclosure of Major Customers

 

Major customers who accounted for more than 10% of the Company’s total sales were as follows:

 

 

 

Three months ended

 

 

Six months ended

 

Major Customers

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Horizon Ventures - Related Party

 

 

10.2%

 

*

 

 

*

 

 

*

 

A.S. Watson Group - Related Party

 

*

 

 

 

17.2%

 

 

10.6%

 

 

15.1%

 

Major accounts which had more than 10% of the Company’s total trade receivables were as follows:

  

 

 

Percentage of the Company's Total Trade Receivables

 

Major Accounts

 

At June 30, 2020

 

 

At December 31, 2019

 

 

 

 

 

 

 

 

A.S. Watson Group - Related Party (1)

 

 

26.7%

 

 

39.0%

Dr. Loges

 

 

15.4%

 

*

 

Thorne Research

 

 

12.1%

 

*

 

Life Extension

 

 

10.1%

 

 

27.4%

Amazon Marketplaces

 

*

 

 

 

10.3%

_____________________

 

 

 

 

 

 

 

 

* Represents less than 10%.

 

 

 

 

 

 

 

 

(1) Includes approximately $0.1 million trade receivables from Horizon Ventures.

  

 
19

Table of Contents

 

Note 12. Commitments and Contingencies

  

Inventory Purchase Obligations

 

In the second quarter of 2020, the Company entered into an amended manufacturing and supply agreement whereby the Company is obligated to purchase approximately $17.4 million of total inventory through June 30, 2021.The Company’s remaining purchase obligations as of June 30, 2020 were as follows:

 

Six Months Ending December 31, 2020

 

$7.3

 

 

Million

Six Months Ending June 30, 2021

 

$4.3

 

 

Million

Total

 

$11.6

 

 

Million

  

Legal proceedings - Elysium Health, LLC

 

(A) California Action

 

On December 29, 2016, ChromaDex, Inc. filed a complaint in the United States District Court for the Central District of California, naming Elysium Health, Inc. (together with Elysium Health, LLC, “Elysium”) as defendant (the “Complaint”). On January 25, 2017, Elysium filed an answer and counterclaims in response to the Complaint (together with the Complaint, the “California Action”). Over the course of the California Action, the parties have each filed amended pleadings several times and have each engaged in several rounds of motions to dismiss and one round of motion for judgment on the pleadings with respect to various claims. Most recently, on November 27, 2018, ChromaDex, Inc. filed a fifth amended complaint that added an individual, Mark Morris, as a defendant. Elysium and Morris (“the Defendants”) moved to dismiss on December 21, 2018. The court denied Defendants’ motion on February 4, 2019. Defendants filed their answer to ChromaDex, Inc.'s fifth amended complaint on February 19, 2019. ChromaDex, Inc. filed an answer to Elysium’s restated counterclaims on March 5, 2019. Discovery closed on August 9, 2019.

On August 16, 2019, the parties filed motions for partial summary judgment as to certain claims and counterclaims. The parties filed opposition briefs on August 28, 2019, and reply briefs on September 4, 2019. On October 9, 2019, among other things, the court vacated the previously scheduled trial date, ordered supplemental briefing with respect to certain issues related to summary judgment. Elysium filed its opening supplemental brief on October 30, 2019, ChromaDex filed its opening supplemental brief on November 18, 2019, and Elysium filed a reply brief on November 27, 2019, and the court heard argument on January 13, 2020. On January 16, 2020, the court granted both parties’ motions for summary judgment in part and denied both in part. On ChromaDex’s motion, the court granted summary judgment in favor of ChromaDex on Elysium’s counterclaims for (i) breach of contract related to manufacturing NIAGEN® according to the defined standard, selling NIAGEN and ingredients that are substantially similar to pterostilbene to other customers, distributing the NIAGEN® product specifications, and failing to provide information concerning the quality and identity of NIAGEN®, and (ii) breach of the implied covenant of good faith and fair dealing. The court denied summary judgment on Elysium’s counterclaims for (i) fraudulent inducement of the Trademark License and Royalty Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium (the “License Agreement”), (ii) patent misuse, and (iii) unjust enrichment. On Elysium’s motion, the court granted summary judgment in favor of Elysium on ChromaDex’s claim for damages related to $110,000in avoided costs arising from documents that Elysium used in violation of the Supply Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium, as amended (the “NIAGEN® Supply Agreement”). The court denied summary judgment on Elysium’s counterclaim for breach of contract related to certain refunds or credits to Elysium. The court also denied summary judgment on ChromaDex’s breach of contract claim against Morris and claims for disgorgement of $8.3 million in Elysium’s resale profits, $600,000 for a price discount received by Elysium, and $684,781 in Morris’s compensation.

 

 
20

Table of Contents

 

Following the court’s January 16, 2020 order, the claims that ChromaDex, Inc. presently asserts in the California Action, among other allegations, are that (i) Elysium breached the Supply Agreement, dated June 26, 2014, by and between ChromaDex, Inc. and Elysium (the “pTeroPure® Supply Agreement”), by failing to make payments to ChromaDex, Inc. for purchases of pTeroPure® and by improper disclosure of confidential ChromaDex, Inc. information pursuant to the pTeroPure® Supply Agreement, (ii) Elysium breached the NIAGEN® Supply Agreement, by failing to make payments to ChromaDex, Inc. for purchases of NIAGEN®, (iii) Defendants willfully and maliciously misappropriated ChromaDex, Inc. trade secrets concerning its ingredient sales business under both the California Uniform Trade Secrets Act and the Federal Defend Trade Secrets Act, (iv) Morris breached two confidentiality agreements he signed by improperly stealing confidential ChromaDex, Inc. documents and information, (v) Morris breached his fiduciary duty to ChromaDex, Inc. by lying to and competing with ChromaDex, Inc. while still employed there, and (vi) Elysium aided and abetted Morris’s breach of fiduciary duty. ChromaDex, Inc. is seeking damages and interest for Elysium’s alleged breaches of the NIAGEN® Supply Agreement and pTeroPure® Supply Agreement and Morris’s alleged breaches of his confidentiality agreements, compensatory damages and interest, punitive damages, injunctive relief, and attorney’s fees for Defendants’ alleged willful and malicious misappropriation of ChromaDex, Inc.’s trade secrets, and compensatory damages and interest, disgorgement of all benefits received, and punitive damages for Morris’s alleged breach of his fiduciary duty and Elysium’s aiding and abetting of that alleged breach.

 

The claims that Elysium presently alleges in the California Action are that (i) ChromaDex, Inc. breached the NIAGEN® Supply Agreement by not issuing certain refunds or credits to Elysium, (ii) ChromaDex, Inc. fraudulently induced Elysium into entering into the License Agreement, (iv) ChromaDex, Inc.’s conduct constitutes misuse of its patent rights, and (v) ChromaDex, Inc. was unjustly enriched by the royalties Elysium paid pursuant to the License Agreement. Elysium is seeking damages for ChromaDex, Inc.’s alleged breaches of the NIAGEN® Supply Agreement, and compensatory damages, punitive damages, and/or rescission of the License Agreement and restitution of any royalty payments conveyed by Elysium pursuant to the License Agreement, and a declaratory judgment that ChromaDex, Inc. has engaged in patent misuse.

 

On January 17, 2020, Elysium moved to substitute its counsel. The same day, the court ordered hearing on that motion for January 21, 2020, and granted Elysium’s motion at the hearing. On January 23, 2020, the court issued a scheduling order that, among other things, set trial on the remaining claims to begin on May 12, 2020. On March 19, 2020, in light of the global COVID-19 pandemic and ongoing private mediation efforts, the parties jointly stipulated to adjourn the trial date. The Court vacated the trial date on March 20, 2020. The Court held a telephonic status conference on June 9, 2020, during which the Court indicated that it will reschedule the jury trial as soon as conditions permit.

 

(B) Patent Office Proceedings

 

On July 17, 2017, Elysium filed petitions with the U.S. Patent and Trademark Office for inter partes review of U.S. Patents 8,197,807 (the “’807 Patent”) and 8,383,086 (the “’086 Patent”), patents to which ChromaDex, Inc. is the exclusive licensee. The Patent Trial and Appeal Board (“PTAB”) denied institution of the inter partes review for the ’807 Patent on January 18, 2018. On January 29, 2018, the PTAB granted institution of the inter partes review as to claims 1 and 3-5 and denied institution as to claim 2 of the ’086 Patent. Based upon a recent U.S. Supreme Court decision, and solely on a procedural basis, the PTAB was required to include claim 2 in the trial of the inter partes review. The matter was heard on October 2, 2018. The PTAB issued its written decision on January 16, 2019, upholding claim 2 of the ’086 Patent which relates to the use of isolated NR in a pharmaceutical composition as valid. Elysium is now prevented from raising invalidity arguments against the ’086 Patent in the ongoing patent litigation in Delaware that it brought or could have brought before the PTAB in its inter partes review. Elysium appealed the PTAB’s decision with respect to claim 2 on March 6, 2019. A cross-appeal with respect to claims 1 and 3–5 was filed on March 20, 2019. Elysium filed its opening brief on June 17, 2019. Dartmouth moved to voluntarily dismiss its cross-appeal on August 14, 2019. The motion was granted on August 18, 2019. Dartmouth’s response brief was filed on August 28, 2019. Elysium’s reply brief was filed on October 9, 2019. Oral argument on Elysium’s appeal was heard on March 5, 2020. On March 6, 2020, the United States Court of Appeals for the Federal Circuit affirmed the PTAB’s decision, rejecting Elysium's attempt to invalidate claim 2 of the '086 patent.

 

(C) Southern District of New York Action

On September 27, 2017, Elysium Health Inc. ("Elysium Health") filed a complaint in the United States District Court for the Southern District of New York, against ChromaDex, Inc. (the “Elysium SDNY Complaint”). Elysium Health alleges in the Elysium SDNY Complaint that ChromaDex, Inc. made false and misleading statements in a citizen petition to the Food and Drug Administration it filed on or about August 18, 2017. Among other allegations, Elysium Health avers that the citizen petition made Elysium Health’s product appear dangerous, while casting ChromaDex, Inc.’s own product as safe. The Elysium SDNY Complaint asserts four claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. § 1125(a); (ii) trade libel; (iii) deceptive business practices under New York General Business Law § 349; and (iv) tortious interference with prospective economic relations. ChromaDex, Inc. denies the claims in the Elysium SDNY Complaint and intends to defend against them vigorously. On October 26, 2017, ChromaDex, Inc. moved to dismiss the Elysium SDNY Complaint on the grounds that, inter alia, its statements in the citizen petition are immune from liability under the Noerr-Pennington Doctrine, the litigation privilege, and New York’s Anti-SLAPP statute, and that the Elysium SDNY Complaint failed to state a claim. Elysium Health opposed the motion on November 2, 2017. ChromaDex, Inc. filed its reply on November 9, 2017.

 

 
21

Table of Contents

 

On October 26, 2017, ChromaDex, Inc. filed a complaint in the United States District Court for the Southern District of New York against Elysium Health (the “ChromaDex SDNY Complaint”). ChromaDex, Inc. alleges that Elysium Health made material false and misleading statements to consumers in the promotion, marketing, and sale of its health supplement product, Basis, and asserts five claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); (iii) deceptive practices under New York General Business Law § 349; (iv) deceptive practices under New York General Business Law § 350; and (v) tortious interference with prospective economic advantage. On November 16, 2017, Elysium Health moved to dismiss for failure to state a claim. ChromaDex, Inc. opposed the motion on November 30, 2017 and Elysium Health filed a reply on December 7, 2017.

 

On November 3, 2017, the Court consolidated the Elysium SDNY Complaint and the ChromaDex SDNY Complaint actions under the caption In re Elysium Health-ChromaDex Litigation, 17-cv-7394, and stayed discovery in the consolidated action pending a Court-ordered mediation. The mediation was unsuccessful. On September 27, 2018, the Court issued a combined ruling on both parties’ motions to dismiss. For ChromaDex’s motion to dismiss, the Court converted the part of the motion on the issue of whether the citizen petition is immune under the Noerr-Pennington Doctrine into a motion for summary judgment, and requested supplemental evidence from both parties, which were submitted on October 29, 2018. The Court otherwise denied the motion to dismiss. On January 3, 2019, the Court granted ChromaDex, Inc.’s motion for summary judgment under the Noerr-Pennington Doctrine and dismissed all claims in the Elysium SDNY Complaint. Elysium moved for reconsideration on January 17, 2019. The Court denied Elysium’s motion for reconsideration on February 6, 2019, and issued an amended final order granting ChromaDex, Inc.’s motion for summary judgment on February 7, 2019.

 

The Court granted in part and denied in part Elysium’s motion to dismiss, sustaining three grounds for ChromaDex’s Lanham Act claims while dismissing two others, sustaining the claim under New York General Business Law § 349, and dismissing the claims under New York General Business Law § 350 and for tortious interference. Elysium filed an answer and counterclaims on October 10, 2018, alleging claims for (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); and (iii) deceptive practices under New York General Business Law § 349. ChromaDex answered Elysium’s counterclaims on November 2, 2018.

 

ChromaDex, Inc. filed an amended complaint on March 27, 2019, adding new claims against Elysium Health for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On April 10, 2019, Elysium Health answered the amended complaint and filed amended counterclaims, also adding new claims against ChromaDex, Inc. for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On July 1, 2019, Elysium Health filed further amended counterclaims, adding new claims under the Copyright Act §§ 106 & 501. On February 9, 2020, ChromaDex, Inc. filed a motion for leave to amend its complaint to add additional claims against Elysium Health for false advertising and unfair competition. On February 10, 2020, Elysium Health filed a motion for leave to amend its counterclaims to identify allegedly false and misleading statements in ChromaDex’s advertising. Those motions were both granted after respective stipulations. On March 12, 2020, Elysium Health answered the second amended complaint. On March 13, 2020, ChromaDex, Inc. filed an answer and objection to Elysium Health’s third amended counterclaims.

 

The Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to the legal proceedings discussed herein. As of June 30, 2020, ChromaDex, Inc. did not accrue a potential loss for the California Action or the Elysium SDNY Complaint because ChromaDex, Inc. believes that the allegations are without merit and thus it is not probable that a liability has been incurred.

 

(D) Delaware – Patent Infringement Action

On September 17, 2018, ChromaDex, Inc. and Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. The complaint alleges that Elysium’s BASIS® dietary supplement violates U.S. Patents 8,197,807 (the “’807 Patent”) and 8,383,086 (the “’086 Patent”) that comprise compositions containing isolated nicotinamide riboside held by Dartmouth and licensed exclusively to ChromaDex, Inc. On October 23, 2018, Elysium filed an answer to the complaint. The answer asserts various affirmative defenses and denies that Plaintiffs are entitled to any relief.

 

 
22

Table of Contents

 

On November 7, 2018, Elysium filed a motion to stay the patent infringement proceedings pending resolution of (1) the inter partes review of the ’807 Patent and the ’086 Patent before the Patent Trial and Appeal Board (“PTAB”) and (2) the outcome of the litigation in the California Action. ChromaDex, Inc. filed an opposition brief on November 21, 2018 detailing the issues with Elysium’s motion to stay. In particular, ChromaDex, Inc. argued that given claim 2 of the ’086 Patent was only included in the PTAB’s inter partes review for procedural reasons the PTAB was unlikely to invalidate claim 2 and therefore litigation in Delaware would continue regardless. In addition, ChromaDex, Inc. argued that the litigation in the California Action is unlikely to have a significant effect on the ongoing patent litigation. After the PTAB released its written decision upholding claim 2 of the ’086 Patent, proving right ChromaDex, Inc.’s prediction, ChromaDex, Inc. informed the Delaware court of the PTAB’s decision on January 17, 2019. On June 19, 2019, the Delaware court granted in part and denied in part Elysium’s motion, ordering that the case was stayed pending the resolution of Elysium’s patent misuse counterclaim in the California Action.

 

On November 1, 2019, ChromaDex, Inc. filed a motion to lift the stay due to changed circumstances in the California Action, among other reasons. Briefing on the motion was completed on November 22, 2019. On January 6, 2020, the Delaware court issued an oral order instructing the parties to submit a joint status report after the January 13, 2020 motions hearing in the California Action. The joint status report was submitted on January 30, 2020. On February 4, 2020, the Delaware court issued an order granting ChromaDex, Inc.’s motion to lift the stay and setting a scheduling conference for March 10, 2020. On March 19, 2020, the Delaware court entered a scheduling order, which, among other things, set the claim-construction hearing for December 17, 2020 and trial for the week of September 27, 2021. On April 17, 2020, ChromaDex, Inc. served infringement contentions. On April 24, 2020, ChromaDex, Inc. moved for leave to amend the complaint to add Healthspan Research, LLC as a plaintiff. On May 5, 2020, Elysium filed its opposition to ChromaDex, Inc.’s motion for leave to amend and moved to dismiss ChromaDex, Inc. for alleged lack of standing. ChromaDex, Inc. filed its opposition to Elysium’s motion to dismiss and reply in support of its motion to amend on May 19, 2020. Elysium filed its reply in support of its motion to dismiss on May 26, 2020. Elysium filed a Second Amended Answer on July 10, 2020. On July 22, 2020 the parties filed a Joint Claim Construction Chart and respective motions for claim construction. The parties’ Joint Claim Construction Brief is due on November 5, 2020. The Court will hold a Markman hearing on claim-construction issues on December 17, 2020.

 

From time to time we are involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.

 

Contingencies

In September 2019, the Company received a letter from a licensor stating that the Company owed the licensor $1.6 million plus interest of sublicense fees as a result of the Company entering into the supply agreement with a customer. After reviewing the relevant facts and circumstances, the Company believes that the Company does not owe any sublicense fees to the licensor and has corresponded with the licensor to resolve the matter. The Company does not believe that the ultimate resolution of this matter will be material to the Company’s results of operations, financial condition or cash flows.

  

Note 13. Subsequent Event

 

Subsequent to the period ended June 30, 2020, the Company entered into a lease amendment to lease additional space located in Longmont, Colorado. The lease amendment also extends the expiration of the lease period from February 2024 to December 2025. Pursuant to the lease amendment, the Company will make additional total lease payments of approximately $1.1 million during the term of the lease.

 

 
23

Table of Contents

  

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Certain statements in this Management's Discussion and Analysis (“MD&A”), other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “would,” “expect,” “intend,” “could,” “estimate,” “should,” “anticipate,” or “believe,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers should carefully review the risk factors and related notes set forth below in Part II, Item 1A, “Risk Factors” and included under Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 10, 2020, as amended on May 18, 2020 (our “Annual Report”).

 

The following MD&A is intended to help readers understand the results of our operation and financial condition, and is provided as a supplement to, and should be read in conjunction with, our Interim Unaudited Financial Statements and the accompanying Notes to Interim Unaudited Financial Statements under Part 1, Item 1 of this Quarterly Report on Form 10-Q.

 

Growth and percentage comparisons made herein generally refer to the three and the six months ended June 30, 2020 compared with the three and the six months ended June 30, 2019 unless otherwise noted. Unless otherwise indicated or unless the context otherwise requires, all references in this document to “we,” “us,” “our,” the “Company,” “ChromaDex” and similar expressions refer to ChromaDex Corporation, and depending on the context, its subsidiaries.

 

Company Overview

 

ChromaDex is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide ("NAD") and its impact on human health.

 

NAD is an essential coenzyme and a key regulator of cellular metabolism. Best known for its role in cellular energy production, NAD is now thought to play an important role in healthy aging. Many cellular functions related to health and healthy aging are sensitive to levels of locally available NAD and this represents an active area of research in the field of NAD.

 

NAD levels are not constant, and in humans, NAD levels have been shown to decline by more than 50% from young adulthood to middle age. NAD continues to decline as humans grow older. There are other causes of NAD depletion, such as poor diet, alcohol consumption and a number of disease states. NAD levels may also be increased, including through calorie restriction and moderate exercise. Healthy aging, mitochondrial health and NAD continue to be areas of focus in the research community. As of 2020, there were over 350 published human clinical studies related to NAD. The areas of study include understanding NAD’s role in Alzheimer’s disease, Parkinson’s disease, neuropathy and heart failure.

 

In 2013, ChromaDex commercialized NIAGEN® nicotinamide riboside ("NR"), a novel form of vitamin B3. Data from numerous preclinical studies, and confirmed in human clinical trials, show that NR is a highly efficient NAD precursor that significantly raises NAD levels. NIAGEN® is safe for human consumption. NIAGEN® has twice been successfully reviewed under the U.S. Food and Drug Administration’s new dietary ingredient (“NDI”) notification program, has been successfully notified to the U.S. Food and Drug Administration (the “FDA”) as generally recognized as safe (“GRAS”), and has been approved by Health Canada, the European Commission and the Therapeutic Goods Administration of Australia. Clinical studies of NIAGEN® have demonstrated a variety of outcomes including increased NAD levels, increased cellular metabolism and increased energy production. NIAGEN® is the trade name for our proprietary ingredient NR, and is protected by patents to which we are the exclusive licensee.

 

ChromaDex is the world leader in the emerging NAD space. ChromaDex has amassed more than 200 research partnerships with leading universities and research institutions around the world including the National Institutes of Health, Cornell, Dartmouth, Harvard, Massachusetts Institute of Technology, University of Cambridge and the Mayo Clinic. Additional relationships are currently being developed.

 

 
24

Table of Contents

 

Our scientific advisory board is led by Chairman Dr. Roger Kornberg, Nobel Laureate Stanford Professor, Dr. Charles Brenner, one of the world’s recognized experts in NAD and inventor of nicotinamide riboside, Dr. Rudi Tanzi, the co-chair of the department of neurology at Harvard Medical School and one of the world’s leading experts in food and nutrition, Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of Cambridge, England, Dr. Bruce German, Chairman of food, nutrition and health at the University of California, Davis, and Dr. Brunie Felding, Associate Professor, Department of Molecular Medicine at Scripps Research Institute, California Campus.

 

Impact of COVID-19

 

The COVID-19 pandemic continues to drive global uncertainty and disruption, which has created headwinds for our business. Our ecommerce business continues to perform relatively well in this challenging environment. Our retail business, including sales to A.S. Watson group and other partners in international markets, has been more impacted by the effects of COVID-19, due to store closures and reduced operating hours. To date, we have successfully navigated the business during the COVID-19 pandemic, managing our working capital effectively.

 

We have experienced shipment delays from our suppliers; however, we have not encountered any major disruptions in our supply chain. We have been increasing our overall inventory levels since 2018 in anticipation of high sales growth and have maintained adequate safety stocks to support such growth. We currently have adequate inventory on hand to meet our current demands. Overall, we believe the supply chain disruptions arising from COVID-19 will not have a material impact to our business operations.

 

In response to the outbreak, we prioritized the health and safety of our employees by closing our offices or enhancing safety protocols in place to ensure the well-being of our employees. We have been able to successfully conduct business virtually.

  

Financial Condition and Results of Operations

  

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues, if any, and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

  

On April 27, 2020, the Company entered into a Securities Purchase Agreement with its existing stockholders Winsave Resources Limited and Pioneer Step Holdings Limited, pursuant to which the Company agreed to sell and issue an aggregate of $5.0 million of the Company’s common stock at a purchase price of $4.08 per share. The selling price was determined by the average closing price over the ten trading days immediately preceding the date of Securities Purchase Agreement. The financing closed on May 7, 2020, pursuant to which the Company issued approximately 1.2 million shares of its common stock. The Company received proceeds of $4.9 million, net of offering costs.

 

In June 2020, the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc. (“B. Riley FBR”) and Raymond James & Associates, Inc. (“Raymond James” and together with B. Riley FBR, the “Sales Agents”) under which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through the Sales Agents (the “ATM Facility”). As of June 30, 2020, the Company has not sold any shares of its common stock pursuant to the ATM Facility.

 

 
25

Table of Contents

 

As of June 30, 2020, the Company had approximately $18.9 million of cash and cash equivalents on hand. We anticipate that our current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet our projected operating plans for at least the next twelve months. We may, however, seek additional capital in the next twelve months, both to meet our projected operating plans after the next twelve months and/or to fund our longer term strategic objectives. In June 2020, we filed a $125.0 million registration statement on Form S-3 with the Commission, utilizing a “shelf” registration process. Under this shelf registration process, we may sell securities from time to time, including up to $50.0 million pursuant to the ATM Facility.

 

Additional capital may come from other public and/or private stock or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. Further, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution and the new equity or debt securities we issue may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products or proprietary technologies, or to grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to develop or enhance our products, obtain the required regulatory clearances or approvals, achieve long term strategic objectives, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition. Further, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive.

  

Our net sales and net loss for the three- and the six-month periods ending on June 30, 2020 and June 30, 2019 were as follows: 

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$15,287

 

 

$11,101

 

 

$29,632

 

 

$21,149

 

Net loss

 

 

(3,711)

 

 

(7,755)

 

 

(9,613)

 

 

(16,092)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$(0.06)

 

$(0.14)

 

$(0.16)

 

$(0.29)

 

Net Sales

 

Net sales consist of gross sales less discounts and returns.  

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Consumer Products

 

$11,720

 

 

$8,744

 

 

 

34%

 

$22,864

 

 

$16,198

 

 

 

41%

  Ingredients

 

 

2,850

 

 

 

1,387

 

 

 

105%

 

 

5,325

 

 

 

2,881

 

 

 

85%

  Analytical reference standards and services

 

 

717

 

 

 

970

 

 

 

-26%

 

 

1,443

 

 

 

2,070

 

 

 

-30%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total net sales

 

$15,287

 

 

$11,101

 

 

 

38%

 

$29,632

 

 

$21,149

 

 

 

40%

  

 
26

Table of Contents

 

Total net sales increased by 38% and 40% for the three- and six-month periods ended June 30, 2020, respectively, compared to the comparable periods in 2019.

 

 

·

The Company's TRU NIAGEN® sales for the consumer products segment continue to increase after the Company's strategic shift towards consumer products in 2017.

 

 

 

 

·

The increase in sales for the ingredients segment is largely due to strong demand from our NIAGEN® ingredient customers, who resell NIAGEN® under their own brands.

 

 

 

 

·

The decrease in sales for the analytical reference standards and services is largely due to the spinoff of the regulatory consulting business unit in November 2019.The regulatory consulting business generated net sales of approximately $417,000 in the first half of 2019.In addition, sales of analytical reference standards decreased largely due to the effects of COVID-19.

 

Cost of Sales

 

Cost of sales include raw materials, labor, overhead, and delivery costs.

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

 

Amount

 

 

% of
net sales

 

 

Amount

 

 

% of
net sales

 

 

Amount

 

 

% of
net sales

 

 

Amount

 

 

% of
net sales

 

Cost of sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Consumer Products

 

$4,339

 

 

 

37%

 

$3,519

 

 

 

40%

 

$8,641

 

 

 

38%

 

$6,590

 

 

 

41%

  Ingredients

 

 

1,135

 

 

 

40%

 

 

641

 

 

 

46%

 

 

2,191

 

 

 

41%

 

 

1,454

 

 

 

50%

  Analytical reference standards and services

 

 

725

 

 

 

101%

 

 

687

 

 

 

71%

 

 

1,401

 

 

 

97%

 

 

1,550

 

 

 

75%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total cost of sales

 

$6,199

 

 

 

41%

 

$4,847

 

 

 

44%

 

$12,233

 

 

 

41%

 

$9,594

 

 

 

45%

  

The cost of sales, as a percentage of net sales, decreased by 3% and 4% for the three- and six-month periods ended June 30, 2020, respectively, compared to the comparable periods in 2019.

 

 

·

The cost of sales, as a percentage of net sales, for the consumer products segment decreased by 3% for each of the three- and six-month periods ended June 30, 2020, compared to the comparable periods in 2019. Product cost savings initiatives and overall scale on our supply chain drove the decrease in cost of sales.

 

 

 

 

·

The cost of sales, as a percentage of net sales, for the ingredients segment decreased 6% and 9% for the three- and six-month periods ended June 30, 2020, compared to the comparable periods in 2019.A portion of this decrease was realized in the form of a rebate from a supplier for prior year efficiency initiatives, which was recorded in the second quarter of 2020.In addition, we had an inventory write off of approximately $154,000 related to our decision to wind down sales for a certain ingredient in the first half of 2019.

 

 

 

 

·

The cost of sales, as a percentage of net sales for the analytical reference standards and services segment, increased 30% and 22% for the three- and the six-month periods ended June 30, 2020, compared to the comparable periods in 2019.The decrease in sales of analytical reference standards and services due to the spinoff of the regulatory consulting business in November 2019 and the effects of COVID-19 led to a lower labor and overhead utilization rate, which resulted in our cost of sales increasing as a percentage of net sales.

  

 
27

Table of Contents

 

Gross Profit

 

Gross profit is net sales less the cost of sales and is affected by a number of factors including business and product mix, competitive pricing and costs of products, labor, overhead, services and delivery.

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

Gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Consumer Products

 

$7,381

 

 

$5,225

 

 

 

41%

 

$14,223

 

 

$9,608

 

 

 

48%

  Ingredients

 

 

1,715

 

 

 

746

 

 

 

130%

 

 

3,134

 

 

 

1,427

 

 

 

120%

  Analytical reference standards and services

 

 

(8)

 

 

283

 

 

 

-103%

 

 

42

 

 

 

520

 

 

 

-92%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total gross profit

 

$9,088

 

 

$6,254

 

 

 

45%

 

$17,399

 

 

$11,555

 

 

 

51%

 

 

·

The consumer products segment posted gross profit of $7.4 million and $14.2 million for the three- and the six-month periods ending June 30, 2020, an increase of 41% and 48%, respectively, compared to the comparable periods in 2019. The increased gross profit was due to higher sales, product cost savings initiatives and scale on our supply chain operations.

 

 

 

 

·

The ingredients segment posted gross profit of $1.7 million and $3.1 million for the three- and the six-month periods ending June 30, 2020, respectively, an increase of 130% and 120%, respectively, compared to the comparable periods in 2019. The increased gross profit for the ingredients segment was largely due to higher sales to key customers, scale on our supply chain operations, and a rebate related to savings from prior year efficiency initiatives.

 

 

 

 

·

The decreased gross profit for the analytical reference standards and services segment was largely due to the decreased sales resulting from the spinoff of the regulatory consulting business and the effects of COVID-19. Fixed supply chain labor and overhead costs make up a substantial portion of the costs and these fixed labor and overhead costs did not decrease in proportion to sales, yielding lower profit margin.

   

Operating Expenses-Sales and Marketing

 

Sales and marketing expenses consist of salaries, advertising, public relations and marketing expenses. 

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

Sales and marketing expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Consumer Products

 

$4,743

 

 

$4,072

 

 

 

16%

 

$9,152

 

 

$7,989

 

 

 

15%

  Ingredients

 

 

76

 

 

 

79

 

 

 

-4%

 

 

(8)

 

 

191

 

 

 

-104%

  Analytical reference standards and services

 

 

140

 

 

 

157

 

 

 

-11%

 

 

262

 

 

 

302

 

 

 

-13%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total sales and marketing expenses

 

$4,959

 

 

$4,308

 

 

 

15%

 

$9,406

 

 

$8,482

 

 

 

11%

  

 
28

Table of Contents

 

 

·

For the consumer products segment, the increase during the three- and six-month periods ended June 30, 2020 is largely due to increased staffing as well as direct marketing expenses associated with social media, public relations and other customer awareness and acquisition programs.

 

 

 

 

·

For the ingredients segment, selling and marketing expenses decreased slightly.We reversed approximately $114,000 of certain accrued commission expense during the first quarter of 2020, as we were no longer obligated to pay the commission.

 

 

 

 

·

For the analytical reference standards and services segment, the decrease in selling and marketing expenses during the three- and six-month periods ended June 30, 2020 is mainly due to our efforts to optimize our spending during the COVID-19 pandemic.

  

Operating Expenses-Research and Development

 

Research and development expenses mainly consist primarily of clinical trials, regulatory approvals, product development and process development expenses.

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Consumer Products

 

$805

 

 

$875

 

 

 

-8%

 

$1,587

 

 

$1,844

 

 

 

-14%

  Ingredients

 

 

137

 

 

 

194

 

 

 

-29%

 

 

274

 

 

 

393

 

 

 

-30%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total research and development expenses

 

$942

 

 

$1,069

 

 

 

-12%

 

$1,861

 

 

$2,237

 

 

 

-17%

 

 

·

We are allocating the research and development expenses related to our NIAGEN® branded ingredient to the consumer products and ingredients segment, based on revenues recorded. Overall, we decreased our research and development efforts during the three- and the six-month periods ended June 30, 2020 as we evaluate and realign the priorities of our ongoing research and development efforts of our flagship ingredient, NIAGEN® nicotinamide riboside.

 

Operating Expenses-General and Administrative

 

General and administrative expenses consist of general company administration, legal, royalties, IT, accounting and executive management expenses.

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     General and administrative

 

$6,874

 

 

$7,932

 

 

 

-13%

 

$15,709

 

 

$16,263

 

 

 

-3%

  

 
29

Table of Contents

 

 

·

The decrease in general and administrative expenses for the three- and six-month periods ended June 30, 2020, compared to the comparable periods in 2019 was largely due to a decrease in legal expenses.Our legal expenses decreased to approximately $1.8 million and $4.2 million in the three- and six-month periods ended June 30, 2020, compared to approximately $2.9 million and $6.2 million in the comparable periods in 2019.

 

 

 

 

·

During the three- and six-month periods ended June 30, 2020, we incurred approximately $0.3 million and $1.2 million, respectively, of severance and restructuring expenses.These expenses relate to realignment of the business operations to reduce redundancies and improve efficiencies as we scale the business.

 

Non-operating Expenses-Interest Expense, net

 

Interest expense, net consists of interest earned from bank deposit accounts less interest expenses on convertible notes and finance leases.

   

 

 

Three months ending

 

Six months ending

 

(In thousands)

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Interest expense, net

 

$(24)

 

$(575)

 

Not Meaningful

 

$(36)

 

$(540)

 

Not Meaningful

 

 

 

In the second quarter of 2019, we incurred debt issuance costs of approximately $0.6 million in connection with the issuance of convertible promissory notes in the aggregate principal amount of $10.0 million to Winsave Resources Limited and Pioneer Step Holdings Limited. The issuance costs were recorded as a debt discount and have been amortized as interest expense using the effective interest method. We did not incur debt issuance costs in the three- or six-month periods ended June 30, 2020.

 

Income Taxes

 

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. At June 30, 2020, and June 30, 2019, we maintained a full valuation allowance against the entire deferred income tax balance which resulted in an effective tax rate of approximately 0% for the three- and the six-month periods ended June 30, 2020, and June 30, 2019, respectively. As defined in ASC 740, Income Taxes, future realization of the tax benefit will depend on the existence of sufficient taxable income, including the expectation of continued future taxable income.

 

Depreciation and Amortization

 

Depreciation expense for the six-month period ended June 30, 2020 was approximately $432,000 as compared to $363,000 for the six-month period ended June 30, 2019. We depreciate our assets on a straight-line basis, based on the estimated useful lives of the respective assets.

 

Amortization expense of intangible assets for the six-month period ended June 30, 2020 was approximately $122,000 as compared to $122,000 for the six-month period ended June 30, 2019. We amortize intangible assets using a straight-line method, generally over 10 years. For licensed patent rights, the useful lives are 10 years or the remaining term of the patents underlying licensing rights, whichever is shorter. The useful lives of subsequent milestone payments that are capitalized are the remaining useful life of the initial licensing payment that was capitalized.

 

 
30

Table of Contents

 

Amortization expense of right of use assets for the six-month period ended June 30, 2020 was approximately $187,000 as compared to $279,000 for the six-month period ended June 30, 2019.

 

Liquidity and Capital Resources

 

From inception through June 30, 2020, we have incurred aggregate losses of approximately $131.5 million. These losses are primarily due to expenses associated with the development and expansion of our operations. These operations have been financed through capital contributions, the issuance of common stock and warrants through private placements, and the issuance of debt.

 

Our board of directors periodically reviews our capital requirements in light of our proposed business plan. Our future capital requirements will remain dependent upon a variety of factors, including cash flow from operations, the ability to increase sales, increasing our gross profits from current levels, reducing selling and administrative expenses as a percentage of net sales, continued development of customer relationships, and our ability to market our new products successfully. However, based on our results from operations, we may determine that we need additional financing to implement our business plan. There can be no assurance that any such financing will be available on terms favorable to us or at all. Without adequate financing we may have to delay or terminate product and service expansion and curtail certain selling, general and administrative expenses. Any inability to raise additional financing would have a material adverse effect on us.

 

On April 27, 2020, the Company entered into a Securities Purchase Agreement with its existing stockholders, Winsave Resources Limited and Pioneer Step Holdings Limited, pursuant to which the Company agreed to sell and issue an aggregate of $5.0 million of the Company’s common stock at a purchase price of $4.08 per share. The selling price was determined by the average closing price over the ten trading days immediately preceding the date of Securities Purchase Agreement. The financing closed on May 7, 2020, pursuant to which the Company issued approximately 1.2 million shares of its common stock. The Company received proceeds of $4.9 million, net of offering costs.

 

While we anticipate that our current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet our projected operating plans for at least the next twelve months, we may seek additional funds, either through additional equity or debt financings or collaborative agreements or from other sources. In June 2020, we filed a $125.0 million registration statement on Form S-3 with the Commission, utilizing a “shelf” registration process. Under this shelf registration process, we may sell securities from time to time, including up to $50.0 million pursuant to the ATM Facility.

 

As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive.

  

Net cash provided by (used in) operating activities

 

Net cash used in operating activities for the six months ended June 30, 2020 was approximately $6.8 million as compared to approximately $12.1 million for the six months ended June 30, 2019. Along with the net loss, a decrease in allowance for doubtful trade receivables and an increase in inventories were the largest uses of cash during the six-month period ended June 30, 2020, partially offset by a decrease in trade receivables, an increase in accrued expenses and noncash share-based compensation expense. Net cash used in operating activities for the six months ended June 30, 2019 largely reflects the net loss, partially offset by an increase in deferred revenue and noncash share-based compensation expense.

 

We expect our operating cash flows to fluctuate significantly in future periods as a result of fluctuations in our operating results, shipment timetables, trade receivable collections, inventory management, and the timing of our payments, among other factors.

  

Net cash provided by (used in) investing activities

 

Net cash used in investing activities was approximately $0.1 million for the six months ended June 30, 2020, compared to approximately $0.4 million for the six months ended June 30, 2019. Net cash used in investing activities for the six months ended June 30, 2020 mainly consisted of purchases of leasehold improvements and equipment. Net cash used in investing activities for the six months ended June 30, 2019 also consisted of purchases of leasehold improvements and equipment.

 

 
31

Table of Contents

 

Net cash provided by (used in) financing activities

 

Net cash provided by financing activities was approximately $7.0 million for the six months ended June 30, 2020, compared to approximately $9.6 million for the six months ended June 30, 2019. Net cash provided by financing activities for the six months ended June 30, 2020 primarily consisted of proceeds from the issuance of common stock and the exercise of stock options. Net cash provided by financing activities for the six months ended June 30, 2019 consisted of proceeds from the sale of convertible notes and the exercise of stock options.

 

Contractual Obligations and Commitments

  

During the six months ended June 30, 2020, there were no material changes outside of the ordinary course of business in the specified contractual obligations disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as contained in our Annual Report, other than as disclosed in “Item 1 Financial Statements” of this Quarterly Report.

  

Off-Balance Sheet Arrangements

 

During the six months ended June 30, 2020, we had no material off-balance sheet arrangements.

  

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

  

Not applicable.

  

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the supervision of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2020, our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting discussed below.

 

 
32

Table of Contents

 

The material weakness in internal control over financial reporting resulted from a deficiency in our disclosure controls and procedures which could have resulted in the Company not disclosing a material potential loss that was reasonably possible, and therefore requiring a qualitative disclosure in consolidated financial statements under ASC 450 – Contingencies.

 

The Company has developed and adopted an applicable remedial control addressing the material weakness that existed in its control over its financial reporting for the quarter ended June 30, 2020. The material weakness will not be considered remediated until the applicable remedial control operates for a sufficient period of time and management has concluded, through testing, that this control is operating effectively. We expect that the remediation of this material weakness will be completed prior to the end of year 2020.

 

Our Chief Executive Officer and Chief Financial Officer believe that, notwithstanding the material weakness discussed above, the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented.

 

Changes in Internal Control over Financial Reporting

 

An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting (as defined in Rule 13a−15(f) promulgated under the Exchange Act) that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Other than as discussed above, there were no changes in internal control over financial reporting that occurred during the Company’s second fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 
33

Table of Contents

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

  

For a description of our legal proceedings, see Note 12, Commitments and Contingencies, Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

  

ITEM 1A. RISK FACTORS

  

Investing in our common stock involves a high degree of risk. Current investors and potential investors should consider carefully the risks and uncertainties described below and in our Annual Report, together with all other information contained in this Quarterly Report on Form 10-Q and our Annual Report, including our financial statements, the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before making investment decisions with respect to our common stock. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. Under these circumstances, the trading price and value of our common stock could decline, and you may lose all or part of your investment. The risks and uncertainties described in this Quarterly Report on Form 10-Q and in our Annual Report are not the only ones facing our Company. Additional risks and uncertainties of which we are not presently aware, or that we currently consider immaterial, may also impair our business operations. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Part I, Item 1A of our Annual Report.

  

Risks Related to our Company and our Business

 

*The COVID-19 pandemic has adversely affected, and is expected to continue to pose risks to our business, results of operations, financial condition and cash flows, and other epidemics or outbreaks of infectious diseases may have a similar impact.

 

As previously disclosed, we face risks related to the ongoing COVID-19 pandemic. COVID-19 has spread across the globe during 2020 and is impacting economic activity worldwide. COVID-19 has caused disruption and volatility in the global capital markets, and has caused an economic slowdown. The COVID-19 pandemic and its associated economic uncertainty may negatively impact our sales volumes in 2020. In response to COVID-19, national and local governments around the world have instituted certain measures, including travel bans, prohibitions on group events and gatherings, shutdowns of certain businesses, curfews, shelter-in-place orders and recommendations to practice social distancing. The duration of these measures is unknown, may be extended and additional measures may be imposed.

 

Among the potential effects of COVID-19 include, but are not limited to, the following:

 

 

·

Reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, and reduced business and consumer spending, which may adversely affect our results of operations by reducing our sales, margins and/or net income as a result of a slowdown in customer orders.

 

·

Reduced demand for our products due to store closures and reduced operating hours of our customers.

 

·

Disruptions in supply chain, leading to inadequate levels of inventory that may lower our sales.

  

 
34

Table of Contents

 

For example, our retail business, including sales to A.S. Watson group and other partners in international markets, has been impacted by the effects of COVID-19, due to store closures and reduced operating hours. 

 

To the extent the COVID-19 pandemic adversely affects our business, results of operations, financial condition and cash flows, it may also heighten many of the other risks described in this section. The ultimate impact of COVID-19 on our business, results of operations, financial condition and cash flows is dependent on future developments, including the duration of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time.

 

*We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.

 

We have recorded a net loss of approximately $9.6 million for the six months ended June 30, 2020 and we have a history of losses and may continue to incur operating and net losses for the foreseeable future. We incurred net losses of approximately $32.1 million and $33.3 million for the years ended December 31, 2019 and December 31, 2018, respectively. As of June 30, 2020, our accumulated deficit was approximately $131.5 million. We have not achieved profitability on an annual basis. We may not be able to reach a level of revenue to continue to achieve and sustain profitability. If our revenues grow slower than anticipated, or if operating expenses exceed expectations, then we may not be able to achieve and sustain profitability in the near future or at all, which may depress our stock price.

 

As of June 30, 2020, our cash and cash equivalents totaled approximately $18.9 million. While we anticipate that our current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet our projected operating plans through at least the next twelve months, we may require additional funds, either through additional equity or debt financings, including pursuant to the ATM Facility, or collaborative agreements or from other sources. We have no commitments to obtain such additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. Further, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. If equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

  

*Failure to remediate a material weakness in internal accounting controls could result in material misstatements in our financial statements.

 

Our management has identified a material weakness in our internal control over financial reporting and has concluded that, due to such material weakness, our disclosure controls and procedures were not effective as of June 30, 2020. The material weakness in internal control over financial reporting resulted from a deficiency in our disclosure controls and procedures which could have resulted in us not disclosing a material potential loss that was reasonably possible, and therefore requiring a qualitative disclosure in our consolidated financial statements under ASC 450 – Contingencies. The material weakness has not been remediated as of June 30, 2020. If not remediated, or if we identify further material weaknesses in our internal controls, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

 

 
35

Table of Contents

 

Our capital requirements will depend on many factors.

 

Our capital requirements will depend on many factors, including:

 

 

·

the revenues generated by sales of our products;

 

 

 

 

·

the costs associated with expanding our sales and marketing efforts, including efforts to hire independent agents and sales representatives and obtain required regulatory approvals and clearances;

 

 

 

 

·

the expenses we incur in developing and commercializing our products, including the cost of obtaining and maintaining regulatory approvals; and

 

 

 

 

·

unanticipated general and administrative expenses, including expenses involved with our ongoing litigation with Elysium.

  

Because of these factors, we may seek to raise additional capital within the next twelve months both to meet our projected operating plans after the next twelve months and to fund our longer term strategic objectives. Additional capital may come from public and private equity or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all. There can be no assurance we will be successful in raising these additional funds. Furthermore, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution and the new equity or debt securities we issue may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products or proprietary technologies, or grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to develop or enhance our products, obtain the required regulatory clearances or approvals, execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition.

  

*We are currently engaged in substantial and complex litigation with Elysium Health, Inc. and Elysium Health LLC ("Elysium"), the outcome of which could materially harm our business and financial results.

 

We are currently engaged in litigation with Elysium, a customer that represented 19% of our net sales for the year ended December 31, 2016. Elysium has made no purchases from us since August 9, 2016. The litigation includes multiple complaints and counterclaims by us and Elysium in venues in California and New York, as well as a patent infringement complaint filed by the Company and Trustees of Dartmouth College. For further details on this litigation, please refer to Part II, Item 1 of this Quarterly Report on Form 10-Q.

 

The litigation is substantial and complex, and it has caused and could continue to cause us to incur significant costs, as well as distract our management over an extended period. The litigation may substantially disrupt our business and we cannot assure you that we will be able to resolve the litigation on terms favorable to us. If we are unsuccessful in resolving the litigation on favorable terms to us, we may be forced to pay compensatory and punitive damages and restitution for any royalty payments that we received from Elysium, which payments could materially harm our business, or be subject to other remedies, including injunctive relief. In addition, Elysium has not paid us approximately $2.7 million for previous purchase orders. We may not collect the full amount owed to us by Elysium, and as a result, we wrote off the full amount as uncollectible expense. We cannot predict the outcome of our litigation with Elysium, which could have any of the results described above or other results that could materially adversely affect our business.

 

 
36

Table of Contents

 

*Interruptions in our relationships or declines in our business with major customers could materially harm our business and financial results.

 

A.S. Watson Group accounted for approximately 11% of our sales during the six months ended June 30, 2020. Due to COVID-19, our sales to A.S. Watson Group decreased in the second quarter of 2020 compared to the first quarter of 2020 as A.S. Watson Group was negatively impacted by store closures and reduced operating hours. Any interruption in our relationship or decline in our business with this customer or other customers upon whom we become highly dependent could cause harm to our business. Factors that could influence our relationship with our customers upon whom we may become highly dependent include:

 

 

·

our ability to maintain our products at prices that are competitive with those of our competitors;

 

 

 

 

·

our ability to maintain quality levels for our products sufficient to meet the expectations of our customers;

 

 

 

 

·

our ability to produce, ship and deliver a sufficient quantity of our products in a timely manner to meet the needs of our customers;

 

 

 

 

·

our ability to continue to develop and launch new products that our customers feel meet their needs and requirements, with respect to cost, timeliness, features, performance and other factors;

 

 

 

 

·

our ability to provide timely, responsive and accurate customer support to our customers; and

 

 

 

 

·

the ability of our customers to effectively deliver, market and increase sales of their own products based on ours.

  

Our future success largely depends on sales of our TRU NIAGEN® product.

 

In connection with our strategic shift from an ingredient and testing company to a consumer-focused company, we expect to generate a significant percentage of our future revenue from sales of our TRU NIAGEN® product. As a result, the market acceptance of TRU NIAGEN® is critical to our continued success, and if we are unable to expand market acceptance of TRU NIAGEN®, our business, results of operations, financial condition, liquidity and growth prospects would be materially adversely affected.

  

*Decline in the state of the global economy and financial market conditions could adversely affect our ability to conduct business and our results of operations.

 

Global economic and financial market conditions, including disruptions in the credit markets and the impact of the global economic deterioration may materially impact our customers and other parties with whom we do business. For example, the COVID-19 pandemic and actions taken to slow its spread, have caused the global credit and financial markets to experience extreme volatility, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. These conditions could negatively affect our future sales of our ingredient lines as many consumers consider the purchase of nutritional products discretionary. Decline in general economic and financial market conditions could materially adversely affect our financial condition and results of operations. Specifically, the impact of these volatile and negative conditions may include decreased demand for our products and services, a decrease in our ability to accurately forecast future product trends and demand, and a negative impact on our ability to timely collect receivables from our customers. The foregoing economic conditions may lead to increased levels of bankruptcies, restructurings and liquidations for our customers, scaling back of research and development expenditures, delays in planned projects and shifts in business strategies for many of our customers. Such events could, in turn, adversely affect our business through loss of sales.

 

 
37

Table of Contents

 

We may need to increase the size of our organization, and we can provide no assurance that we will successfully expand operations or manage growth effectively.

 

Our significant increase in the scope and the scale of our product launches, including the hiring of additional personnel, has resulted in significantly higher operating expenses. As a result, we anticipate that our operating expenses will continue to increase. Expansion of our operations may also cause a significant demand on our management, finances and other resources. Our ability to manage the anticipated future growth, should it occur, will depend upon a significant expansion of our accounting and other internal management systems and the implementation and subsequent improvement of a variety of systems, procedures and controls. There can be no assurance that significant problems in these areas will not occur. Any failure to expand these areas and implement and improve such systems, procedures and controls in an efficient manner at a pace consistent with our business could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that our attempts to expand our marketing, sales, manufacturing and customer support efforts will be successful or will result in additional sales or profitability in any future period. As a result of the expansion of our operations and the anticipated increase in our operating expenses, as well as the difficulty in forecasting revenue levels, we expect to continue to experience significant fluctuations in our results of operations.

  

Changes in our business strategy, including entering the consumer product market, or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses.

 

As changes in our business environment occur we may adjust our business strategies to meet these changes or we may otherwise decide to restructure our operations or businesses or assets. In addition, external events including changing technology, changing consumer patterns and changes in macroeconomic conditions may impair the value of our assets. When these changes or events occur, we may incur costs to change our business strategy and may need to write down the value of assets. In any of these events, our costs may increase, we may have significant charges associated with the write-down of assets or returns on new investments may be lower than prior to the change in strategy or restructuring. For example, if we are not successful in developing our consumer product business, our sales may decrease and our costs may increase.

  

The success of our consumer product and ingredient business is linked to the size and growth rate of the vitamin, mineral and dietary supplement market and an adverse change in the size or growth rate of that market could have a material adverse effect on us.

 

An adverse change in the size or growth rate of the vitamin, mineral and dietary supplement market could have a material adverse effect on our business. Underlying market conditions are subject to change based on economic conditions, consumer preferences and other factors that are beyond our control, including media attention and scientific research, which may be positive or negative.

 

The future growth and profitability of our consumer product business will depend in large part upon the effectiveness and efficiency of our marketing efforts and our ability to select effective markets and media in which to market and advertise.

 

Our consumer products business success depends on our ability to attract and retain customers, which significantly depends on our marketing practices. Our future growth and profitability will depend in large part upon the effectiveness and efficiency of our marketing efforts, including our ability to:

 

 

·

create greater awareness of our brand;

 

 

 

 

·

identify the most effective and efficient levels of spending in each market, media and specific media vehicle;

 

 

 

 

·

determine the appropriate creative messages and media mix for advertising, marketing and promotional expenditures;

 

 

 

 

·

effectively manage marketing costs (including creative and media) to maintain acceptable customer acquisition costs;

 

 

 

 

·

acquire cost-effective television advertising;

 

 

 

 

·

select the most effective markets, media and specific media vehicles in which to market and advertise; and

 

 

 

 

·

convert consumer inquiries into actual orders.

  

 
38

Table of Contents

 

Unfavorable publicity or consumer perception of our products and any similar products distributed by other companies could have a material adverse effect on our business.

 

We believe the nutritional supplement market is highly dependent upon consumer perception regarding the safety, efficacy and quality of nutritional supplements generally, as well as of products distributed specifically by us. Consumer perception of our products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, national media attention and other publicity regarding the consumption of nutritional supplements. We cannot assure you that future scientific research, findings, regulatory proceedings, litigation, media attention or other favorable research findings or publicity will be favorable to the nutritional supplement market or any product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, such earlier research reports, findings or publicity could have a material adverse effect on the demand for our products and consequently on our business, results of operations, financial condition and cash flows.

 

Our dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, if accurate or with merit, could have a material adverse effect on the demand for our products, the availability and pricing of our ingredients, and our business, results of operations, financial condition and cash flows. Further, adverse public reports or other media attention regarding the safety, efficacy and quality of nutritional supplements in general, or our products specifically, or associating the consumption of nutritional supplements with illness, could have such a material adverse effect. Any such adverse public reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately or as directed and the content of such public reports and other media attention may be beyond our control.

 

We may incur material product liability claims, which could increase our costs and adversely affect our reputation, revenues and operating income.

 

As a consumer product and ingredient supplier we market and manufacture products designed for human and animal consumption, we are subject to product liability claims if the use of our products is alleged to have resulted in injury. Our products consist of vitamins, minerals, herbs and other ingredients that are classified as food ingredients, dietary supplements, or natural health products, and, in most cases, are not necessarily subject to pre-market regulatory approval in the United States. Some of our products contain innovative ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur. In addition, the products we sell are produced by third-party manufacturers. As a marketer of products manufactured by third parties, we also may be liable for various product liability claims for products we do not manufacture. We may, in the future, be subject to various product liability claims, including, among others, that our products include inadequate instructions for use or inadequate warnings concerning possible side effects and interactions with other substances. A product liability claim against us could result in increased costs and could adversely affect our reputation with our customers, which, in turn, could have a materially adverse effect on our business, results of operations, financial condition and cash flows.

 

*We acquire ingredients for our products from foreign suppliers, and may be negatively affected by the risks associated with international trade and importation issues.

 

We acquire ingredients for a number of our products from suppliers outside of the United States. Accordingly, the acquisition of these ingredients is subject to the risks generally associated with importing raw materials, including, among other factors, delays in shipments, changes in economic and political conditions, quality assurance, health epidemics affecting the region of such suppliers, including COVID-19, nonconformity to specifications or laws and regulations, tariffs, trade disputes and foreign currency fluctuations. While we have a supplier certification program and audit and inspect our suppliers’ facilities as necessary both in the United States and internationally, we cannot assure you that raw materials received from suppliers outside of the United States will conform to all specifications, laws and regulations. There have in the past been quality and safety issues in our industry with certain items imported from overseas. We may incur additional expenses and experience shipment delays due to preventative measures adopted by the U.S. governments, our suppliers and our company.

 

The insurance industry has become more selective in offering some types of coverage and we may not be able to obtain insurance coverage in the future.

 

The insurance industry has become more selective in offering some types of insurance, such as product liability, product recall, property and directors’ and officers’ liability insurance. Our current insurance program is consistent with both our past level of coverage and our risk management policies. However, we cannot assure you that we will be able to obtain comparable insurance coverage on favorable terms, or at all, in the future. Certain of our customers as well as prospective customers require that we maintain minimum levels of coverage for our products. Lack of coverage or coverage below these minimum required levels could cause these customers to materially change business terms or to cease doing business with us entirely.

 

 
39

Table of Contents

 

If we experience product recalls, we may incur significant and unexpected costs, and our business reputation could be adversely affected.

 

We may be exposed to product recalls and adverse public relations if our products are alleged to be mislabeled or to cause injury or illness, or if we are alleged to have violated governmental regulations. A product recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. Product recalls may hurt the value of our brands and lead to decreased demand for our products. Product recalls also may lead to increased scrutiny by federal, state or international regulatory agencies of our operations and increased litigation and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

  

*We depend on key personnel, the loss of any of which could negatively affect our business.

 

We depend greatly on Frank L. Jaksch Jr., Robert N. Fried, Kevin M. Farr, Mark J. Friedman and Megan Jordan, who are our Executive Chairman of the Board, Chief Executive Officer, Chief Financial Officer, General Counsel and Chief Communications Officer, respectively. We also depend greatly on other key employees, including key scientific and marketing personnel. In general, only highly qualified and trained scientists have the necessary skills to develop our products and provide our services. Only marketing personnel with specific experience and knowledge in health care are able to effectively market our products. In addition, some of our manufacturing, quality control, safety and compliance, information technology, sales and e-commerce related positions are highly technical as well. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout the industries in which we compete. Our success will depend, in part, upon our ability to attract and retain additional skilled personnel, which will require substantial additional funds. There can be no assurance that we will be able to find and attract additional qualified employees or retain any such personnel. Our inability to hire qualified personnel, the loss of services of our key personnel, or the loss of services of executive officers or key employees that may be hired in the future may have a material and adverse effect on our business.

  

*Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.

 

We are subject to the following factors, among others, that may negatively affect our operating results:

 

 

·

the announcement or introduction of new products by our competitors;

 

 

 

 

·

our ability to upgrade and develop our systems and infrastructure to accommodate growth;

 

 

 

 

·

the decision by significant customers to reduce purchases;

 

 

 

 

·

disputes and litigation with competitors;

 

 

 

 

·

our ability to attract and retain key personnel in a timely and cost-effective manner;

 

 

 

 

·

technical difficulties;

 

 

 

 

·

the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure;

 

 

 

 

·

regulation by federal, state or local governments; and

 

 

 

 

·

general economic conditions as well as economic conditions specific to the healthcare industry.

  

 
40

Table of Contents

 

For example, our operating results may be harmed by the effect of the COVID-19 pandemic on global economic conditions. As a result of our limited operating history and the nature of the markets in which we compete, it is extremely difficult for us to make accurate forecasts. We have based our current and future expense levels largely on our investment plans and estimates of future events although certain of our expense levels are, to a large extent, fixed. Assuming our products reach the market, we may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in revenues relative to our planned expenditures would have an immediate adverse effect on our business, results of operations and financial condition. Further, as a strategic response to changes in the competitive environment, we may from time to time make certain pricing, service or marketing decisions that could have a material and adverse effect on our business, results of operations and financial condition. Due to the foregoing factors, our revenues and operating results are and will remain difficult to forecast.

  

We face significant competition, including changes in pricing.

 

The markets for our products and services are both competitive and price sensitive. Many of our competitors have significant financial, operations, sales and marketing resources and experience in research and development. Competitors could develop new technologies that compete with our products and services or even render our products obsolete. If a competitor develops superior technology or cost-effective alternatives to our products and services, our business could be seriously harmed.

 

The markets for some of our products are also subject to specific competitive risks because these markets are highly price competitive. Our competitors have competed in the past by lowering prices on certain products. If they do so again, we may be forced to respond by lowering our prices. This would reduce sales revenues and increase losses. Failure to anticipate and respond to price competition may also impact sales and aggravate losses.

 

We believe that customers in our markets display a significant amount of loyalty to their supplier of a particular product. To the extent we are not the first to develop, offer and/or supply new products, customers may buy from our competitors or make materials themselves, causing our competitive position to suffer.

 

Many of our competitors are larger and have greater financial and other resources than we do.

 

Our products compete and will compete with other similar products produced by our competitors. These competitive products could be marketed by well-established, successful companies that possess greater financial, marketing, distributional, personnel and other resources than we possess. Using these resources, these companies can implement extensive advertising and promotional campaigns, both generally and in response to specific marketing efforts by competitors, and enter into new markets more rapidly to introduce new products. In certain instances, competitors with greater financial resources also may be able to enter a market in direct competition with us, offering attractive marketing tools to encourage the sale of products that compete with our products or present cost features that consumers may find attractive.

  

We may never develop any additional products to commercialize.

 

We have invested a substantial amount of our time and resources in developing various new products. Commercialization of these products will require additional development, clinical evaluation, regulatory approval, significant marketing efforts and substantial additional investment before they can provide us with any revenue. Despite our efforts, these products may not become commercially successful products for a number of reasons, including but not limited to:

 

 

·

we may not be able to obtain regulatory approvals for our products, or the approved indication may be narrower than we seek;

 

 

 

 

·

our products may not prove to be safe and effective in clinical trials;

 

 

 

 

·

we may experience delays in our development program;

 

 

 

 

·

any products that are approved may not be accepted in the marketplace;

 

 

 

 

 
41

Table of Contents

 

 

·

we may not have adequate financial or other resources to complete the development or to commence the commercialization of our products or will not have adequate financial or other resources to achieve significant commercialization of our products;

 

 

 

 

·

we may not be able to manufacture any of our products in commercial quantities or at an acceptable cost;

 

 

 

 

·

rapid technological change may make our products obsolete;

 

 

 

 

·

we may be unable to effectively protect our intellectual property rights or we may become subject to claims that our activities have infringed the intellectual property rights of others; and

 

 

 

 

·

we may be unable to obtain or defend patent rights for our products.

  

In addition, we may never achieve technical feasibility under the supply agreement with Nestec Ltd., and therefore our sales and profit expectations resulting from this agreement may be reduced.

 

We may not be able to partner with others for technological capabilities and new products and services.

 

Our ability to remain competitive may depend, in part, on our ability to continue to seek partners that can offer technological improvements and improve existing products and services that are offered to our customers. We are committed to attempting to keep pace with technological change, to stay abreast of technology changes and to look for partners that will develop new products and services for our customer base. We cannot assure prospective investors that we will be successful in finding partners or be able to continue to incorporate new developments in technology, to improve existing products and services, or to develop successful new products and services, nor can we be certain that newly developed products and services will perform satisfactorily or be widely accepted in the marketplace or that the costs involved in these efforts will not be substantial.

 

If we fail to maintain adequate quality standards for our products and services, our business may be adversely affected and our reputation harmed.

 

Dietary supplement, nutraceutical, food and beverage, functional food, analytical laboratories, pharmaceutical and cosmetic customers are often subject to rigorous quality standards to obtain and maintain regulatory approval of their products and the manufacturing processes that generate them. A failure to maintain, or, in some instances, upgrade our quality standards to meet our customers’ needs, could cause damage to our reputation and potentially substantial sales losses.

 

Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which would have a material and adverse effect on us.

 

Our success depends significantly on our ability to protect our proprietary rights to the technologies used in our products. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology, including our licensed technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. For example, our pending United States and foreign patent applications may not issue as patents in a form that will be advantageous to us or may issue and be subsequently successfully challenged by others and invalidated. In addition, our pending patent applications include claims to material aspects of our products and procedures that are not currently protected by issued patents. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Competitors may be able to design around our patents or develop products which provide outcomes which are comparable or even superior to ours. Steps that we have taken to protect our intellectual property and proprietary technology, including entering into confidentiality agreements and intellectual property assignment agreements with some of our officers, employees, consultants and advisors, may not provide us with meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements. Furthermore, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States.

 

 
42

Table of Contents

 

In the event a competitor infringes our licensed or pending patent or other intellectual property rights, enforcing those rights may be costly, uncertain, difficult and time consuming. Even if successful, litigation to enforce our intellectual property rights or to defend our patents against challenge could be expensive and time consuming and could divert our management’s attention. We may not have sufficient resources to enforce our intellectual property rights or to defend our patents rights against a challenge. The failure to obtain patents and/or protect our intellectual property rights could have a material and adverse effect on our business, results of operations and financial condition.

 

Our patents and licenses may be subject to challenge on validity grounds, and our patent applications may be rejected.

 

We rely on our patents, patent applications, licenses and other intellectual property rights to give us a competitive advantage. Whether a patent is valid, or whether a patent application should be granted, is a complex matter of science and law, and therefore we cannot be certain that, if challenged, our patents, patent applications and/or other intellectual property rights would be upheld. If one or more of those patents, patent applications, licenses and other intellectual property rights are invalidated, rejected or found unenforceable, that could reduce or eliminate any competitive advantage we might otherwise have had.

 

We may become subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives and subject us to substantial monetary damages.

 

Third parties could, in the future, assert infringement or misappropriation claims against us with respect to products we develop. Whether a product infringes a patent or misappropriates other intellectual property involves complex legal and factual issues, the determination of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of others. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for use related to the use or manufacture of our products, and our potential competitors may assert that some aspect of our product infringes their patents. Because patent applications may take years to issue, there also may be applications now pending of which we are unaware that may later result in issued patents upon which our products could infringe. There also may be existing patents or pending patent applications of which we are unaware upon which our products may inadvertently infringe.

 

Any infringement or misappropriation claim could cause us to incur significant costs, place significant strain on our financial resources, divert management’s attention from our business and harm our reputation. If the relevant patents in such claim were upheld as valid and enforceable and we were found to infringe them, we could be prohibited from manufacturing or selling any product that is found to infringe unless we could obtain licenses to use the technology covered by the patent or are able to design around the patent. We may be unable to obtain such a license on terms acceptable to us, if at all, and we may not be able to redesign our products to avoid infringement, which could materially impact our revenue. A court could also order us to pay compensatory damages for such infringement, plus prejudgment interest and could, in addition, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently enjoin us and our customers from making, using, or selling products, and could enter an order mandating that we undertake certain remedial activities. Depending on the nature of the relief ordered by the court, we could become liable for additional damages to third parties.

 

The prosecution and enforcement of patents licensed to us by third parties are not within our control. Without these technologies, our products may not be successful and our business would be harmed if the patents were infringed on or misappropriated without action by such third parties.

 

We have obtained licenses from third parties for patents and patent application rights related to the products we are developing, allowing us to use intellectual property rights owned by or licensed to these third parties. We do not control the maintenance, prosecution, enforcement or strategy for many of these patents or patent application rights and as such are dependent in part on the owners of the intellectual property rights to maintain their viability. If any third-party licensor is unable to successfully maintain, prosecute or enforce the licensed patents and/or patent application rights related to our products, we may become subject to infringement or misappropriate claims or lose our competitive advantage. Without access to these technologies or suitable design-around or alternative technology options, our ability to conduct our business could be impaired significantly. 

 

 
43

Table of Contents

 

We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets of others.

 

Some of our employees were previously employed at other dietary supplement, nutraceutical, food and beverage, functional food, analytical laboratories, pharmaceutical and cosmetic companies. We may also hire additional employees who are currently employed at other such companies, including our competitors. Additionally, consultants or other independent agents with which we may contract may be or have been in a contractual arrangement with one or more of our competitors. We may be subject to claims that these employees or independent contractors have used or disclosed such other party’s trade secrets or other proprietary information. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management. If we fail to defend such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to market existing or new products, which could severely harm our business.

 

*Litigation may harm our business.

 

Substantial, complex or extended litigation could cause us to incur significant costs and distract our management. For example, lawsuits by employees, stockholders, collaborators, distributors, customers, competitors or others could be very costly and substantially disrupt our business. Disputes from time to time with such companies, organizations or individuals are not uncommon, and we cannot assure you that we will always be able to resolve such disputes or on terms favorable to us. As further described in Part II, Item 1 of this Quarterly Report on Form 10-Q, we are currently involved in substantial and complex litigation with Elysium. Unexpected results could cause us to have financial exposure in these matters in excess of recorded reserves and insurance coverage, requiring us to provide additional reserves to address these liabilities, therefore impacting profits.

 

Our sales and results of operations for our analytical reference standards and services segment depend on our customers’ research and development efforts and their ability to obtain funding for these efforts.

 

Our analytical reference standards and services segment customers include researchers at pharmaceutical and biotechnology companies, chemical and related companies, academic institutions, government laboratories and private foundations. Fluctuations in the research and development budgets of these researchers and their organizations could have a significant effect on the demand for our products. Our customers determine their research and development budgets based on several factors, including the need to develop new products, the availability of governmental and other funding, competition and the general availability of resources. As we continue to expand our international operations, we expect research and development spending levels in markets outside of the United States will become increasingly important to us.

 

Research and development budgets fluctuate due to changes in available resources, spending priorities, general economic conditions, institutional and governmental budgetary limitations and mergers of pharmaceutical and biotechnology companies. Our business could be harmed by any significant decrease in life science and high technology research and development expenditures by our customers. In particular, a small portion of our sales has been to researchers whose funding is dependent on grants from government agencies such as the United States National Institute of Health, the National Science Foundation, the National Cancer Institute and similar agencies or organizations. Government funding of research and development is subject to the political process, which is often unpredictable. Other departments, such as Homeland Security or Defense, or general efforts to reduce the United States federal budget deficit could be viewed by the government as a higher priority. Any shift away from funding of life science and high technology research and development or delays surrounding the approval of governmental budget proposals may cause our customers to delay or forego purchases of our products and services, which could seriously damage our business.

 

Some of our customers receive funds from approved grants at a particular time of year, many times set by government budget cycles. In the past, such grants have been frozen for extended periods or have otherwise become unavailable to various institutions without notice. The timing of the receipt of grant funds may affect the timing of purchase decisions by our customers and, as a result, cause fluctuations in our sales and operating results.

 

 
44

Table of Contents

 

Demand for our products and services are subject to the commercial success of our customers’ products, which may vary for reasons outside our control.

 

Even if we are successful in securing utilization of our products in a customer’s manufacturing process, sales of many of our products and services remain dependent on the timing and volume of the customer’s production, over which we have no control. The demand for our products depends on regulatory approvals and frequently depends on the commercial success of the customer’s supported product. Regulatory processes are complex, lengthy, expensive, and can often take years to complete.

 

We may bear financial risk if we underprice our contracts or overrun cost estimates.

 

In cases where our contracts are structured as fixed price or fee-for-service with a cap, we bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates. Such underpricing or significant cost overruns could have a material adverse effect on our business, results of operations, financial condition and cash flows. 

 

*We rely on single or a limited number of third-party suppliers for the raw materials required to produce our products.

 

Our dependence on a limited number of third-party suppliers or on a single supplier, and the challenges we may face in obtaining adequate supplies of raw materials, involve several risks, including limited control over pricing, availability, health epidemics affecting the region of such suppliers (including the coronavirus), quality and delivery schedules. We cannot be certain that our current suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Due to COVID-19, there may be delays in shipments from our suppliers. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our products until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and commercialization of our products, or interrupt production of then existing products that are already marketed, which would have a material adverse effect on our business. For example, W.R. Grace & Co.-Conn. (“Grace”) is the exclusive manufacturer to us for the supply of NR. There is no guarantee that we will be able to continue to contract with Grace for the supply of NR, or that such terms will be favorable to us.

  

We may not be successful in acquiring complementary businesses or products on favorable terms.

 

As part of our business strategy, we intend to consider acquisitions of similar or complementary businesses or products. No assurance can be given that we will be successful in identifying attractive acquisition candidates or completing acquisitions on favorable terms. In addition, any future acquisitions will be accompanied by the risks commonly associated with acquisitions. These risks include potential exposure to unknown liabilities of acquired companies or to acquisition costs and expenses, the difficulty and expense of integrating the operations and personnel of the acquired companies, the potential disruption to the business of the combined company and potential diversion of our management's time and attention, the impairment of relationships with and the possible loss of key employees and clients as a result of the changes in management, the incurrence of amortization expenses and write-downs and dilution to the shareholders of the combined company if the acquisition is made for stock of the combined company. In addition, successful completion of an acquisition may depend on consents from third parties, including regulatory authorities and private parties, which consents are beyond our control. There can be no assurance that products, technologies or businesses of acquired companies will be effectively assimilated into the business or product offerings of the combined company or will have a positive effect on the combined company's revenues or earnings. Further, the combined company may incur significant expense to complete acquisitions and to support the acquired products and businesses. Any such acquisitions may be funded with cash, debt or equity, which could have the effect of diluting or otherwise adversely affecting the holdings or the rights of our existing stockholders.

  

 
45

Table of Contents

 

*If we experience a significant disruption in our information technology systems or if we fail to implement new systems and software successfully, our business could be adversely affected.

 

We depend on information systems throughout our company to control our manufacturing processes, process orders, manage inventory, process and bill shipments and collect cash from our customers, respond to customer inquiries, contribute to our overall internal control processes, maintain records of our property, plant and equipment, and record and pay amounts due vendors and other creditors. Due to COVID-19, most of our employees have been working remotely from home and we have depended on communication tools and remote connections to our information technology systems to conduct business virtually. If we were to experience a prolonged disruption in our information systems that involve interactions amongst employees as well as with customers and suppliers, it could result in the loss of sales and customers and/or increased costs, which could adversely affect our overall business operation.

  

If we are unable to maintain sales, marketing and distribution capabilities or maintain arrangements with third parties to sell, market and distribute our products, our business may be harmed.

 

To achieve commercial success for our products, we must sell our product lines and/or technologies at favorable prices. In addition to being expensive, maintaining such a sales force is time-consuming. Qualified direct sales personnel with experience in the natural products industry are in high demand, and there can be no assurance that we will be able to hire or retain an effective direct sales team. Similarly, qualified independent sales representatives both within and outside the United States are in high demand, and we may not be able to build an effective network for the distribution of our product through such representatives. There can be no assurance that we will be able to enter into contracts with representatives on terms acceptable to us. Furthermore, there can be no assurance that we will be able to build an alternate distribution framework should we attempt to do so.

 

We may also need to contract with third parties in order to market our products. To the extent that we enter into arrangements with third parties to perform marketing and distribution services, our product revenue could be lower and our costs higher than if we directly marketed our products. Furthermore, to the extent that we enter into co-promotion or other marketing and sales arrangements with other companies, any revenue received will depend on the skills and efforts of others, and we do not know whether these efforts will be successful. If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, independently or with others, we will not be able to generate product revenue, and may not become profitable.

  

*Our business could be negatively impacted by cyber security threats.

 

In the ordinary course of our business, we use our data centers and our networks to store and access our proprietary business information. We face various cyber security threats, including cyber security attacks to our information technology infrastructure and attempts by others to gain access to our proprietary or sensitive information. Due to COVID-19, there may be additional cyber security threats as most of our employees work from home, utilizing network connections outside of the Company premises. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, data and related privacy breaches, terrorists and other external parties, including foreign private parties and state actors. The procedures and controls we use to monitor these threats and mitigate our exposure may not be sufficient to prevent cyber security incidents. The result of these incidents could include disrupted operations, lost opportunities, misstated financial data, liability for stolen assets or information, theft of our intellectual property, loss of data and other personally identifiable information, increased costs arising from the implementation of additional security protective measures, litigation and reputational damage. Any remedial costs or other liabilities related to cyber security incidents may not be fully insured or indemnified by other means.

  

Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and, if applicable, process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.

 

The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the European Union’s General Data Protection Regulation (“GDPR”) imposes strict obligations on the processing of personal data, including, without limitation, personal health data, and the free movement of such data. The GDPR applies to any company established in the European Union as well as any company outside the European Union that processes personal data in connection with the offering of goods or services to individuals in the European Union or the monitoring of their behavior. The GDPR provides data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of personal data; and transferring personal data to countries outside the European Union, including the U.S. The GDPR imposes fines for breaches of data protection requirements and provides other remedies for parties who suffer harm as a result of a data breach. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.

 

 
46

Table of Contents

 

Additionally, California recently enacted legislation that has been dubbed the first “GDPR-like” law in the U.S. Known as the California Consumer Privacy Act (the “CCPA”), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers. The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new disclosures to California consumers, and provides such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for penalties for violations, as well as other remedies for parties who suffer harm as a result of a data breach, which may increase data breach litigation. The CCPA may increase our compliance costs and potential liability.

  

*We are subject to financial and operating covenants in our business financing agreement with Western Alliance Bank (the “Credit Agreement”) and any failure to comply with such covenants, or obtain waivers in the event of non-compliance, could limit our borrowing availability under the Credit Agreement, resulting in our being unable to borrow under the Credit Agreement and materially adversely impact our liquidity. In addition, our operations may not provide sufficient cash to meet the repayment obligations of debt incurred under the Credit Agreement.

 

The Credit Agreement contains affirmative and restrictive covenants, including covenants regarding delivery of financial statements, maintenance of inventory, payment of taxes, maintenance of insurance, dispositions of property, business combinations or acquisitions and incurrence of additional indebtedness, among other customary covenants, in each case subject to limited exceptions.

 

There can be no assurance that we will be able to comply with the financial and other covenants in the Credit Agreement, and the effects of COVID-19 may make it more difficult for us to comply with such covenants. Our failure to comply with these covenants could cause us to be unable to borrow under the Credit Agreement and may constitute an event of default which, if not cured or waived, could result in the acceleration of the maturity of any indebtedness then outstanding under the Credit Agreement, which would require us to pay all amounts then outstanding. If we are unable to repay those amounts, Western Alliance Bank could proceed against the collateral granted to them to secure that debt, which would seriously harm our business. Such an event could materially adversely affect our financial condition and liquidity. Additionally, such events of non-compliance could impact the terms of any additional borrowings and/or any credit renewal terms. Any failure to comply with such covenants may be a disclosable event and may be perceived negatively. Such perception could adversely affect the market price for our common stock and our ability to obtain financing in the future.

  

Risks Related to Regulatory Approval of Our Products and Other Government Regulations

  

We are subject to regulation by various federal, state and foreign agencies that require us to comply with a wide variety of regulations, including those regarding the manufacture of products, advertising and product label claims, the distribution of our products and environmental matters. Failure to comply with these regulations could subject us to fines, penalties and additional costs.

 

Some of our operations are subject to regulation by various United States federal agencies and similar state and international agencies, including the Department of Commerce, the FDA, the FTC, the Department of Transportation and the Department of Agriculture. These regulations govern a wide variety of product activities, from design and development to labeling, manufacturing, handling, sales and distribution of products. If we fail to comply with any of these regulations, we may be subject to fines or penalties, have to recall products and/or cease their manufacture and distribution, which would increase our costs and reduce our sales.

 

We are also subject to various federal, state, local and international laws and regulations that govern the handling, transportation, manufacture, use and sale of substances that are or could be classified as toxic or hazardous substances. Some risk of environmental damage is inherent in our operations and the products we manufacture, sell, or distribute. Any failure by us to comply with the applicable government regulations could also result in product recalls or impositions of fines and restrictions on our ability to carry on with or expand in a portion or possibly all of our operations. If we fail to comply with any or all of these regulations, we may be subject to fines or penalties, have to recall products and/or cease their manufacture and distribution, which would increase our costs and reduce our sales.

 

 
47

Table of Contents

 

*Government regulations of our customer’s business are extensive and are constantly changing. Changes in these regulations can significantly affect customer demand for our products and services.

 

The process by which our customers’ industries are regulated is controlled by government agencies and depending on the market segment can be very expensive, time consuming, and uncertain. Changes in regulations or the enforcement practices of current regulations could have a negative impact on our customers and, in turn, our business. At this time, it is unknown how the FDA will interpret and to what extent it will enforce GMPs, and other regulations that will likely affect many of our customers. These uncertainties may have a material impact on our results of operations, as lack of enforcement or an interpretation of the regulations that lessens the burden of compliance for the dietary supplement marketplace may cause a reduced demand for our products and services.

 

*Changes in government regulation or in practices relating to the pharmaceutical, dietary supplement, food and cosmetic industry could decrease the need for the services we provide.

 

Governmental agencies throughout the world, including in the United States, strictly regulate the pharmaceutical, dietary supplement, food and cosmetic industries. Changes in regulation, such as a relaxation in regulatory requirements or the introduction of simplified drug approval procedures, or an increase in regulatory requirements that we have difficulty satisfying or that make our services less competitive, could eliminate or substantially reduce the demand for our services. Also, if the government makes efforts to contain drug costs and pharmaceutical and biotechnology company profits from new drugs, our customers may spend less, or reduce their spending on research and development. If health insurers were to change their practices with respect to reimbursements for pharmaceutical products, our customers may spend less, or reduce their spending on research and development.

  

If we should in the future become required to obtain regulatory approval to market and sell our goods we will not be able to generate any revenues until such approval is received.

 

The pharmaceutical industry is subject to stringent regulation by a wide range of authorities. While we believe that, given our present business, we are not currently required to obtain regulatory approval to market our goods because, among other things, we do not (i) produce or market any clinical devices or other products, or (ii) sell any medical products or services to the customer, we cannot predict whether regulatory clearance will be required in the future and, if so, whether such clearance will at such time be obtained for any products that we are developing or may attempt to develop. Should such regulatory approval in the future be required, our goods may be suspended or may not be able to be marketed and sold in the United States until we have completed the regulatory clearance process as and if implemented by the FDA. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product or service and would require the expenditure of substantial resources.

 

If regulatory clearance of a good that we propose to propose to market and sell is granted, this clearance may be limited to those particular states and conditions for which the good is demonstrated to be safe and effective, which would limit our ability to generate revenue. We cannot ensure that any good that we develop will meet all of the applicable regulatory requirements needed to receive marketing clearance. Failure to obtain regulatory approval will prevent commercialization of our goods where such clearance is necessary. There can be no assurance that we will obtain regulatory approval of our proposed goods that may require it.

  

Risks Related to the Securities Markets and Ownership of our Equity Securities

 

*The market price of our common stock may be volatile and adversely affected by several factors.

 

The market price of our common stock could fluctuate significantly in response to various factors and events, including, but not limited to:

 

 

·

our ability to integrate operations, technology, products and services;

 

 

 

 

·

our ability to execute our business plan;

 

 

 

 

·

our operating results are below expectations;

 

 
48

Table of Contents

 

 

·

our issuance of additional securities, including debt or equity or a combination thereof,;

 

 

 

 

·

announcements of technological innovations or new products by us or our competitors;

 

 

 

 

·

acceptance of and demand for our products by consumers;

 

 

 

 

·

media coverage regarding our industry or us;

 

 

 

 

·

litigation;

 

 

 

 

·

disputes with or our inability to collect from significant customers;

 

 

 

 

·

loss of any strategic relationship;

 

 

 

 

·

industry developments, including, without limitation, changes in healthcare policies or practices;

 

 

 

 

·

economic and other external factors, including effects of the COVID-19 pandemic;

 

 

 

 

·

reductions in purchases from our large customers;

 

 

 

 

·

period-to-period fluctuations in our financial results; and

 

 

 

 

·

whether an active trading market in our common stock develops and is maintained.

 

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

 

Our shares of common stock may be thinly traded, so you may be unable to sell at or near ask prices or at all.

 

We cannot predict the extent to which an active public market for our common stock will develop or be sustained. This situation may be attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community who generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we have become more seasoned and viable. As a consequence, there may be periods of several days or weeks when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot assure you that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained or not diminish.

 

 
49

Table of Contents

 

We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.

 

We have never paid cash dividends on our capital stock and do not anticipate paying cash dividends on our capital stock in the foreseeable future. The payment of dividends on our capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the common stock price appreciates.

 

*Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.

 

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017 informally titled the Tax Cuts and Jobs Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect us, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), modified certain provisions of the Tax Cuts and Jobs Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

 

*Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

 

Our federal net operating losses (“NOL”s) generated in taxable years ending prior to December 31, 2017 could expire unused. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, federal NOLs incurred in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

  

Stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.

 

If future operations or acquisitions are financed through the issuance of additional equity securities, stockholders could experience significant dilution. Securities issued in connection with future financing activities or potential acquisitions may have rights and preferences senior to the rights and preferences of our common stock. In addition, the issuance of shares of our common stock upon the exercise of outstanding options or warrants may result in dilution to our stockholders.

 

We may become involved in securities class action litigation that could divert management’s attention and harm our business.

 

The stock market in general, and the stocks of early stage companies in particular, have experienced extreme price and volume fluctuations. These fluctuations have often been unrelated or disproportionate to the operating performance of the companies involved. If these fluctuations occur in the future, the market price of our shares could fall regardless of our operating performance. In the past, following periods of volatility in the market price of a particular company’s securities, securities class action litigation has often been brought against that company. If the market price or volume of our shares suffers extreme fluctuations, then we may become involved in this type of litigation, which would be expensive and divert management’s attention and resources from managing our business.

 

 
50

Table of Contents

 

As a public company, we may also from time to time make forward-looking statements about future operating results and provide some financial guidance to the public markets. Projections may not be made in a timely manner or we might fail to reach expected performance levels and could materially affect the price of our shares. Any failure to meet published forward-looking statements that adversely affect the stock price could result in losses to investors, stockholder lawsuits or other litigation, sanctions or restrictions issued by the Securities and Exchange Commission.

 

*We have a significant number of outstanding options. Future sales of these shares could adversely affect the market price of our common stock.

 

As of June 30, 2020, we had outstanding options for an aggregate of approximately 11.5 million shares of common stock at a weighted average exercise price of $3.86 per share. The holders may sell many of these shares in the public markets from time to time, without limitations on the timing, amount or method of sale. As and when our stock price rises, if at all, more outstanding options will be in-the-money and the holders may exercise their options and sell a large number of shares. This could cause the market price of our common stock to decline.

  

*Our amended and restated bylaws, as amended (our “Bylaws”) provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

 

Our Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or our stockholders, (iii) any action asserting a claim against our company arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or Bylaws, or (iv) any action asserting a claim against our company governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.

 

This choice of forum provision may limit a stockholder’s ability to bring certain claims in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. If a court were to find this choice of forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

  

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

  

On April 27, 2020, the Company entered into a Securities Purchase Agreement with certain purchasers named therein, pursuant to which the Company agreed to sell and issue an aggregate of $5.0 million of the Company’s Common Stock, par value $0.001 per share at a purchase price of $4.08 per share. The selling price was determined by the average closing price over the ten trading days immediately preceding the date of Securities Purchase Agreement (the “Financing”). On May 7, 2020, the Company closed the Financing and issued approximately 1.2 million shares of its Common Stock. The Company received proceeds of $4.9 million, net of offering costs. The shares issued pursuant to the Financing were not registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. The Company relied on the exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

  

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

  

Not applicable.

 

ITEM 5. OTHER INFORMATION

  

None.

 

 
51

Table of Contents

  

ITEM 6. EXHIBITS

 

Exhibit No.

 

Description of Exhibits

 

 

 

2.1

 

Agreement and Plan of Merger, dated as of May 21, 2008, by and among Cody Resources, Inc., CDI Acquisition, Inc. and ChromaDex, Inc., as amended on June 10, 2008 (incorporated by reference to, and filed as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008) (1)

2.2

 

Asset Purchase Agreement, dated as of August 21, 2017, by and among Covance Laboratories Inc., ChromaDex, Inc., ChromaDex Analytics, Inc., and ChromaDex Corporation (incorporated by reference from, and filed as Exhibit 2.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37752) filed with the Commission on November 9, 2017)*

2.3

 

Amendment to Asset Purchase Agreement, dated as of September 5, 2017, by and among Covance Laboratories Inc., ChromaDex, Inc., ChromaDex Analytics, Inc., and ChromaDex Corporation (incorporated by reference from, and filed as Exhibit 2.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37752) filed with the Commission on November 9, 2017)

3.1

 

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the Commission on March 15, 2018)

3.2

 

Bylaws of the Registrant (incorporated by reference to, and filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008)

3.3

 

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 000-53290) filed with the Commission on April 12, 2016)

3.4

 

Amendment to Bylaws of the Registrant (incorporated by reference to, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the Commission on July 19, 2016)

4.1

 

Form of Stock Certificate representing shares of the Registrant’s Common Stock (incorporated by reference to, and filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K (File No. 000-53290) filed with the Commission on April 3, 2009)

4.2

 

 

Investor’s Rights Agreement, effective as of December 31, 2005, by and between The University of Mississippi Research Foundation and the Registrant (incorporated by reference to, and filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008)

4.3

 

Tag-Along Agreement effective as of December 31, 2005, by and among the Registrant, Frank Louis Jaksch, Snr. & Maria Jaksch, Trustees of the Jaksch Family Trust, Margery Germain, Lauren Germain, Emily Germain, Lucie Germain, Frank Louis Jaksch, Jr., and the University of Mississippi Research Foundation (incorporated by reference to, and filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No. 333-140056) filed with the Commission on June 24, 2008)

4.4

 

Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of January 1, 2016 (incorporated by reference to, and filed as Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the Commission on March 17, 2016)

4.5

 

Form of Stock Certificate representing shares of the Registrant’s Common Stock effective as of December 10, 2018 (incorporated by reference to, and filed as Exhibit 4.5 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the Commission on March 7, 2019)

4.6

 

 

Registration Rights Agreement, dated as of May 9, 2019, by and among the Registrant and the parties thereto (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 10, 2019)

4.7

 

 

Registration Rights Agreement, dated as of August 15, 2019, by and among the Registrant and the parties thereto (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 15, 2019)

4.8

 

 

Registration Rights Agreement, dated as of April 27, 2020, by and among the Registrant and the parties thereto (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 29, 2020)

10.1

 

 

Securities Purchase Agreement, dated April 27, 2020, by and among ChromaDex Corporation and Winsave Resources Limited and Pioneer Step Holdings Limited (incorporated by reference to, and filed as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the Commission on April 29, 2020)

10.2

 

 

At Market Issuance Sales Agreement, dated as of June 12, 2020, by and among ChromaDex Corporation, B. Riley FBR, Inc. and Raymond James & Associates, Inc. (incorporated by reference to, and filed as Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-239144) filed with the Commission on June 12, 2020)

10.3

 

ChromaDex Corporation 2017 Equity Incentive Plan, as amended (incorporated by reference to, and filed as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the Commission on June 22, 2020)+ 

31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended❖

31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended❖

32.1

 

Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)❖

101.INS

 

Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

 

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

__________________ 

❖ Filed herewith.

(1) Plan and related Forms were assumed by ChromaDex Corporation pursuant to Agreement and Plan of Merger, dated as of May 21, 2008, among ChromaDex Corporation (formerly Cody Resources, Inc.), CDI Acquisition, Inc. and ChromaDex, Inc.

* This Exhibit has been granted confidential treatment and has been filed separately with the Commission. The confidential portions of this Exhibit have been omitted and are marked by an asterisk.

+ Indicates management contract or compensatory plan or arrangement. 

 

 
52

Table of Contents

  

SIGNATURES 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

 

 

CHROMADEX CORPORATION

    
Date: August 6, 2020By:/s/ KEVIN M. FARR

 

 

Kevin M. Farr 
  Chief Financial Officer 
  (principal financial and accounting officer and duly authorized on behalf of the registrant) 

  

 

 
53

 

EX-31.1 2 cdxc_ex311.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER cdxc_ex311.htm

EXHIBIT 31.1

 

Certification of the Chief Executive Officer

Pursuant to

Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended,

as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Robert N. Fried, certify that:

 

1. I have reviewed this Quarterly Report on Form 10−Q of ChromaDex Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a−15(e) and 15d−15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 6, 2020   

/s/ ROBERT N. FRIED

Robert N. Fried

Chief Executive Officer

EX-31.2 3 cdxc_ex312.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER cdxc_ex312.htm

EXHIBIT 31.2

  

Certification of the Chief Financial Officer

Pursuant to

Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended,

as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Kevin M. Farr, certify that:

 

1. I have reviewed this Quarterly Report on Form 10−Q of ChromaDex Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a−15(e) and 15d−15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 6, 2020

/s/ KEVIN M. FARR

Kevin M. Farr

Chief Financial Officer

EX-32.1 4 cdxc_ex321.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 cdxc_ex321.htm

EXHIBIT 32.1

 

Certification Pursuant to 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)

 

                In connection with this Quarterly Report of ChromaDex Corporation (the “Company”) on Form 10−Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Robert N. Fried, Chief Executive Officer of the Company, and Kevin M. Farr, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002, that, to our knowledge:

 

 

1.

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

 

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

Date: August 6, 2020   

/s/ ROBERT N. FRIED

Robert N. Fried

Chief Executive Officer

 

/s/ KEVIN M. FARR

Kevin M. Farr

Chief Financial Officer

 

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 

 

 

 

 

 

 

EX-101.SCH 5 cdxc-20200630.xsd XBRL SCHEMA FILE 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Interim Financial Statements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Earnings Per Share Applicable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Stock Issuance link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - ShareBased Compensation link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Earnings Per Share Applicable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - ShareBased Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Earnings Per Share Applicable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Stock Issuance (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Leases (Details 3) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - Leases (Details 4) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - Leases (Details 5) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - ShareBased Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - ShareBased Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - ShareBased Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - ShareBased Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - ShareBased Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - Business Segments (Details) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - Business Segments (Details 1) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - Business Segments (Details 2) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cdxc-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 cdxc-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 cdxc-20200630_lab.xml XBRL LABEL FILE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity Interactive Data Current Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Condensed Consolidated Balance Sheets (Unaudited) Assets Current Assets Cash, including restricted cash of $0.2 million and $0.2 million, respectively Trade receivables, net of allowances of $0.0 million and $2.8 million, respectively; Receivables from Related Party: $1.1 million and $0.8 million, respectively Inventories [Inventory, Net] Prepaid expenses and other assets Total current assets [Assets, Current] Leasehold Improvements and Equipment, net Intangible Assets, net Right of Use Assets Other Long-term Assets Total assets [Assets] Liabilities and Stockholders' Equity Current Liabilities Accounts payable Accrued expenses Current maturities of operating lease obligations Current maturities of finance lease obligations Customer deposits Total current liabilities [Liabilities, Current] Deferred Revenue Operating Lease Obligations, Less Current Maturities Finance Lease Obligations, Less Current Maturities Total liabilities [Liabilities] Stockholders' Equity Common stock, $.001 par value; authorized 150,000 shares; issued and outstanding June 30, 2020 61,421 shares and December 31, 2019 59,562 shares Additional paid-in capital Accumulated deficit Cumulative translation adjustments Total stockholders' equity [Stockholders' Equity Attributable to Parent] Total liabilities and stockholders' equity [Liabilities and Equity] Restricted cash Trade receivables, allowances Receivables from related party, Allowances Common stock, par value per share Common stock, shares authorized (in thousands) Common stock, shares, issued (in thousands) Common stock, shares, outstanding (in thousands) Condensed Consolidated Statements of Operations (Unaudited) Sales, net Cost of sales Gross profit [Gross Profit] Operating expenses: Sales and marketing Research and development General and administrative Other Operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Nonoperating expense: Interest expense, net [Interest Expense] Nonoperating expense [Nonoperating Income (Expense)] Net loss [Net Income (Loss) Attributable to Parent] Basic and diluted loss per common share Basic and diluted weighted average common shares outstanding Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Cumulative Translation Adjustments Balance, shares [Shares, Issued] Balance, amount Issuance of common stock, net of offering costs of $0.1 million, shares Issuance of common stock, net of offering costs of $0.1 million, amount Exercise of stock options, shares Exercise of stock options, amount Share-based compensation Translation adjustment Net loss Share-based compensation, shares Share-based compensation, amount Balance, shares Balance, amount Condensed Consolidated Statements of Cash Flows (Unaudited) Cash Flows From Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation of leasehold improvements and equipment Amortization of intangibles Amortization of right of use assets Share-based compensation expense Allowance for doubtful trade receivables [Accounts Receivable, Credit Loss Expense (Reversal)] Amortization of convertible notes issuance costs Non-cash financing costs Changes in operating assets and liabilities: Trade receivables Contract assets Inventories [Increase (Decrease) in Inventories] Prepaid expenses and other assets [Increase (Decrease) in Prepaid Expense and Other Assets] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Deferred revenue Customer deposits and other Principal payments on operating leases Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Cash Flows From Investing Activities Purchases of leasehold improvements and equipment [Payments to Acquire Property, Plant, and Equipment] Purchases of intangible assets [Payments to Acquire Intangible Assets] Investment in other long-term assets [Payments to Acquire Investments] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Cash Flows From Financing Activities Proceeds from issuance of common stock, net Proceeds from sale of convertible notes Payment of convertible notes issuance costs [Payment of Financing and Stock Issuance Costs] Proceeds from exercise of stock options Payment of debt issuance costs [Payments of Debt Issuance Costs] Principal payments on finance leases [Finance Lease, Principal Payments] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Net increase (decrease) in cash [Cash and Cash Equivalents, Period Increase (Decrease)] Cash Beginning of Period, including restricted cash of $0.2 million for both 2020 and 2019 Cash Ending of Period, including restricted cash $0.2 million for both 2020 and 2019 Supplemental Disclosures of Cash Flow Information Cash payments for interest on finance leases Supplemental Schedule of Noncash Operating Activity Financing lease obligation incurred for prepayment of licensing fees Supplemental Schedule of Noncash Investing Activity Financing lease obligation incurred for purchase of computer equipment and software Operating lease obligation incurred for tenant improvement credit received Restricted cash Interim Financial Statements 1. Interim Financial Statements Nature of Business 2. Nature of Business 3. Liquidity Significant Accounting Policies 4. Significant Accounting Policies Earnings Per Share Applicable to Common Stockholders 5. Earnings Per Share Applicable to Common Stockholders Related Party Transactions 6. Related Party Transactions Inventories 7. Inventories Stock Issuance 8. Stock Issuance Leases 9. Leases ShareBased Compensation 10. Share-Based Compensation Business Segments 11. Business Segments Commitments and Contingencies 12. Commitments and Contingencies Subsequent Events 13. Subsequent events Basis of presentation Recent accounting standards Schedule of loss per share amounts applicable to common stockholders Schedule of net amount of assets and liabilities acquired Schedule of inventories Schedule of operating leases expenses Schedule of operating lease additional lease information Schedule of minimum future lease payments under operating leases Schedule of finance lease expenses Schedule of finance lease additional lease information Schedule of minimum future lease payments under finance leases Schedule of weighted average assumptions of stock options granted Schedule of stock option activity Schedule of share-based compensation Schedule of business segmentation Schedule of disaggregation of revenue Schedule of disclosure of major customers Schedule of inventory purchase obligations Title of Individual [Axis] Western Alliance Bank [Member] Cash and cash equivalents Restricted cash Line of credit, maximum borrowing capacity Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Stock Option [Member] Warrant [Member] Convertible notes [Member] Basic and diluted loss per common share Basic and diluted weighted average common shares outstanding Potentially dilutive securities (in thousands) Related Party Transactions By Related Party Axis A.S. Watson Group [Member] Horizon Ventures [Member] Net sales Trade receivable Consumer products - finished goods Consumer Products - work in process Bulk ingredients Reference standards Inventories Plan Name [Axis] Securities Purchase Agreement [Member] Shares issued to related parties, shares Shares issued to related parties, amount Shares issued price per share Proceeds from issuance of stock Operating leases Operating lease expense Variable lease expense Operating lease expense [Operating lease expense] Short-term lease rent expense Total expense Weighted-average remaining lease term (years) - operating leases Weighted-average discount rate - operating leases Six months ending December 31, 2020 Year ending December 31, 2021 Year ending December 31, 2022 Year ending December 31, 2023 Year ending December 31, 2024 Total [Operating Leases, Future Minimum Payments Due] Less present value discount Operating lease liabilities Long-term obligations under operating leases Finance leases Amotization of equipment assets Interest on lease liabilities Total expenses Weighted-average remaining lease term (years) - finance leases Weighted-average discount rate - finance leases Six months ending December 31, 2020 [Capital Leases, Future Minimum Payments Due, Next Twelve Months] Year ending December 31, 2021 [Capital Leases, Future Minimum Payments Due in Two Years] Year ending December 31, 2022 [Capital Leases, Future Minimum Payments Due in Three Years] Total [Capital Leases, Future Minimum Payments Due] Less present value discount [Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments] Finance lease liabilities Less current portion Long-term obligations under finance leases Operating lease - right of use assets Operating lease liability Finance lease - right of use assets Finance lease liability Expected term Expected volatility Risk-free rate Expected dividends Financial Instrument [Axis] Service Period Based Stock Options [Member] Number of shares, Outstanding, Beginning [Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number] Number of shares, Options Granted Number of shares, Options Exercised Number of shares, Options Expired Number of shares, Outstanding, Ending Number of shares, Options Forfeited Number of shares, Exercisable Weighted Average Exercise price Exercise price, Outstanding, Beginning [Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Exercise price, Options Granted Exercise price, Options Exercised Exercise price, Options Expired Exercise price, Options Forfeited Exercise price, Outstanding, Ending Exercise price, Exercisable Weighted Average Remaining Contatual Term (Years) Weighted Average Remaining Contatual Term, Outstanding, Beginning Weighted Average Remaining Contatual Term, Options Granted Weighted Average Remaining Contatual Term, Outstanding, Ending Weighted Average Remaining Contatual Term, Exercisable Fair Value Fair Value, Options Granted Aggregate Intrinsic Value Aggregate Intrinsic Value, Options Exercised Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic Value, , Exercisable Performance Based Stock Options [Member] Number of shares, Options Granted Number of shares, Options Exercised Number of shares, Options Forfeited Number of shares, Exercisable Weighted Average Exercise price Exercise price, Options Granted Exercise price, Options Exercised Exercise price, Exercisable, Ending Weighted Average Remaining Contatual Term (Years) Weighted Average Remaining Contatual Term, Outstanding, Beginning Weighted Average Remaining Contatual Term, Options Granted Weighted Average Remaining Contatual Term, Outstanding, Ending Fair Value Fair Value, Options Granted Aggregate Intrinsic Value Aggregate Intrinsic Value, , Exercisable Aggregate Intrinsic Value, Outstanding Income Statement Location Axis Cost of Sales [Member] Sales and Marketing [Member] Research and Development [Member] General and Administrative [Member] Share-based compensation Defined Benefit Plan, Plan Assets, Category [Axis] 2017 Equity Incentive Plan [Member] Share price Unrecognized compensation expense Unrecognized compensation expense recognition period Equity incentive plan, description Statement Business Segments Axis Consumer Products Segment [Member] Ingredients Segment [Member] Analytical Reference Standards and Services Segment [Member] Corporate and Other Segment [Member] Net sales Cost of sales Gross profit Operating expenses: Sales and marketing Research and development General and administrative Other Operating expenses Operating income (loss) Total assets Subsegments Axis TRU NIAGEN Consumer Product NIAGEN Ingredient NIAGEN Related Other Ingredients Reference Standards Consulting and Other Other Goods and Services Net sales Concentration Risk By Type Axis Sales Revenue, Net Horizon ventures A.S. Watson Group Trade Receivables Dr. Loges Thorne Research Amazon Marketplaces Customer concentration risk Six Months Ending December 31, 2020 Six Months Ending June 30, 2021 Remaining purchase obligation Manufacturing And Supply Agreement Elysium Health, Inc. Invetory purchase obligation Breach of contract, damages sought Court judgement, description Subsequent Event Type [Axis] Deferred Revenue Arrangement Type [Axis] Subsequent Event [Member] Leasing amendment agreement [Member] Description for the amendment to expiration dates Amount of additional lease payable during lease term EX-101.PRE 9 cdxc-20200630_pre.xml XBRL PRESENTATION FILE XML 10 cdxc_10q_htm.xml IDEA: XBRL DOCUMENT 0001386570 2020-01-01 2020-06-30 0001386570 2020-08-05 0001386570 2020-06-30 0001386570 2019-12-31 0001386570 2020-04-01 2020-06-30 0001386570 2019-04-01 2019-06-30 0001386570 2019-01-01 2019-06-30 0001386570 us-gaap:CommonStockMember 2020-03-31 0001386570 us-gaap:CommonStockMember 2019-12-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001386570 us-gaap:RetainedEarningsMember 2020-03-31 0001386570 us-gaap:RetainedEarningsMember 2019-12-31 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2020-03-31 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2019-12-31 0001386570 2020-03-31 0001386570 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001386570 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001386570 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001386570 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2020-04-01 2020-06-30 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2020-01-01 2020-06-30 0001386570 us-gaap:CommonStockMember 2020-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001386570 us-gaap:RetainedEarningsMember 2020-06-30 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2020-06-30 0001386570 us-gaap:CommonStockMember 2019-03-31 0001386570 us-gaap:CommonStockMember 2018-12-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001386570 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001386570 us-gaap:RetainedEarningsMember 2019-03-31 0001386570 us-gaap:RetainedEarningsMember 2018-12-31 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2019-03-31 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2018-12-31 0001386570 2019-03-31 0001386570 2018-12-31 0001386570 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001386570 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001386570 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001386570 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2019-04-01 2019-06-30 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2019-01-01 2019-06-30 0001386570 us-gaap:CommonStockMember 2019-06-30 0001386570 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001386570 us-gaap:RetainedEarningsMember 2019-06-30 0001386570 cdxc:CumulativeTranslationAdjustmentsMember 2019-06-30 0001386570 2019-06-30 0001386570 cdxc:WesternAllianceBankMember 2020-06-30 0001386570 us-gaap:StockOptionMember 2020-04-01 2020-06-30 0001386570 us-gaap:StockOptionMember 2020-01-01 2020-06-30 0001386570 us-gaap:StockOptionMember 2019-04-01 2019-06-30 0001386570 us-gaap:StockOptionMember 2019-01-01 2019-06-30 0001386570 us-gaap:WarrantMember 2020-04-01 2020-06-30 0001386570 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001386570 us-gaap:WarrantMember 2019-04-01 2019-06-30 0001386570 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001386570 cdxc:ConvertibleNotesMember 2020-04-01 2020-06-30 0001386570 cdxc:ConvertibleNotesMember 2020-01-01 2020-06-30 0001386570 cdxc:ConvertibleNotesMember 2019-04-01 2019-06-30 0001386570 cdxc:ConvertibleNotesMember 2019-01-01 2019-06-30 0001386570 cdxc:ASWatsonGroupMember 2020-04-01 2020-06-30 0001386570 cdxc:ASWatsonGroupMember 2020-01-01 2020-06-30 0001386570 cdxc:ASWatsonGroupMember 2019-04-01 2019-06-30 0001386570 cdxc:ASWatsonGroupMember 2019-01-01 2019-06-30 0001386570 cdxc:ASWatsonGroupMember 2020-06-30 0001386570 cdxc:ASWatsonGroupMember 2019-12-31 0001386570 cdxc:HorizonVenturesMember 2020-04-01 2020-06-30 0001386570 cdxc:HorizonVenturesMember 2020-01-01 2020-06-30 0001386570 cdxc:HorizonVenturesMember 2019-04-01 2019-06-30 0001386570 cdxc:HorizonVenturesMember 2019-01-01 2019-06-30 0001386570 cdxc:HorizonVenturesMember 2020-06-30 0001386570 cdxc:HorizonVenturesMember 2019-12-31 0001386570 cdxc:SecuritiesPurchaseAgreementMember 2020-04-01 2020-04-27 0001386570 cdxc:SecuritiesPurchaseAgreementMember 2020-04-27 0001386570 cdxc:SecuritiesPurchaseAgreementMember 2020-05-01 2020-05-07 0001386570 cdxc:ServicePeriodBasedStockOptionsMember 2019-12-31 0001386570 cdxc:ServicePeriodBasedStockOptionsMember 2020-01-01 2020-06-30 0001386570 cdxc:ServicePeriodBasedStockOptionsMember 2020-06-30 0001386570 cdxc:PerformanceBasedStockOptionsMember 2019-12-31 0001386570 cdxc:PerformanceBasedStockOptionsMember 2020-01-01 2020-06-30 0001386570 cdxc:PerformanceBasedStockOptionsMember 2020-06-30 0001386570 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001386570 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001386570 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001386570 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001386570 cdxc:SalesAndMarketingMember 2020-04-01 2020-06-30 0001386570 cdxc:SalesAndMarketingMember 2020-01-01 2020-06-30 0001386570 cdxc:SalesAndMarketingMember 2019-04-01 2019-06-30 0001386570 cdxc:SalesAndMarketingMember 2019-01-01 2019-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001386570 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001386570 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001386570 cdxc:TwoThousandTwentyEquityIncentivePlanMember 2017-06-01 2017-06-20 0001386570 cdxc:ConsumerProductsSegmentMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember 2019-12-31 0001386570 cdxc:IngredientsSegmentMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember 2020-06-30 0001386570 cdxc:IngredientsSegmentMember 2019-12-31 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember 2019-04-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember 2019-12-31 0001386570 cdxc:OtherSegmentMember 2020-04-01 2020-06-30 0001386570 cdxc:OtherSegmentMember 2020-01-01 2020-06-30 0001386570 cdxc:OtherSegmentMember 2019-04-01 2019-06-30 0001386570 cdxc:OtherSegmentMember 2019-01-01 2019-06-30 0001386570 cdxc:OtherSegmentMember 2020-06-30 0001386570 cdxc:OtherSegmentMember 2019-12-31 0001386570 cdxc:TruniagenConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdxc:TruniagenConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdxc:TruniagenConsumerProductMember 2019-04-01 2019-06-30 0001386570 cdxc:TruniagenConsumerProductMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:TruniagenConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:TruniagenConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:TruniagenConsumerProductMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:TruniagenConsumerProductMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:TruniagenConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:TruniagenConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:TruniagenConsumerProductMember 2019-04-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:TruniagenConsumerProductMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:TruniagenConsumerProductMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:TruniagenConsumerProductMember 2019-04-01 2019-06-30 0001386570 cdxc:NiagenIngredientMember 2020-04-01 2020-06-30 0001386570 cdxc:NiagenIngredientMember 2020-01-01 2020-06-30 0001386570 cdxc:NiagenIngredientMember 2019-04-01 2019-06-30 0001386570 cdxc:NiagenIngredientMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenIngredientMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenIngredientMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenIngredientMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenIngredientMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenIngredientMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenIngredientMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenIngredientMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenIngredientMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:NiagenIngredientMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:NiagenIngredientMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:NiagenIngredientMember 2019-04-01 2019-06-30 0001386570 cdxc:NiagenMember 2020-04-01 2020-06-30 0001386570 cdxc:NiagenMember 2020-01-01 2020-06-30 0001386570 cdxc:NiagenMember 2019-04-01 2019-06-30 0001386570 cdxc:NiagenMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:NiagenMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:NiagenMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:NiagenMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:NiagenMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:NiagenMember 2019-04-01 2019-06-30 0001386570 cdxc:OtherIngredientsMember 2020-04-01 2020-06-30 0001386570 cdxc:OtherIngredientsMember 2020-01-01 2020-06-30 0001386570 cdxc:OtherIngredientsMember 2019-04-01 2019-06-30 0001386570 cdxc:OtherIngredientsMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherIngredientsMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherIngredientsMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherIngredientsMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherIngredientsMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherIngredientsMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherIngredientsMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherIngredientsMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherIngredientsMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherIngredientsMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherIngredientsMember 2019-04-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherIngredientsMember 2019-01-01 2019-06-30 0001386570 cdxc:ReferenceStandardsMember 2020-04-01 2020-06-30 0001386570 cdxc:ReferenceStandardsMember 2020-01-01 2020-06-30 0001386570 cdxc:ReferenceStandardsMember 2019-04-01 2019-06-30 0001386570 cdxc:ReferenceStandardsMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ReferenceStandardsMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ReferenceStandardsMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ReferenceStandardsMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ReferenceStandardsMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ReferenceStandardsMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ReferenceStandardsMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ReferenceStandardsMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ReferenceStandardsMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ReferenceStandardsMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ReferenceStandardsMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ReferenceStandardsMember 2019-04-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ReferenceStandardsMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsultingAndOtherMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsultingAndOtherMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ConsultingAndOtherMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:ConsultingAndOtherMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ConsultingAndOtherMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:ConsultingAndOtherMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ConsultingAndOtherMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ConsultingAndOtherMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ConsultingAndOtherMember 2019-04-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:ConsultingAndOtherMember 2019-01-01 2019-06-30 0001386570 cdxc:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdxc:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdxc:OtherGoodsAndServicesMember 2019-04-01 2019-06-30 0001386570 cdxc:OtherGoodsAndServicesMember 2019-01-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherGoodsAndServicesMember 2019-04-01 2019-06-30 0001386570 cdxc:ConsumerProductsSegmentMember cdxc:OtherGoodsAndServicesMember 2019-01-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherGoodsAndServicesMember 2019-04-01 2019-06-30 0001386570 cdxc:IngredientsSegmentMember cdxc:OtherGoodsAndServicesMember 2019-01-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherGoodsAndServicesMember 2020-04-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherGoodsAndServicesMember 2020-01-01 2020-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherGoodsAndServicesMember 2019-04-01 2019-06-30 0001386570 cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember cdxc:OtherGoodsAndServicesMember 2019-01-01 2019-06-30 0001386570 cdxc:LifeExtensionMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001386570 cdxc:ASWatsonGroupMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001386570 cdxc:ASWatsonGroupMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001386570 cdxc:ASWatsonGroupMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001386570 cdxc:ASWatsonGroupMember us-gaap:TradeAccountsReceivableMember 2020-01-01 2020-06-30 0001386570 cdxc:ASWatsonGroupMember us-gaap:TradeAccountsReceivableMember 2019-01-01 2019-12-31 0001386570 cdxc:DrLogesMember us-gaap:TradeAccountsReceivableMember 2020-01-01 2020-06-30 0001386570 cdxc:ThorneResearchMember us-gaap:TradeAccountsReceivableMember 2020-01-01 2020-06-30 0001386570 cdxc:LifeExtensionMember us-gaap:TradeAccountsReceivableMember 2020-01-01 2020-06-30 0001386570 cdxc:LifeExtensionMember us-gaap:TradeAccountsReceivableMember 2019-01-01 2019-12-31 0001386570 cdxc:AmazonMarketplacesMember us-gaap:TradeAccountsReceivableMember 2019-01-01 2019-12-31 0001386570 cdxc:ManufacturingAndSupplyAgreementMember 2020-06-30 0001386570 cdxc:ElysiumHealthIncMember 2016-12-01 2016-12-29 0001386570 cdxc:LeaseAmendmentMember us-gaap:SubsequentEventMember 2020-01-01 2020-06-30 0001386570 cdxc:LeaseAmendmentMember us-gaap:SubsequentEventMember 2020-06-30 iso4217:USD shares iso4217:USD shares pure 0001386570 false --12-31 false Q2 2020 false 0.001 150000 61421 59562 10-Q true 2020-06-30 001-37752 CHROMADEX CORPORATION DE 26-2940963 10900 Wilshire Blvd Suite 600 Los Angeles CA 90024 310 388-6706 Common Stock, $0.001 par value per share CDXC NASDAQ Yes Yes Accelerated Filer true false 61624426 200000 200000 18890000 18812000 0.0 2800000 1100000 800000 3954000 2175000 12338000 11535000 584000 996000 35766000 33518000 3487000 3765000 1189000 1311000 705000 891000 845000 762000 41992000 40247000 9780000 9626000 5246000 4415000 632000 595000 134000 258000 250000 169000 16042000 15063000 3820000 3873000 522000 848000 27000 18000 20411000 19802000 0.001 150000000 61421000 59562000 61000 60000 153036000 142285000 -131513000 -121900000 -3000 0 21581000 20445000 41992000 40247000 15287000 11101000 29632000 21149000 6199000 4847000 12233000 9594000 9088000 6254000 17399000 11555000 4959000 4308000 9406000 8482000 942000 1069000 1861000 2237000 6874000 7932000 15709000 16263000 0 125000 0 125000 12775000 13434000 26976000 27107000 -3687000 -7180000 -9577000 -15552000 24000 575000 36000 540000 -24000 -575000 -36000 -540000 -3711000 -7755000 -9613000 -16092000 -0.06 -0.14 -0.16 -0.29 60906 55539 60344 55433 59605000 60000 144290000 -127802000 0 16548000 1225000 1000 4855000 0 0 4856000 591000 0 2180000 0 0 2180000 0 1711000 0 0 1711000 0 0 0 -3000 -3000 0 0 -3711000 0 -3711000 61421000 61000 153036000 -131513000 -3000 21581000 55321000 55000 119012000 -98090000 0 20977000 63000 0 164000 0 0 164000 0 1759000 0 0 1759000 0 0 -7755000 0 -7755000 55384000 55000 120935000 -105845000 0 15145000 59562000 60000 142285000 -121900000 0 20445000 1225000 1000 4855000 0 0 4856000 634000 0 2312000 0 0 2312000 0 3584000 0 0 3584000 0 0 0 -3000 -3000 0 0 -9613000 0 -9613000 61421000 61000 153036000 -131513000 -3000 21581000 55089000 55000 116876000 -89753000 0 27178000 128000 0 271000 0 0 271000 167000 0 3788000 0 0 3788000 0 0 -16092000 0 -16092000 55384000 55000 120935000 -105845000 0 15145000 -9613000 -16092000 432000 363000 122000 122000 187000 279000 3584000 3788000 2730000 8000 0 552000 51000 0 952000 -1373000 0 4000 -804000 -2465000 322000 50000 154000 -224000 830000 -671000 -53000 3873000 78000 18000 -289000 -285000 -6777000 -12069000 107000 308000 0 10000 15000 47000 -122000 -365000 4856000 0 0 10000000 0 565000 2312000 271000 30000 0 161000 128000 6977000 9578000 78000 -2856000 200000 18812000 22616000 200000 18890000 19760000 9000 17000 0 99000 47000 143000 0 64000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 1. Interim Financial Statements</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying financial statements of ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., Healthspan Research, LLC, ChromaDex Analytics, Inc. and ChromaDex Asia Limited (collectively referred to herein as “ChromaDex” or the “Company” or, in the first person as “we”, “us” and “our”) include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and results of operations and cash flows for the three and the six months ended June 30, 2020 and June 30, 2019. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2019 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 10, 2020, as amended on May 18, 2020. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results to be achieved for the full year ending on December 31, 2020.The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</p> <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 2. Nature of Business</strong></p><p style="margin:0px">  </p><p style="MARGIN: 0px; text-align:justify;">ChromaDex is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide and its impact on human health.Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive intellectual property protection.The Company also has analytical reference standards and services segment, which focuses on natural product fine chemicals (known as “phytochemicals”) and related chemistry services.</p> <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 3. Liquidity</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company's net cash outflow from operating activities was approximately $6.8 million for the six-month period ended June 30, 2020.As of June 30, 2020, cash and cash equivalents totaled approximately $18.9 million, which includes restricted cash of approximately $0.2 million.</p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company anticipates that its current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet its projected operating plans through at least the next twelve months from the issuance date of this report. The Company may, however, seek additional capital within the next twelve months, both to meet its projected operating plans within the next twelve months and/or to fund its longer-term strategic objectives. </p> 18900000 200000 7000000.0 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 4. Significant Accounting Policies</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Basis of presentation</span>:The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on December 31.</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Recent accounting standards</span>: In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit loss impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company can elect to defer compliance effective for fiscal years beginning after December 15, 2022. We are currently evaluating the impact of our pending adoption of ASU 2016-13 on our consolidated financial statements.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Basis of presentation</span>:The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on December 31.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Recent accounting standards</span>: In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit loss impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company can elect to defer compliance effective for fiscal years beginning after December 15, 2022. We are currently evaluating the impact of our pending adoption of ASU 2016-13 on our consolidated financial statements.</p> <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 5. Earnings Per Share Applicable to Common Stockholders</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and the six months ended June 30, 2020 and June 30, 2019:</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(In thousands, except per share data)</p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(3,711</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,755</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(9,613</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(16,092</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.06</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.16</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.29</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td/><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Basic and diluted weighted average common shares outstanding (1):</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>60,906</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,539</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>60,344</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,433</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Potentially dilutive securities (2):</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Stock options</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>11,457</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,174</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>11,457</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,174</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Convertible notes</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,192</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,192</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px">____________________________</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td colspan="7" style="width:78%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(1) Includes approximately 0.2 million and 0.2 million nonvested restricted stock for the periods ending June 30, 2020and June 30, 2019, respectively, which are participating securities that feature voting and dividend rights.</p></td></tr><tr style="height:15px"><td colspan="6" style="width:67%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(2) Excluded from the computation of loss per share as their impact is antidilutive.</p></td><td style="width:11%;"/></tr></tbody></table> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and the six months ended June 30, 2020 and June 30, 2019:</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(In thousands, except per share data)</p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(3,711</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,755</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(9,613</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(16,092</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.06</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.16</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.29</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td/><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Basic and diluted weighted average common shares outstanding (1):</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>60,906</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,539</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>60,344</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,433</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Potentially dilutive securities (2):</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Stock options</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>11,457</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,174</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>11,457</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,174</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Convertible notes</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,192</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,192</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> -3711000 -7755000 -9613000 -16092000 -0.06 -0.14 -0.16 -0.29 60906 55539 60344 55433 11457000 10174000 11457000 10174000 0 140000 0 140000 0 2192000 0 2192000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 6. Related Party Transactions</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Sale of consumer<strong> </strong>products</em></p><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="margin:0px"> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Three months ended<br/>Jun. 30, 2020</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Three months ended<br/>Jun. 30, 2019</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Six months ended<br/>Jun. 30, 2020</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Six months ended<br/>Jun. 30, 2019</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trade receivable at<br/>Jun. 30, 2020</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trade receivable at<br/>Dec. 31, 2019</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">A.S. Watson Group</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.3 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.9 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$3.1 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$3.2 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.0 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$0.8 million</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Horizon Ventures<sup>(1)</sup></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.6 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">-</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.6 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">-</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$0.1million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">-</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Total </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$2.9 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.9 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$4.7 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$3.2 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.1 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$0.8 million</p></td></tr></tbody></table><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td colspan="6" style="width:90%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">*A.S. Watson Group and Horizon Ventures are related parties through common ownership of an enterprise that beneficially owns more than 10% of the common stock of the Company.</p></td><td style="width:15%;"/></tr><tr style="height:15px"><td colspan="6"><p style="MARGIN: 0px; text-align:justify;">(1) For the three and six months ended June 30, 2020, Horizon Ventures made purchases to donate to the healthcare workers in Hong Kong hospitals.</p></td><td><p style="margin:0px"> </p></td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="margin:0px"> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Three months ended<br/>Jun. 30, 2020</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Three months ended<br/>Jun. 30, 2019</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Six months ended<br/>Jun. 30, 2020</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Net sales<br/>Six months ended<br/>Jun. 30, 2019</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trade receivable at<br/>Jun. 30, 2020</strong></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trade receivable at<br/>Dec. 31, 2019</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">A.S. Watson Group</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.3 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.9 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$3.1 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$3.2 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.0 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$0.8 million</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Horizon Ventures<sup>(1)</sup></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.6 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">-</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.6 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">-</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$0.1million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">-</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Total </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:16%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$2.9 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.9 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$4.7 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:14%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$3.2 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$1.1 million</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:15%;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">$0.8 million</p></td></tr></tbody></table> 1300000 1900000 3100000 3200000 1000000.0 800000 1600000 0 1600000 0 100000 0 2900000 1900000 4700000 3200000 1100000 800000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 7. Inventories</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">The amounts of major classes of inventory as of June 30, 2020 and December 31, 2019 are as follows:</p><p style="MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td><p style="margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2020</strong></p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Dec. 31, 2019</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consumer Products - Finished Goods </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>7,994</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">4,877</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consumer Products - Work in Process</p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2,996</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">4,659</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Bulk ingredients</p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>684</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">1,364</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Reference standards</p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>664</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">635</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>12,338</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">11,535</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td><p style="margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2020</strong></p></td><td><p style="margin:0px"> </p></td><td><p style="margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">Dec. 31, 2019</p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consumer Products - Finished Goods </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>7,994</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">4,877</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consumer Products - Work in Process</p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>2,996</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">4,659</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Bulk ingredients</p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>684</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">1,364</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Reference standards</p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>664</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">635</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>12,338</strong></p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="width:1%;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">$</p></td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"><p style="MARGIN: 0px 0px 0px 0in; text-align:right;">11,535</p></td><td style="width:1%;"><p style="margin:0px"> </p></td></tr></tbody></table> 7994000 4877000 2996000 4659000 684000 1364000 664000 635000 12338000 11535000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 8. Stock Issuance</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">On April 27, 2020, the Company entered into a Securities Purchase Agreement with related parties pursuant to which the Company agreed to sell and issue approximately 1.2 million shares for $5.0 million, or $4.08 per share. The selling price was determined by the average closing price over the ten trading days immediately preceding the date of Securities Purchase Agreement (the “Financing”).On May 7, 2020, the Company closed the Financing and received proceeds of $4.9 million, net of offering costs.</p> 1200000 5000000.0 4.08 4900000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 9. Leases</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><em><strong>Operating Leases</strong></em></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">As of June 30, 2020, the Company had operating lease assets in right of use assets of approximately $0.7 million and corresponding operating lease liabilities of approximately $1.2 million.For the three and the six months ended June 30, 2020 and June 30, 2019, the following were expenses incurred in connection with our operating leases:</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="13" style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Operating lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">360</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Variable lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">66</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">121</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">246</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">374</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">481</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Short-term lease rent expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">64</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">127</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">249</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">247</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">501</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">484</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px">   </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td/><td/><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;"/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Weighted-average remaining lease term (years) – operating leases</p></td><td style="width:1%;white-space: nowrap;"/><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.6</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Weighted-average discount rate – operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="margin:0px"> </p><p style="margin:0px">Minimum future lease payments under operating leases as of June 30, 2020 are as follows:</p><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six months ending December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">347</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">25</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,267</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Less present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">113</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,154</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Long-term obligations under operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">522</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Finance Leases</em></strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">As of June 30, 2020, the Company had finance lease assets in equipment assets of approximately $0.4 million and corresponding finance lease liabilities of approximately $0.2 million.For the three and the six months ended June 30, 2020 and June 30, 2019, the following were expenses incurred in connection with our finance leases:</p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="7" style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Amortization of equipment assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Interest on lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">66</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">54</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>At Jun. 30, 2020 </strong></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted-average remaining lease term (years) finance leases</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average discount rate finance leases</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.9</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Minimum future lease payments under finance leases as of June 30, 2020 are as follows: </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six Months Ending December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">115</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">168</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Less present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Finance lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Less current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Long-term obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 700000 1200000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="13" style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Operating lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">360</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Variable lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">65</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">66</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">121</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">246</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">374</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">481</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Short-term lease rent expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">64</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">127</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total expense</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">249</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">247</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">501</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">484</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 120000 180000 240000 360000 65000 66000 134000 121000 185000 246000 374000 481000 64000 1000 127000 3000 249000 247000 501000 484000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td/><td/><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;"/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Weighted-average remaining lease term (years) – operating leases</p></td><td style="width:1%;white-space: nowrap;"/><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.6</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Weighted-average discount rate – operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> P1Y7M6D 0.80 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six months ending December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">347</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">25</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,267</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Less present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">113</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,154</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Long-term obligations under operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">522</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 347000 614000 138000 143000 25000 1267000 113000 1154000 522000 400000 200000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Three Months Ended Jun. 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the Six Months Ended Jun. 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="7" style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Amortization of equipment assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">   Interest on lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">66</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">54</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 29000 15000 57000 37000 3000 10000 9000 17000 32000 25000 66000 54000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>At Jun. 30, 2020 </strong></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted-average remaining lease term (years) finance leases</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average discount rate finance leases</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.9</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> P1Y1M6D 0.79 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six Months Ending December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">115</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Year Ending December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">168</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Less present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Finance lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Less current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Long-term obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 115000 32000 21000 168000 7000 161000 134000 27000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 10. Share-Based Compensation</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><em><strong>Equity Plans</strong></em></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">On June 20, 2017, the stockholders of the Company approved the ChromaDex Corporation 2017 Equity Incentive Plan (the "2017 Plan"). The Company's Board of Directors amended the 2017 Plan in January 2018 and the stockholders of the Company approved amendments to the 2017 Plan in June 2018 and June 2020. The 2017 Plan is the successor to the ChromaDex Corporation Second Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan"). As of June 30, 2020, under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the 2007 Plan, (iii) any returning shares from the 2007 Plan or the 2017 Plan, such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 6.9 million shares at June 30, 2020. </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>General Vesting Conditions</em></strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">The stock option awards generally vest ratably over a three-year period following grant date after a passage of time. However, some stock option awards are market or performance based and vest based on certain triggering events established by the Compensation Committee of the Board of Directors.</p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The fair value of the Company’s stock options that are not market based was estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted during the six months ended June 30, 2020.</p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px"><strong>Six months Ended June 30, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px">Expected term</p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:right;">6 years </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Risk-free rate</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Expected dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><em><strong>Service Period Based Stock Options</strong></em></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes activity of service period-based stock options at June 30, 2020 and changes during the six months then ended (in thousands except per-share data and remaining contractual term):</p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Dec. 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,509</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.86</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.9</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,133</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.62</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.13</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(592</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.77</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">719</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(239</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.70</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(518</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.44</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,293</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.82</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7.1</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,322</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Exercisable at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,126</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.76</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.7</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,252</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">*</td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">______________</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">*The aggregate intrinsic values in the table above are based on the Company’s stock price of $4.59, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2020. </p><p style="margin:0px">  </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Performance Based</em></strong> <strong><em>Stock Options</em></strong></p><p style="MARGIN: 0px; text-align:justify;"> </p><p style="MARGIN: 0px; text-align:justify;">The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee of the Board of Directors. If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.</p><p style="MARGIN: 0px; text-align:justify;">The following table summarizes performance based stock options activity at June 30, 2020 and changes during the six months then ended (in thousands except per share data and remaining contractual term):</p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Dec. 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.89</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.1</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.26</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(42</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.89</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">164</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">41</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">*</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Exercisable at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">_________________</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">*The aggregate intrinsic values in the table above are based on the Company’s stock price of $4.59, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2020. </p><p style="margin:0px">  </p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong><em>Total Remaining Unamortized Compensation for Stock Options</em></strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">As of June 30, 2020, there was approximately $8.4 million of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options.That cost is expected to be recognized over a weighted average period of 2 years. </p><p style="margin:0px">  </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Share-Based Compensation</em></strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Share-based compensation expenses were as follows: </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ending</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six months ending</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="4" style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Share-based compensation expense</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>42</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>75</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>242</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>474</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>134</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>272</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,293</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>2,763</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,215</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong>     Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,711</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,759</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,584</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,788</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the 2007 Plan, (iii) any returning shares from the 2007 Plan or the 2017 Plan, such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 6.9 million shares at June 30, 2020. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px"><strong>Six months Ended June 30, 2020 </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="margin:0px">Expected term</p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:right;">6 years </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Risk-free rate</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Expected dividends</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> P6Y 66 1 0 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Dec. 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,509</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.86</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.9</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,133</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.62</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.13</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(592</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.77</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">719</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(239</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.70</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(518</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.44</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,293</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.82</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7.1</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,322</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Exercisable at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,126</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.76</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.7</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,252</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">*</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Weighted Average</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Remaining</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Dec. 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.89</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.1</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.26</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(42</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.89</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px;text-indent:11pt">Options Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Outstanding at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">164</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">41</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">*</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px">Exercisable at Jun. 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;"><p style="margin:0px"> </p></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 9509000 3.86 P6Y10M24D 2133000 3.62 P10Y 2.13 -592000 3.77 719000 -239000 4.70 -518000 3.44 10293000 3.82 P7Y1M6D 9322000 6126000 3.76 P5Y8M12D 6252000 4.59 42000 1.89 P3Y1M6D 164000 4.34 P4Y 2.26 -42000 1.89 100000 164 4.34 P3Y7M6D 41000 0 8400000 P2Y <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ending</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six months ending</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in">(In thousands)</p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">June 30, 2019</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="4" style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Share-based compensation expense</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>42</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>75</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>242</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>474</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>134</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>272</strong></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">  General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,293</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>2,763</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,215</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in"><strong>     Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,711</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,759</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,584</strong></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,788</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 42000 34000 75000 60000 242000 144000 474000 263000 134000 127000 272000 250000 1293000 1454000 2763000 3215000 1711000 1759000 3584000 3788000 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong><strong>Note 11.<span style="font:7pt &quot;times new roman&quot;"> </span></strong>Business Segments</strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has the following three reportable segments for the three- and six-month periods ended June 30, 2020: </p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:3%;"><p style="margin:0px"> </p></td><td style="width:3%;vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Consumer products segment: provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers as well as to distributors.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Ingredients segment: develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.</p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td><p style="margin:0px;text-indent:30px"> </p></td><td><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Analytical reference standards and services segment: includes supply of phytochemical reference standards and other research and development services.</p></td></tr></tbody></table><p style="margin:0px">  </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The “Corporate and other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.  </p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,850</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,287</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,339</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">725</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,715</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,088</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,743</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,959</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">805</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">942</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,548</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">213</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">140</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,775</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,833</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,502</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(148</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,687</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,387</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">970</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,101</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,519</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">641</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">687</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,847</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,225</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">283</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,254</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,072</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">157</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,308</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">875</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">194</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,069</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,932</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,932</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,947</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">273</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">157</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,057</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,434</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">278</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">473</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,057</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,180</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,325</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,443</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,632</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,641</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,191</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,401</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,233</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,223</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,399</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,152</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,406</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,587</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">274</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,861</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,739</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">266</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">262</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,976</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,484</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,868</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(220</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,577</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,881</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,070</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,149</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,590</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,550</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,594</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,608</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,427</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">520</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,555</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,989</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">302</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,482</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,844</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,237</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,263</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,263</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,833</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">584</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">302</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,107</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(225</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">843</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">218</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,388</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,552</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>At June 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,392</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,280</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">950</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24,370</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">41,992</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>At December 31, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">918</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,057</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,247</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Disaggregation of Revenue</em></strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">We disaggregate our revenue from contracts with customers by type of goods or services for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. See details in the tables below. </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Three Months Ended June 30, 2020<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">TRU NIAGEN®, Consumer Product</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">NIAGEN® Ingredient</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,995</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,995</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,995</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,715</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">855</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">855</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">686</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">686</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">31</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">31</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">855</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">717</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,572</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,850</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">717</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,287</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:left;"><strong>Three Months Ended June 30, 2019<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">TRU NIAGEN , Consumer Product</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">NIAGEN Ingredient</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,824</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">253</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">253</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">307</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">970</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,277</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">970</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,101</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six Months Ended June 30, 2020<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">TRU NIAGEN®, Consumer Product</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">NIAGEN® Ingredient</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 75px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,820</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,369</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,369</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,359</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,359</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">84</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">84</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,369</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,443</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,812</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,325</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,443</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,632</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six Months Ended June 30, 2019<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">TRU NIAGEN®, Consumer Product</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">NIAGEN® Ingredient</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,190</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,190</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,190</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">691</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">691</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,547</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,547</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">523</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">523</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">691</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,070</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,761</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,881</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,070</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,149</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px">  </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Disclosure of Major Customers</em></strong></p><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Major customers who accounted for more than 10% of the Company’s total sales were as follows:</p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Major Customers</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Horizon Ventures - Related Party</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">A.S. Watson Group - Related Party</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="mso-bookmark:_toc205655642"><span style="mso-bookmark:_toc205655952">Major accounts which had more than 10% of the Company’s total trade receivables were as follows:</span></span></p><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Percentage of the Company's Total Trade Receivables</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Major Accounts</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>At June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>At December 31, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">A.S. Watson Group - Related Party (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Dr. Loges</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Thorne Research</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Life Extension</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Amazon Marketplaces</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">_____________________</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">* Represents less than 10%.</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(1) Includes approximately $0.1 million trade receivables from Horizon Ventures.</p></td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,850</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,287</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,339</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">725</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,199</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,715</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,088</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,743</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,959</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">805</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">942</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,548</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">213</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">140</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,775</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,833</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,502</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(148</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,874</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,687</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,387</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">970</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,101</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,519</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">641</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">687</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,847</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,225</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">283</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,254</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,072</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">157</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,308</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">875</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">194</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,069</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,932</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,932</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,947</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">273</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">157</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,057</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,434</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">278</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">473</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">126</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,057</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,180</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,325</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,443</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,632</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,641</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,191</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,401</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,233</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,223</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,134</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,399</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,152</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,406</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,587</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">274</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,861</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,739</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">266</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">262</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,976</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,484</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,868</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(220</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,709</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,577</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>June 30, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,881</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,070</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,149</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,590</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,454</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,550</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,594</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Gross profit</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,608</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,427</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">520</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,555</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Sales and marketing</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,989</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">302</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,482</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,844</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,237</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,263</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,263</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:10pt">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">125</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,833</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">584</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">302</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,107</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in;text-indent:40.15pt"><strong>Operating income (loss)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(225</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">843</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">218</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,388</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,552</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>At June 30, 2020</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,392</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,280</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">950</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24,370</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">41,992</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>At December 31, 2019</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Products</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Standards and </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Corporate</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Services segment </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and other</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">918</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,057</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">40,247</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 11720000 2850000 717000 0 15287000 4339000 1135000 725000 0 6199000 7381000 1715000 -8000 0 9088000 4743000 76000 140000 0 4959000 805000 137000 0 0 942000 0 0 0 6874000 6874000 5548000 213000 140000 6874000 12775000 1833000 1502000 -148000 -6874000 -3687000 8744000 1387000 970000 0 11101000 3519000 641000 687000 0 4847000 5225000 746000 283000 0 6254000 4072000 79000 157000 0 4308000 875000 194000 0 0 1069000 0 0 0 7932000 7932000 0 0 0 125000 125000 4947000 273000 157000 8057000 13434000 278000 473000 126000 -8057000 -7180000 22864000 5325000 1443000 0 29632000 8641000 2191000 1401000 0 12233000 14223000 3134000 42000 0 17399000 9152000 8000 262000 0 9406000 1587000 274000 0 0 1861000 0 0 0 15709000 15709000 10739000 266000 262000 15709000 26976000 3484000 2868000 -220000 -15709000 -9577000 16198000 2881000 2070000 0 21149000 6590000 1454000 1550000 9594000 9608000 1427000 520000 0 11555000 7989000 191000 302000 0 8482000 1844000 393000 0 0 2237000 0 0 16263000 16263000 0 125000 125000 9833000 584000 302000 16388000 27107000 -225000 843000 218000 -16388000 -15552000 14392000 2280000 950000 24370000 41992000 12137000 2135000 918000 25057000 40247000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Three Months Ended June 30, 2020<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">TRU NIAGEN®, Consumer Product</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">NIAGEN® Ingredient</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,995</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,995</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,995</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,715</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">855</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">855</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">686</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">686</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">31</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">31</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">855</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">717</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,572</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,720</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,850</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">717</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,287</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:left;"><strong>Three Months Ended June 30, 2019<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">TRU NIAGEN , Consumer Product</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">NIAGEN Ingredient</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,824</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">253</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">253</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">307</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">970</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,277</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,744</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">970</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,101</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six Months Ended June 30, 2020<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">TRU NIAGEN®, Consumer Product</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">NIAGEN® Ingredient</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 75px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,820</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,369</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,369</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,359</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,359</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; text-align:left;">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">84</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">84</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,369</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,443</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,812</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,864</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,325</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,443</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,632</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Six Months Ended June 30, 2019<br/>(In thousands)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consumer<br/>Products<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Ingredients<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Analytical Reference Standards<br/>and Services<br/>Segment</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">TRU NIAGEN®, Consumer Product</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">NIAGEN® Ingredient</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,190</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,190</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Subtotal NIAGEN Related</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,190</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">18,388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="MARGIN: 0px; text-align:left;"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Other Ingredients</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">691</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">691</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Reference Standards</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,547</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,547</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Consulting and Other</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">523</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">523</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:left;">Subtotal Other Goods and Services</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">691</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,070</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,761</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px; text-align:left;">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,198</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,881</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,070</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,149</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr></tbody></table> 11720000 0 0 11720000 0 1995000 0 1995000 11720000 1995000 0 13715000 0 855000 0 855000 0 0 686000 686000 0 0 31000 31000 0 855000 717000 1572000 11720000 2850000 717000 15287000 8744000 0 0 8744000 0 1080000 0 1080000 8744000 1080000 0 9824000 0 307000 0 307000 0 0 717000 717000 0 0 253000 253000 0 307000 970000 1277000 8744000 1387000 970000 11101000 22864000 0 22864000 0 3956000 0 3956000 22864000 3956000 0 26820000 0 1369000 1369000 0 0 1359000 1359000 0 0 84000 84000 0 1369000 1443000 2812000 22864000 5325000 1443000 29632000 16198000 0 16198000 0 2190000 2190000 16198000 2190000 18388000 0 691000 0 691000 0 0 1547000 1547000 0 0 523000 523000 0 691000 2070000 2761000 16198000 2881000 2070000 21149000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Major Customers</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Jun. 30, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Horizon Ventures - Related Party</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">A.S. Watson Group - Related Party</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="margin:0px"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="mso-bookmark:_toc205655642"><span style="mso-bookmark:_toc205655952">Major accounts which had more than 10% of the Company’s total trade receivables were as follows:</span></span></p><p style="margin:0px">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Percentage of the Company's Total Trade Receivables</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="margin:0px 0px 0px 0in"><strong>Major Accounts</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>At June 30, 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>At December 31, 2019</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">A.S. Watson Group - Related Party (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Dr. Loges</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Thorne Research</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Life Extension</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Amazon Marketplaces</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td colspan="2"><p style="MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">_____________________</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">* Represents less than 10%.</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">(1) Includes approximately $0.1 million trade receivables from Horizon Ventures.</p></td></tr></tbody></table> 1.02 1.72 1.06 1.51 2.67 3.90 1.54 1.21 1.01 2.74 1.03 <p style="margin:0px 0px 0px 0in;text-indent:0in"><strong>Note 12. Commitments and Contingencies</strong></p><p style="margin:0px">  </p><p style="margin:0px"><strong><em>Inventory Purchase Obligations </em></strong></p><p style="MARGIN: 0px; text-align:justify;"> </p><p style="MARGIN: 0px; text-align:justify;"><span style="mso-bookmark:_toc205655642"><span style="mso-bookmark:_toc205655952">In the second quarter of 2020, the Company entered into an amended manufacturing and supply agreement whereby the Company is obligated to purchase approximately $17.4 million of total inventory through June 30, 2021.The Company’s remaining purchase obligations as of June 30, 2020 were as follows:</span></span></p><p style="margin:0px"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:50%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six Months Ending December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.3</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td><p style="margin:0px">Million</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six Months Ending June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td><p style="margin:0px">Million</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px; text-align:left;"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>11.6</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td><p style="margin:0px"><strong>Million</strong></p></td></tr></tbody></table><p style="margin:0px">  </p><p style="margin:0px"><strong><em>Legal</em></strong> <strong><em>proceedings - Elysium Health, LLC</em></strong> </p><p style="margin:0px"> </p><p style="margin:0px"><strong><em>(A) California Action</em></strong> </p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">On December 29, 2016, ChromaDex, Inc. filed a complaint in the United States District Court for the Central District of California, naming Elysium Health, Inc. (together with Elysium Health, LLC, “Elysium”) as defendant (the “Complaint”). On January 25, 2017, Elysium filed an answer and counterclaims in response to the Complaint (together with the Complaint, the “California Action”). Over the course of the California Action, the parties have each filed amended pleadings several times and have each engaged in several rounds of motions to dismiss and one round of motion for judgment on the pleadings with respect to various claims. Most recently, on November 27, 2018, ChromaDex, Inc. filed a fifth amended complaint that added an individual, Mark Morris, as a defendant. Elysium and Morris (“the Defendants”) moved to dismiss on December 21, 2018. The court denied Defendants’ motion on February 4, 2019. Defendants filed their answer to ChromaDex, Inc.'s fifth amended complaint on February 19, 2019. ChromaDex, Inc. filed an answer to Elysium’s restated counterclaims on March 5, 2019. Discovery closed on August 9, 2019.</p><p style="MARGIN: 0px; text-align:justify;">On August 16, 2019, the parties filed motions for partial summary judgment as to certain claims and counterclaims. The parties filed opposition briefs on August 28, 2019, and reply briefs on September 4, 2019. On October 9, 2019, among other things, the court vacated the previously scheduled trial date, ordered supplemental briefing with respect to certain issues related to summary judgment. Elysium filed its opening supplemental brief on October 30, 2019, ChromaDex filed its opening supplemental brief on November 18, 2019, and Elysium filed a reply brief on November 27, 2019, and the court heard argument on January 13, 2020. On January 16, 2020, the court granted both parties’ motions for summary judgment in part and denied both in part. On ChromaDex’s motion, the court granted summary judgment in favor of ChromaDex on Elysium’s counterclaims for (i) breach of contract related to manufacturing NIAGEN® according to the defined standard, selling NIAGEN and ingredients that are substantially similar to pterostilbene to other customers, distributing the NIAGEN® product specifications, and failing to provide information concerning the quality and identity of NIAGEN®, and (ii) breach of the implied covenant of good faith and fair dealing. The court denied summary judgment on Elysium’s counterclaims for (i) fraudulent inducement of the Trademark License and Royalty Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium (the “License Agreement”), (ii) patent misuse, and (iii) unjust enrichment. On Elysium’s motion, the court granted summary judgment in favor of Elysium on ChromaDex’s claim for damages related to $110,000in avoided costs arising from documents that Elysium used in violation of the Supply Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium, as amended (the “NIAGEN® Supply Agreement”). The court denied summary judgment on Elysium’s counterclaim for breach of contract related to certain refunds or credits to Elysium. The court also denied summary judgment on ChromaDex’s breach of contract claim against Morris and claims for disgorgement of $8.3 million in Elysium’s resale profits, $600,000 for a price discount received by Elysium, and $684,781 in Morris’s compensation.</p><p style="MARGIN: 0px; text-align:justify;">Following the court’s January 16, 2020 order, the claims that ChromaDex, Inc. presently asserts in the California Action, among other allegations, are that (i) Elysium breached the Supply Agreement, dated June 26, 2014, by and between ChromaDex, Inc. and Elysium (the “pTeroPure® Supply Agreement”), by failing to make payments to ChromaDex, Inc. for purchases of pTeroPure® and by improper disclosure of confidential ChromaDex, Inc. information pursuant to the pTeroPure® Supply Agreement, (ii) Elysium breached the NIAGEN® Supply Agreement, by failing to make payments to ChromaDex, Inc. for purchases of NIAGEN®, (iii) Defendants willfully and maliciously misappropriated ChromaDex, Inc. trade secrets concerning its ingredient sales business under both the California Uniform Trade Secrets Act and the Federal Defend Trade Secrets Act, (iv) Morris breached two confidentiality agreements he signed by improperly stealing confidential ChromaDex, Inc. documents and information, (v) Morris breached his fiduciary duty to ChromaDex, Inc. by lying to and competing with ChromaDex, Inc. while still employed there, and (vi) Elysium aided and abetted Morris’s breach of fiduciary duty. ChromaDex, Inc. is seeking damages and interest for Elysium’s alleged breaches of the NIAGEN® Supply Agreement and pTeroPure® Supply Agreement and Morris’s alleged breaches of his confidentiality agreements, compensatory damages and interest, punitive damages, injunctive relief, and attorney’s fees for Defendants’ alleged willful and malicious misappropriation of ChromaDex, Inc.’s trade secrets, and compensatory damages and interest, disgorgement of all benefits received, and punitive damages for Morris’s alleged breach of his fiduciary duty and Elysium’s aiding and abetting of that alleged breach.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">The claims that Elysium presently alleges in the California Action are that (i) ChromaDex, Inc. breached the NIAGEN® Supply Agreement by not issuing certain refunds or credits to Elysium, (ii) ChromaDex, Inc. fraudulently induced Elysium into entering into the License Agreement, (iv) ChromaDex, Inc.’s conduct constitutes misuse of its patent rights, and (v) ChromaDex, Inc. was unjustly enriched by the royalties Elysium paid pursuant to the License Agreement. Elysium is seeking damages for ChromaDex, Inc.’s alleged breaches of the NIAGEN® Supply Agreement, and compensatory damages, punitive damages, and/or rescission of the License Agreement and restitution of any royalty payments conveyed by Elysium pursuant to the License Agreement, and a declaratory judgment that ChromaDex, Inc. has engaged in patent misuse.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">On January 17, 2020, Elysium moved to substitute its counsel. The same day, the court ordered hearing on that motion for January 21, 2020, and granted Elysium’s motion at the hearing. On January 23, 2020, the court issued a scheduling order that, among other things, set trial on the remaining claims to begin on May 12, 2020. On March 19, 2020, in light of the global COVID-19 pandemic and ongoing private mediation efforts, the parties jointly stipulated to adjourn the trial date. The Court vacated the trial date on March 20, 2020. The Court held a telephonic status conference on June 9, 2020, during which the Court indicated that it will reschedule the jury trial as soon as conditions permit.</p><p style="margin:0px"> </p><p style="margin:0px"><strong><em>(B) Patent Office Proceedings</em></strong> </p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">On July 17, 2017, Elysium filed petitions with the U.S. Patent and Trademark Office for <em>inter partes</em> review of U.S. Patents 8,197,807 (the “’807 Patent”) and 8,383,086 (the “’086 Patent”), patents to which ChromaDex, Inc. is the exclusive licensee. The Patent Trial and Appeal Board (“PTAB”) denied institution of the <em>inter partes</em> review for the ’807 Patent on January 18, 2018. On January 29, 2018, the PTAB granted institution of the <em>inter partes</em> review as to claims 1 and 3-5 and denied institution as to claim 2 of the ’086 Patent. Based upon a recent U.S. Supreme Court decision, and solely on a procedural basis, the PTAB was required to include claim 2 in the trial of the <em>inter partes</em> review. The matter was heard on October 2, 2018. The PTAB issued its written decision on January 16, 2019, upholding claim 2 of the ’086 Patent which relates to the use of isolated NR in a pharmaceutical composition as valid. Elysium is now prevented from raising invalidity arguments against the ’086 Patent in the ongoing patent litigation in Delaware that it brought or could have brought before the PTAB in its <em>inter partes</em> review. Elysium appealed the PTAB’s decision with respect to claim 2 on March 6, 2019. A cross-appeal with respect to claims 1 and 3–5 was filed on March 20, 2019. Elysium filed its opening brief on June 17, 2019. Dartmouth moved to voluntarily dismiss its cross-appeal on August 14, 2019. The motion was granted on August 18, 2019. Dartmouth’s response brief was filed on August 28, 2019. Elysium’s reply brief was filed on October 9, 2019. Oral argument on Elysium’s appeal was heard on March 5, 2020. On March 6, 2020, the United States Court of Appeals for the Federal Circuit affirmed the PTAB’s decision, rejecting Elysium's attempt to invalidate claim 2 of the '086 patent. </p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>(C) Southern District of New York Action</em></strong> </p><p style="MARGIN: 0px; text-align:justify;">On September 27, 2017, Elysium Health Inc. ("Elysium Health") filed a complaint in the United States District Court for the Southern District of New York, against ChromaDex, Inc. (the “Elysium SDNY Complaint”). Elysium Health alleges in the Elysium SDNY Complaint that ChromaDex, Inc. made false and misleading statements in a citizen petition to the Food and Drug Administration it filed on or about August 18, 2017. Among other allegations, Elysium Health avers that the citizen petition made Elysium Health’s product appear dangerous, while casting ChromaDex, Inc.’s own product as safe. The Elysium SDNY Complaint asserts four claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. § 1125(a); (ii) trade libel; (iii) deceptive business practices under New York General Business Law § 349; and (iv) tortious interference with prospective economic relations. ChromaDex, Inc. denies the claims in the Elysium SDNY Complaint and intends to defend against them vigorously. On October 26, 2017, ChromaDex, Inc. moved to dismiss the Elysium SDNY Complaint on the grounds that, inter alia, its statements in the citizen petition are immune from liability under the Noerr-Pennington Doctrine, the litigation privilege, and New York’s Anti-SLAPP statute, and that the Elysium SDNY Complaint failed to state a claim. Elysium Health opposed the motion on November 2, 2017. ChromaDex, Inc. filed its reply on November 9, 2017.</p><p style="MARGIN: 0px; text-align:justify;">On October 26, 2017, ChromaDex, Inc. filed a complaint in the United States District Court for the Southern District of New York against Elysium Health (the “ChromaDex SDNY Complaint”). ChromaDex, Inc. alleges that Elysium Health made material false and misleading statements to consumers in the promotion, marketing, and sale of its health supplement product, Basis, and asserts five claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); (iii) deceptive practices under New York General Business Law § 349; (iv) deceptive practices under New York General Business Law § 350; and (v) tortious interference with prospective economic advantage. On November 16, 2017, Elysium Health moved to dismiss for failure to state a claim. ChromaDex, Inc. opposed the motion on November 30, 2017 and Elysium Health filed a reply on December 7, 2017.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">On November 3, 2017, the Court consolidated the Elysium SDNY Complaint and the ChromaDex SDNY Complaint actions under the caption In re Elysium Health-ChromaDex Litigation, 17-cv-7394, and stayed discovery in the consolidated action pending a Court-ordered mediation. The mediation was unsuccessful. On September 27, 2018, the Court issued a combined ruling on both parties’ motions to dismiss. For ChromaDex’s motion to dismiss, the Court converted the part of the motion on the issue of whether the citizen petition is immune under the Noerr-Pennington Doctrine into a motion for summary judgment, and requested supplemental evidence from both parties, which were submitted on October 29, 2018. The Court otherwise denied the motion to dismiss. On January 3, 2019, the Court granted ChromaDex, Inc.’s motion for summary judgment under the Noerr-Pennington Doctrine and dismissed all claims in the Elysium SDNY Complaint. Elysium moved for reconsideration on January 17, 2019. The Court denied Elysium’s motion for reconsideration on February 6, 2019, and issued an amended final order granting ChromaDex, Inc.’s motion for summary judgment on February 7, 2019.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">The Court granted in part and denied in part Elysium’s motion to dismiss, sustaining three grounds for ChromaDex’s Lanham Act claims while dismissing two others, sustaining the claim under New York General Business Law § 349, and dismissing the claims under New York General Business Law § 350 and for tortious interference. Elysium filed an answer and counterclaims on October 10, 2018, alleging claims for (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); and (iii) deceptive practices under New York General Business Law § 349. ChromaDex answered Elysium’s counterclaims on November 2, 2018.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">ChromaDex, Inc. filed an amended complaint on March 27, 2019, adding new claims against Elysium Health for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On April 10, 2019, Elysium Health answered the amended complaint and filed amended counterclaims, also adding new claims against ChromaDex, Inc. for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On July 1, 2019, Elysium Health filed further amended counterclaims, adding new claims under the Copyright Act §§ 106 &amp; 501. On February 9, 2020, ChromaDex, Inc. filed a motion for leave to amend its complaint to add additional claims against Elysium Health for false advertising and unfair competition. On February 10, 2020, Elysium Health filed a motion for leave to amend its counterclaims to identify allegedly false and misleading statements in ChromaDex’s advertising. Those motions were both granted after respective stipulations. On March 12, 2020, Elysium Health answered the second amended complaint. On March 13, 2020, ChromaDex, Inc. filed an answer and objection to Elysium Health’s third amended counterclaims.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">The Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to the legal proceedings discussed herein. As of June 30, 2020, ChromaDex, Inc. did not accrue a potential loss for the California Action or the Elysium SDNY Complaint because ChromaDex, Inc. believes that the allegations are without merit and thus it is not probable that a liability has been incurred. </p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>(D) Delaware – Patent Infringement Action</em></strong> </p><p style="MARGIN: 0px; text-align:justify;">On September 17, 2018, ChromaDex, Inc. and Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. The complaint alleges that Elysium’s BASIS® dietary supplement violates U.S. Patents 8,197,807 (the “’807 Patent”) and 8,383,086 (the “’086 Patent”) that comprise compositions containing isolated nicotinamide riboside held by Dartmouth and licensed exclusively to ChromaDex, Inc. On October 23, 2018, Elysium filed an answer to the complaint. The answer asserts various affirmative defenses and denies that Plaintiffs are entitled to any relief.</p><p style="MARGIN: 0px; text-align:justify;">On November 7, 2018, Elysium filed a motion to stay the patent infringement proceedings pending resolution of (1) the <em>inter partes</em> review of the ’807 Patent and the ’086 Patent before the Patent Trial and Appeal Board (“PTAB”) and (2) the outcome of the litigation in the California Action. ChromaDex, Inc. filed an opposition brief on November 21, 2018 detailing the issues with Elysium’s motion to stay. In particular, ChromaDex, Inc. argued that given claim 2 of the ’086 Patent was only included in the PTAB’s <em>inter partes</em> review for procedural reasons the PTAB was unlikely to invalidate claim 2 and therefore litigation in Delaware would continue regardless. In addition, ChromaDex, Inc. argued that the litigation in the California Action is unlikely to have a significant effect on the ongoing patent litigation. After the PTAB released its written decision upholding claim 2 of the ’086 Patent, proving right ChromaDex, Inc.’s prediction, ChromaDex, Inc. informed the Delaware court of the PTAB’s decision on January 17, 2019. On June 19, 2019, the Delaware court granted in part and denied in part Elysium’s motion, ordering that the case was stayed pending the resolution of Elysium’s patent misuse counterclaim in the California Action.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">On November 1, 2019, ChromaDex, Inc. filed a motion to lift the stay due to changed circumstances in the California Action, among other reasons. Briefing on the motion was completed on November 22, 2019. On January 6, 2020, the Delaware court issued an oral order instructing the parties to submit a joint status report after the January 13, 2020 motions hearing in the California Action. The joint status report was submitted on January 30, 2020. On February 4, 2020, the Delaware court issued an order granting ChromaDex, Inc.’s motion to lift the stay and setting a scheduling conference for March 10, 2020. On March 19, 2020, the Delaware court entered a scheduling order, which, among other things, set the claim-construction hearing for December 17, 2020 and trial for the week of September 27, 2021. On April 17, 2020, ChromaDex, Inc. served infringement contentions. On April 24, 2020, ChromaDex, Inc. moved for leave to amend the complaint to add Healthspan Research, LLC as a plaintiff. On May 5, 2020, Elysium filed its opposition to ChromaDex, Inc.’s motion for leave to amend and moved to dismiss ChromaDex, Inc. for alleged lack of standing. ChromaDex, Inc. filed its opposition to Elysium’s motion to dismiss and reply in support of its motion to amend on May 19, 2020. Elysium filed its reply in support of its motion to dismiss on May 26, 2020. Elysium filed a Second Amended Answer on July 10, 2020. On July 22, 2020 the parties filed a Joint Claim Construction Chart and respective motions for claim construction. The parties’ Joint Claim Construction Brief is due on November 5, 2020. The Court will hold a <em>Markman</em> hearing on claim-construction issues on December 17, 2020.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;">From time to time we are involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.</p><p style="margin:0px"> </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Contingencies</em></strong></p><p style="MARGIN: 0px; text-align:justify;">In September 2019, the Company received a letter from a licensor stating that the Company owed the licensor $1.6 million plus interest of sublicense fees as a result of the Company entering into the supply agreement with a customer. After reviewing the relevant facts and circumstances, the Company believes that the Company does not owe any sublicense fees to the licensor and has corresponded with the licensor to resolve the matter. The Company does not believe that the ultimate resolution of this matter will be material to the Company’s results of operations, financial condition or cash flows.</p> 17400000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:50%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six Months Ending December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.3</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td><p style="margin:0px">Million</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="margin:0px 0px 0px 0in">Six Months Ending June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td><p style="margin:0px">Million</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px; text-align:left;"><strong>Total</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>11.6</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px"> </p></td><td><p style="margin:0px"><strong>Million</strong></p></td></tr></tbody></table> 7300000 4300000 11600000 110000 The court also denied summary judgment on ChromaDex’s breach of contract claim against Morris and claims for disgorgement of $8.3 million in Elysium’s resale profits, $600,000 for a price discount received by Elysium, and $684,781 in Morris’s compensation. <strong>Note 13. Subsequent Event</strong> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"> </p><p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Subsequent to the period ended June 30, 2020, the Company entered into a lease amendment to lease additional space located in Longmont, Colorado. The lease amendment also extends the expiration of the lease period from February 2024 to December 2025. Pursuant to the lease amendment, the Company will make additional total lease payments of approximately $1.1 million during the term of the lease.</p> from February 2024 to December 2025 1100000 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover - shares
6 Months Ended
Jun. 30, 2020
Aug. 05, 2020
Cover [Abstract]    
Entity Registrant Name CHROMADEX CORPORATION  
Entity Central Index Key 0001386570  
Document Type 10-Q  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Current Reporting Status Yes  
Document Period End Date Jun. 30, 2020  
Entity Filer Category Accelerated Filer  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2020  
Entity Common Stock Shares Outstanding   61,624,426
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Entity File Number 001-37752  
Entity Incorporation State Country Code DE  
Entity Tax Identification Number 26-2940963  
Entity Address Address Line 1 10900 Wilshire Blvd  
Entity Address Address Line 2 Suite 600  
Entity Address City Or Town Los Angeles  
Entity Address State Or Province CA  
Entity Address Postal Zip Code 90024  
City Area Code 310  
Local Phone Number 388-6706  
Security 12b Title Common Stock, $0.001 par value per share  
Trading Symbol CDXC  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2020
Dec. 31, 2019
Current Assets    
Cash, including restricted cash of $0.2 million and $0.2 million, respectively $ 18,890,000 $ 18,812,000
Trade receivables, net of allowances of $0.0 million and $2.8 million, respectively; Receivables from Related Party: $1.1 million and $0.8 million, respectively 3,954,000 2,175,000
Inventories 12,338,000 11,535,000
Prepaid expenses and other assets 584,000 996,000
Total current assets 35,766,000 33,518,000
Leasehold Improvements and Equipment, net 3,487,000 3,765,000
Intangible Assets, net 1,189,000 1,311,000
Right of Use Assets 705,000 891,000
Other Long-term Assets 845,000 762,000
Total assets 41,992,000 40,247,000
Current Liabilities    
Accounts payable 9,780,000 9,626,000
Accrued expenses 5,246,000 4,415,000
Current maturities of operating lease obligations 632,000 595,000
Current maturities of finance lease obligations 134,000 258,000
Customer deposits 250,000 169,000
Total current liabilities 16,042,000 15,063,000
Deferred Revenue 3,820,000 3,873,000
Operating Lease Obligations, Less Current Maturities 522,000 848,000
Finance Lease Obligations, Less Current Maturities 27,000 18,000
Total liabilities 20,411,000 19,802,000
Stockholders' Equity    
Common stock, $.001 par value; authorized 150,000 shares; issued and outstanding June 30, 2020 61,421 shares and December 31, 2019 59,562 shares 61,000 60,000
Additional paid-in capital 153,036,000 142,285,000
Accumulated deficit (131,513,000) (121,900,000)
Cumulative translation adjustments (3,000) 0
Total stockholders' equity 21,581,000 20,445,000
Total liabilities and stockholders' equity $ 41,992,000 $ 40,247,000
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Jun. 30, 2020
Dec. 31, 2019
Condensed Consolidated Balance Sheets (Unaudited)    
Restricted cash $ 0.2 $ 0.2
Trade receivables, allowances 0.0 2.8
Receivables from related party, Allowances $ 1.1 $ 0.8
Common stock, par value per share $ 0.001 $ 0.001
Common stock, shares authorized (in thousands) 150,000,000 150,000
Common stock, shares, issued (in thousands) 61,421,000 59,562,000
Common stock, shares, outstanding (in thousands) 61,421 59,562
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Condensed Consolidated Statements of Operations (Unaudited)        
Sales, net $ 15,287,000 $ 11,101,000 $ 29,632,000 $ 21,149,000
Cost of sales 6,199,000 4,847,000 12,233,000 9,594,000
Gross profit 9,088,000 6,254,000 17,399,000 11,555,000
Operating expenses:        
Sales and marketing 4,959,000 4,308,000 9,406,000 8,482,000
Research and development 942,000 1,069,000 1,861,000 2,237,000
General and administrative 6,874,000 7,932,000 15,709,000 16,263,000
Other 0 125,000 0 125,000
Operating expenses 12,775,000 13,434,000 26,976,000 27,107,000
Operating loss (3,687,000) (7,180,000) (9,577,000) (15,552,000)
Nonoperating expense:        
Interest expense, net (24,000) (575,000) (36,000) (540,000)
Nonoperating expense (24,000) (575,000) (36,000) (540,000)
Net loss $ (3,711,000) $ (7,755,000) $ (9,613,000) $ (16,092,000)
Basic and diluted loss per common share $ (0.06) $ (0.14) $ (0.16) $ (0.29)
Basic and diluted weighted average        
common shares outstanding 60,906 55,539 60,344 55,433
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Cumulative Translation Adjustments
Balance, shares at Dec. 31, 2018   55,089      
Balance, amount at Dec. 31, 2018 $ 27,178,000 $ 55,000 $ 116,876,000 $ (89,753,000) $ 0
Exercise of stock options, shares   128      
Exercise of stock options, amount 271,000 $ 0 271,000 0 0
Net loss (16,092,000) $ 0 0 (16,092,000) 0
Share-based compensation, shares   167      
Share-based compensation, amount 3,788,000 $ 0 3,788,000 0 0
Balance, shares at Jun. 30, 2019   55,384      
Balance, amount at Jun. 30, 2019 15,145,000 $ 55,000 120,935,000 (105,845,000) 0
Balance, shares at Mar. 31, 2019   55,321      
Balance, amount at Mar. 31, 2019 20,977,000 $ 55,000 119,012,000 (98,090,000) 0
Exercise of stock options, shares   63      
Exercise of stock options, amount 164,000 $ 0 164,000 0 0
Share-based compensation 1,759,000 0 1,759,000 0 0
Net loss (7,755,000) $ 0 0 (7,755,000) 0
Balance, shares at Jun. 30, 2019   55,384      
Balance, amount at Jun. 30, 2019 15,145,000 $ 55,000 120,935,000 (105,845,000) 0
Balance, shares at Dec. 31, 2019   59,562      
Balance, amount at Dec. 31, 2019 20,445,000 $ 60,000 142,285,000 (121,900,000) 0
Issuance of common stock, net of offering costs of $0.1 million, shares   1,225      
Issuance of common stock, net of offering costs of $0.1 million, amount 4,856,000 $ 1,000 4,855,000 0 0
Exercise of stock options, shares   634      
Exercise of stock options, amount 2,312,000 $ 0 2,312,000 0 0
Share-based compensation 3,584,000 0 3,584,000 0 0
Translation adjustment (3,000) 0 0 0 (3,000)
Net loss (9,613,000) $ 0 0 (9,613,000) 0
Balance, shares at Jun. 30, 2020   61,421      
Balance, amount at Jun. 30, 2020 21,581,000 $ 61,000 153,036,000 (131,513,000) (3,000)
Balance, shares at Mar. 31, 2020   59,605      
Balance, amount at Mar. 31, 2020 16,548,000 $ 60,000 144,290,000 (127,802,000) 0
Issuance of common stock, net of offering costs of $0.1 million, shares   1,225      
Issuance of common stock, net of offering costs of $0.1 million, amount 4,856,000 $ 1,000 4,855,000 0 0
Exercise of stock options, shares   591      
Exercise of stock options, amount 2,180,000 $ 0 2,180,000 0 0
Share-based compensation 1,711,000 0 1,711,000 0 0
Translation adjustment (3,000) 0 0 0 (3,000)
Net loss (3,711,000) $ 0 0 (3,711,000) 0
Balance, shares at Jun. 30, 2020   61,421      
Balance, amount at Jun. 30, 2020 $ 21,581,000 $ 61,000 $ 153,036,000 $ (131,513,000) $ (3,000)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash Flows From Operating Activities    
Net loss $ (9,613,000) $ (16,092,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of leasehold improvements and equipment 432,000 363,000
Amortization of intangibles 122,000 122,000
Amortization of right of use assets 187,000 279,000
Share-based compensation expense 3,584,000 3,788,000
Allowance for doubtful trade receivables (2,730,000) (8,000)
Amortization of convertible notes issuance costs 0 552,000
Non-cash financing costs 51,000 0
Changes in operating assets and liabilities:    
Trade receivables 952,000 (1,373,000)
Contract assets 0 4,000
Inventories (804,000) (2,465,000)
Prepaid expenses and other assets 322,000 50,000
Accounts payable 154,000 (224,000)
Accrued expenses 830,000 (671,000)
Deferred revenue (53,000) 3,873,000
Customer deposits and other 78,000 18,000
Principal payments on operating leases (289,000) (285,000)
Net cash used in operating activities (6,777,000) (12,069,000)
Cash Flows From Investing Activities    
Purchases of leasehold improvements and equipment (107,000) (308,000)
Purchases of intangible assets 0 (10,000)
Investment in other long-term assets (15,000) (47,000)
Net cash used in investing activities (122,000) (365,000)
Cash Flows From Financing Activities    
Proceeds from issuance of common stock, net 4,856,000 0
Proceeds from sale of convertible notes 0 10,000,000
Payment of convertible notes issuance costs 0 (565,000)
Proceeds from exercise of stock options 2,312,000 271,000
Payment of debt issuance costs (30,000) 0
Principal payments on finance leases (161,000) (128,000)
Net cash provided by financing activities 6,977,000 9,578,000
Net increase (decrease) in cash 78,000 (2,856,000)
Cash Beginning of Period, including restricted cash of $0.2 million for both 2020 and 2019 18,812,000 22,616,000
Cash Ending of Period, including restricted cash $0.2 million for both 2020 and 2019 18,890,000 19,760,000
Supplemental Disclosures of Cash Flow Information    
Cash payments for interest on finance leases 9,000 17,000
Supplemental Schedule of Noncash Operating Activity    
Financing lease obligation incurred for prepayment of licensing fees 0 99,000
Supplemental Schedule of Noncash Investing Activity    
Financing lease obligation incurred for purchase of computer equipment and software 47,000 143,000
Operating lease obligation incurred for tenant improvement credit received $ 0 $ 64,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Millions
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Condensed Consolidated Statements of Cash Flows (Unaudited)      
Restricted cash $ 0.2 $ 0.2 $ 0.2
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Interim Financial Statements
6 Months Ended
Jun. 30, 2020
Interim Financial Statements  
1. Interim Financial Statements

Note 1. Interim Financial Statements

 

The accompanying financial statements of ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., Healthspan Research, LLC, ChromaDex Analytics, Inc. and ChromaDex Asia Limited (collectively referred to herein as “ChromaDex” or the “Company” or, in the first person as “we”, “us” and “our”) include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and results of operations and cash flows for the three and the six months ended June 30, 2020 and June 30, 2019. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2019 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 10, 2020, as amended on May 18, 2020. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results to be achieved for the full year ending on December 31, 2020.The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

 

The balance sheet at December 31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business
6 Months Ended
Jun. 30, 2020
Nature of Business  
2. Nature of Business

Note 2. Nature of Business

  

ChromaDex is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide and its impact on human health.Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive intellectual property protection.The Company also has analytical reference standards and services segment, which focuses on natural product fine chemicals (known as “phytochemicals”) and related chemistry services.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Liquidity
6 Months Ended
Jun. 30, 2020
Nature of Business  
3. Liquidity

Note 3. Liquidity

 

The Company's net cash outflow from operating activities was approximately $6.8 million for the six-month period ended June 30, 2020.As of June 30, 2020, cash and cash equivalents totaled approximately $18.9 million, which includes restricted cash of approximately $0.2 million.

 

The Company anticipates that its current cash, cash equivalents, cash to be generated from operations and available line of credit up to $7.0 million from Western Alliance Bank will be sufficient to meet its projected operating plans through at least the next twelve months from the issuance date of this report. The Company may, however, seek additional capital within the next twelve months, both to meet its projected operating plans within the next twelve months and/or to fund its longer-term strategic objectives.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies
6 Months Ended
Jun. 30, 2020
Significant Accounting Policies  
4. Significant Accounting Policies

Note 4. Significant Accounting Policies

 

Basis of presentation:The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on December 31.

Recent accounting standards: In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit loss impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company can elect to defer compliance effective for fiscal years beginning after December 15, 2022. We are currently evaluating the impact of our pending adoption of ASU 2016-13 on our consolidated financial statements.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share Applicable to Common Stockholders
6 Months Ended
Jun. 30, 2020
Earnings Per Share Applicable to Common Stockholders  
5. Earnings Per Share Applicable to Common Stockholders

Note 5. Earnings Per Share Applicable to Common Stockholders

 

The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and the six months ended June 30, 2020 and June 30, 2019:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands, except per share data)

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(3,711)

 

$(7,755)

 

$(9,613)

 

$(16,092)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$(0.06)

 

$(0.14)

 

$(0.16)

 

$(0.29)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted weighted average common shares outstanding (1):

 

 

60,906

 

 

 

55,539

 

 

 

60,344

 

 

 

55,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potentially dilutive securities (2):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Stock options

 

 

11,457

 

 

 

10,174

 

 

 

11,457

 

 

 

10,174

 

  Warrants

 

 

-

 

 

 

140

 

 

 

-

 

 

 

140

 

  Convertible notes

 

 

-

 

 

 

2,192

 

 

 

-

 

 

 

2,192

 

____________________________

(1) Includes approximately 0.2 million and 0.2 million nonvested restricted stock for the periods ending June 30, 2020and June 30, 2019, respectively, which are participating securities that feature voting and dividend rights.

(2) Excluded from the computation of loss per share as their impact is antidilutive.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions
6 Months Ended
Jun. 30, 2020
Related Party Transactions  
6. Related Party Transactions

Note 6. Related Party Transactions

 

Sale of consumer products

  

 

Net sales
Three months ended
Jun. 30, 2020

Net sales
Three months ended
Jun. 30, 2019

Net sales
Six months ended
Jun. 30, 2020

Net sales
Six months ended
Jun. 30, 2019

Trade receivable at
Jun. 30, 2020

Trade receivable at
Dec. 31, 2019

A.S. Watson Group

$1.3 million

$1.9 million

$3.1 million

$3.2 million

$1.0 million

$0.8 million

Horizon Ventures(1)

$1.6 million

-

$1.6 million

-

$0.1million

-

Total

$2.9 million

$1.9 million

$4.7 million

$3.2 million

$1.1 million

$0.8 million

 

*A.S. Watson Group and Horizon Ventures are related parties through common ownership of an enterprise that beneficially owns more than 10% of the common stock of the Company.

(1) For the three and six months ended June 30, 2020, Horizon Ventures made purchases to donate to the healthcare workers in Hong Kong hospitals.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories
6 Months Ended
Jun. 30, 2020
Inventories  
7. Inventories

Note 7. Inventories

 

The amounts of major classes of inventory as of June 30, 2020 and December 31, 2019 are as follows:

 

(In thousands)

 

Jun. 30, 2020

 

 

Dec. 31, 2019

 

Consumer Products - Finished Goods

 

$

7,994

 

 

 

4,877

 

Consumer Products - Work in Process

 

 

2,996

 

 

 

4,659

 

Bulk ingredients

 

 

684

 

 

$

1,364

 

Reference standards

 

 

664

 

 

 

635

 

 

 

$

12,338

 

 

$

11,535

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Stock Issuance
6 Months Ended
Jun. 30, 2020
Stock Issuance  
8. Stock Issuance

Note 8. Stock Issuance

 

On April 27, 2020, the Company entered into a Securities Purchase Agreement with related parties pursuant to which the Company agreed to sell and issue approximately 1.2 million shares for $5.0 million, or $4.08 per share. The selling price was determined by the average closing price over the ten trading days immediately preceding the date of Securities Purchase Agreement (the “Financing”).On May 7, 2020, the Company closed the Financing and received proceeds of $4.9 million, net of offering costs.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
6 Months Ended
Jun. 30, 2020
Leases  
9. Leases

Note 9. Leases

 

Operating Leases

 

As of June 30, 2020, the Company had operating lease assets in right of use assets of approximately $0.7 million and corresponding operating lease liabilities of approximately $1.2 million.For the three and the six months ended June 30, 2020 and June 30, 2019, the following were expenses incurred in connection with our operating leases:

 

 

 

For the Three Months Ended Jun. 30, 2020

 

 

For the Three Months Ended Jun. 30, 2019

 

 

For the Six Months Ended Jun. 30, 2020

 

 

For the Six Months Ended Jun. 30, 2019

 

(In thousands)

 

 

 

 

Operating leases

 

 

 

 

 

 

 

 

 

 

 

 

   Operating lease expense

 

$120

 

 

$180

 

 

$240

 

 

$360

 

   Variable lease expense

 

 

65

 

 

 

66

 

 

 

134

 

 

 

121

 

Operating lease expense

 

 

185

 

 

 

246

 

 

 

374

 

 

 

481

 

Short-term lease rent expense

 

 

64

 

 

 

1

 

 

 

127

 

 

 

3

 

Total expense

 

$249

 

 

$247

 

 

$501

 

 

$484

 

  

 

Weighted-average remaining lease term (years) – operating leases

 

1.6

 

Weighted-average discount rate – operating leases

 

 

8.0%

 

Minimum future lease payments under operating leases as of June 30, 2020 are as follows:

  

 

 

 

 

Six months ending December 31, 2020

 

$347

 

Year Ending December 31, 2021

 

 

614

 

Year Ending December 31, 2022

 

 

138

 

Year Ending December 31, 2023

 

 

143

 

Year Ending December 31, 2024

 

 

25

 

Total

 

 

1,267

 

Less present value discount

 

 

113

 

Operating lease liabilities

 

 

1,154

 

Long-term obligations under operating leases

 

$522

 

Finance Leases

 

As of June 30, 2020, the Company had finance lease assets in equipment assets of approximately $0.4 million and corresponding finance lease liabilities of approximately $0.2 million.For the three and the six months ended June 30, 2020 and June 30, 2019, the following were expenses incurred in connection with our finance leases:

 

 

 

For the Three Months Ended Jun. 30, 2020

 

 

For the Three Months Ended Jun. 30, 2019

 

 

For the Six Months Ended Jun. 30, 2020

 

 

For the Six Months Ended Jun. 30, 2019

 

(In thousands)

 

 

 

 

 

 

 

 

Finance leases

 

 

 

 

 

 

 

 

 

 

 

 

   Amortization of equipment assets

 

$29

 

 

$15

 

 

$57

 

 

$37

 

   Interest on lease liabilities

 

 

3

 

 

 

10

 

 

 

9

 

 

 

17

 

Total expenses

 

$32

 

 

$25

 

 

$66

 

 

$54

 

 

 

 

At Jun. 30, 2020

 

Weighted-average remaining lease term (years) finance leases

 

 

1.1

 

Weighted-average discount rate finance leases

 

 

7.9%

 

Minimum future lease payments under finance leases as of June 30, 2020 are as follows: 

 

(In thousands)

 

 

 

Six Months Ending December 31, 2020

 

$115

 

Year Ending December 31, 2021

 

 

32

 

Year Ending December 31, 2022

 

 

21

 

Total

 

 

168

 

Less present value discount

 

 

7

 

Finance lease liabilities

 

 

161

 

Less current portion

 

 

134

 

Long-term obligations under finance leases

 

$27

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation
6 Months Ended
Jun. 30, 2020
ShareBased Compensation  
10. Share-Based Compensation

Note 10. Share-Based Compensation

 

Equity Plans

 

On June 20, 2017, the stockholders of the Company approved the ChromaDex Corporation 2017 Equity Incentive Plan (the "2017 Plan"). The Company's Board of Directors amended the 2017 Plan in January 2018 and the stockholders of the Company approved amendments to the 2017 Plan in June 2018 and June 2020. The 2017 Plan is the successor to the ChromaDex Corporation Second Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan"). As of June 30, 2020, under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the 2007 Plan, (iii) any returning shares from the 2007 Plan or the 2017 Plan, such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 6.9 million shares at June 30, 2020.

General Vesting Conditions

 

The stock option awards generally vest ratably over a three-year period following grant date after a passage of time. However, some stock option awards are market or performance based and vest based on certain triggering events established by the Compensation Committee of the Board of Directors.

 

The fair value of the Company’s stock options that are not market based was estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted during the six months ended June 30, 2020.

 

Six months Ended June 30, 2020

 

 

Expected term

 

6 years

 

Expected volatility

 

 

66%

Risk-free rate

 

 

1%

Expected dividends

 

 

0%

 

Service Period Based Stock Options

 

The following table summarizes activity of service period-based stock options at June 30, 2020 and changes during the six months then ended (in thousands except per-share data and remaining contractual term):

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Fair

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

 

Value

 

Outstanding at Dec. 31, 2019

 

 

9,509

 

 

$3.86

 

 

 

6.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

2,133

 

 

 

3.62

 

 

 

10.0

 

 

$2.13

 

 

 

 

Options Exercised

 

 

(592)

 

 

3.77

 

 

 

 

 

 

 

 

 

 

$719

 

Options Expired

 

 

(239)

 

 

4.70

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Forfeited

 

 

(518)

 

 

3.44

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at Jun. 30, 2020

 

 

10,293

 

 

$3.82

 

 

 

7.1

 

 

 

 

 

 

$9,322*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at Jun. 30, 2020

 

 

6,126

 

 

$3.76

 

 

 

5.7

 

 

 

 

 

 

$6,252*

______________

*The aggregate intrinsic values in the table above are based on the Company’s stock price of $4.59, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2020.

  

Performance Based Stock Options

 

The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee of the Board of Directors. If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.

The following table summarizes performance based stock options activity at June 30, 2020 and changes during the six months then ended (in thousands except per share data and remaining contractual term):

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Fair

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

 

Value

 

Outstanding at Dec. 31, 2019

 

 

42

 

 

$1.89

 

 

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

164

 

 

 

4.34

 

 

 

4.0

 

 

$2.26

 

 

 

 

Options Exercised

 

 

(42)

 

 

1.89

 

 

 

 

 

 

 

 

 

 

$100

 

Options Forfeited

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at Jun. 30, 2020

 

 

164

 

 

$4.34

 

 

 

3.6

 

 

 

 

 

 

$41*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at Jun. 30, 2020

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

_________________

*The aggregate intrinsic values in the table above are based on the Company’s stock price of $4.59, which is the closing price of the Company’s stock on the last day of business for the period ended June 30, 2020.

  

Total Remaining Unamortized Compensation for Stock Options

 

As of June 30, 2020, there was approximately $8.4 million of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options.That cost is expected to be recognized over a weighted average period of 2 years.

  

Share-Based Compensation

 

Share-based compensation expenses were as follows: 

 

 

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

Share-based compensation expense

 

 

 

 

 

 

 

 

 

 

  Cost of sales

 

$42

 

 

$34

 

 

$75

 

 

$60

 

  Sales and marketing

 

 

242

 

 

 

144

 

 

 

474

 

 

 

263

 

  Research and development

 

 

134

 

 

 

127

 

 

 

272

 

 

 

250

 

  General and administrative

 

 

1,293

 

 

 

1,454

 

 

 

2,763

 

 

 

3,215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total

 

$1,711

 

 

$1,759

 

 

$3,584

 

 

$3,788

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segments
6 Months Ended
Jun. 30, 2020
Business Segments  
11. Business Segments

Note 11. Business Segments

 

The Company has the following three reportable segments for the three- and six-month periods ended June 30, 2020:

 

 

·

Consumer products segment: provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers as well as to distributors.

 

 

 

 

·

Ingredients segment: develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

 

 

 

 

·

Analytical reference standards and services segment: includes supply of phytochemical reference standards and other research and development services.

  

The “Corporate and other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination. The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.  

 

Three months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$11,720

 

 

$2,850

 

 

$717

 

 

$-

 

 

$15,287

 

Cost of sales

 

 

4,339

 

 

 

1,135

 

 

 

725

 

 

 

-

 

 

 

6,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

7,381

 

 

 

1,715

 

 

 

(8)

 

 

-

 

 

 

9,088

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,743

 

 

 

76

 

 

 

140

 

 

 

-

 

 

 

4,959

 

Research and development

 

 

805

 

 

 

137

 

 

 

-

 

 

 

-

 

 

 

942

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6,874

 

 

 

6,874

 

Operating expenses

 

 

5,548

 

 

 

213

 

 

 

140

 

 

 

6,874

 

 

 

12,775

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$1,833

 

 

$1,502

 

 

$(148)

 

$(6,874)

 

$(3,687)

  

Three months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$8,744

 

 

$1,387

 

 

$970

 

 

$-

 

 

$11,101

 

Cost of sales

 

 

3,519

 

 

 

641

 

 

 

687

 

 

 

-

 

 

 

4,847

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

5,225

 

 

 

746

 

 

 

283

 

 

 

-

 

 

 

6,254

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,072

 

 

 

79

 

 

 

157

 

 

 

-

 

 

 

4,308

 

Research and development

 

 

875

 

 

 

194

 

 

 

-

 

 

 

-

 

 

 

1,069

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

7,932

 

 

 

7,932

 

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

125

 

 

 

125

 

Operating expenses

 

 

4,947

 

 

 

273

 

 

 

157

 

 

 

8,057

 

 

 

13,434

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$278

 

 

$473

 

 

$126

 

 

$(8,057)

 

$(7,180)

Six months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$22,864

 

 

$5,325

 

 

$1,443

 

 

$-

 

 

$29,632

 

Cost of sales

 

 

8,641

 

 

 

2,191

 

 

 

1,401

 

 

 

-

 

 

 

12,233

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

14,223

 

 

 

3,134

 

 

 

42

 

 

 

-

 

 

 

17,399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

9,152

 

 

 

(8)

 

 

262

 

 

 

-

 

 

 

9,406

 

Research and development

 

 

1,587

 

 

 

274

 

 

 

-

 

 

 

-

 

 

 

1,861

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

15,709

 

 

 

15,709

 

Operating expenses

 

 

10,739

 

 

 

266

 

 

 

262

 

 

 

15,709

 

 

 

26,976

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$3,484

 

 

$2,868

 

 

$(220)

 

$(15,709)

 

$(9,577)

  

Six months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$16,198

 

 

$2,881

 

 

$2,070

 

 

$-

 

 

$21,149

 

Cost of sales

 

 

6,590

 

 

 

1,454

 

 

 

1,550

 

 

 

-

 

 

 

9,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

9,608

 

 

 

1,427

 

 

 

520

 

 

 

-

 

 

 

11,555

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

7,989

 

 

 

191

 

 

 

302

 

 

 

-

 

 

 

8,482

 

Research and development

 

 

1,844

 

 

 

393

 

 

 

-

 

 

 

-

 

 

 

2,237

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

16,263

 

 

 

16,263

 

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

125

 

 

 

125

 

Operating expenses

 

 

9,833

 

 

 

584

 

 

 

302

 

 

 

16,388

 

 

 

27,107

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$(225)

 

$843

 

 

$218

 

 

$(16,388)

 

$(15,552)

 

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

At June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$14,392

 

 

$2,280

 

 

$950

 

 

$24,370

 

 

$41,992

 

  

 

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

At December 31, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$12,137

 

 

$2,135

 

 

$918

 

 

$25,057

 

 

$40,247

 

 

Disaggregation of Revenue

 

We disaggregate our revenue from contracts with customers by type of goods or services for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. See details in the tables below.

 

Three Months Ended June 30, 2020
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$11,720

 

 

$-

 

 

$-

 

 

$11,720

 

NIAGEN® Ingredient

 

 

-

 

 

 

1,995

 

 

 

-

 

 

 

1,995

 

Subtotal NIAGEN Related

 

$11,720

 

 

$1,995

 

 

$-

 

 

$13,715

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

855

 

 

 

-

 

 

 

855

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

686

 

 

 

686

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

31

 

 

 

31

 

Subtotal Other Goods and Services

 

$-

 

 

$855

 

 

$717

 

 

$1,572

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$11,720

 

 

$2,850

 

 

$717

 

 

$15,287

 

Three Months Ended June 30, 2019
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN , Consumer Product

 

$8,744

 

 

$-

 

 

$-

 

 

$8,744

 

NIAGEN Ingredient

 

 

-

 

 

 

1,080

 

 

 

-

 

 

 

1,080

 

Subtotal NIAGEN Related

 

$8,744

 

 

$1,080

 

 

$-

 

 

$9,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

307

 

 

 

-

 

 

 

307

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

717

 

 

 

717

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

253

 

 

 

253

 

Subtotal Other Goods and Services

 

$-

 

 

$307

 

 

$970

 

 

$1,277

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$8,744

 

 

$1,387

 

 

$970

 

 

$11,101

 

 

Six Months Ended June 30, 2020
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$22,864

 

 

$-

 

 

$-

 

 

$22,864

 

NIAGEN® Ingredient

 

 

-

 

 

 

3,956

 

 

 

-

 

 

 

3,956

 

Subtotal NIAGEN Related

 

$22,864

 

 

$3,956

 

 

$-

 

 

$26,820

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

1,369

 

 

 

-

 

 

 

1,369

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

1,359

 

 

 

1,359

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

84

 

 

 

84

 

Subtotal Other Goods and Services

 

$-

 

 

$1,369

 

 

$1,443

 

 

$2,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$22,864

 

 

$5,325

 

 

$1,443

 

 

$29,632

 

 

Six Months Ended June 30, 2019
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$16,198

 

 

$-

 

 

$-

 

 

$16,198

 

NIAGEN® Ingredient

 

 

-

 

 

 

2,190

 

 

 

-

 

 

 

2,190

 

Subtotal NIAGEN Related

 

$16,198

 

 

$2,190

 

 

$-

 

 

$18,388

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

691

 

 

 

-

 

 

 

691

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

1,547

 

 

 

1,547

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

523

 

 

 

523

 

Subtotal Other Goods and Services

 

$-

 

 

$691

 

 

$2,070

 

 

$2,761

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$16,198

 

 

$2,881

 

 

$2,070

 

 

$21,149

 

  

Disclosure of Major Customers

 

Major customers who accounted for more than 10% of the Company’s total sales were as follows:

 

 

 

Three months ended

 

 

Six months ended

 

Major Customers

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Horizon Ventures - Related Party

 

 

10.2%

 

*

 

 

*

 

 

*

 

A.S. Watson Group - Related Party

 

*

 

 

 

17.2%

 

 

10.6%

 

 

15.1%

 

Major accounts which had more than 10% of the Company’s total trade receivables were as follows:

  

 

 

Percentage of the Company's Total Trade Receivables

 

Major Accounts

 

At June 30, 2020

 

 

At December 31, 2019

 

 

 

 

 

 

 

 

A.S. Watson Group - Related Party (1)

 

 

26.7%

 

 

39.0%

Dr. Loges

 

 

15.4%

 

*

 

Thorne Research

 

 

12.1%

 

*

 

Life Extension

 

 

10.1%

 

 

27.4%

Amazon Marketplaces

 

*

 

 

 

10.3%

_____________________

 

 

 

 

 

 

 

 

* Represents less than 10%.

 

 

 

 

 

 

 

 

(1) Includes approximately $0.1 million trade receivables from Horizon Ventures.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2020
Commitments and Contingencies  
12. Commitments and Contingencies

Note 12. Commitments and Contingencies

  

Inventory Purchase Obligations

 

In the second quarter of 2020, the Company entered into an amended manufacturing and supply agreement whereby the Company is obligated to purchase approximately $17.4 million of total inventory through June 30, 2021.The Company’s remaining purchase obligations as of June 30, 2020 were as follows:

 

Six Months Ending December 31, 2020

 

$7.3

 

 

Million

Six Months Ending June 30, 2021

 

$4.3

 

 

Million

Total

 

$11.6

 

 

Million

  

Legal proceedings - Elysium Health, LLC

 

(A) California Action

 

On December 29, 2016, ChromaDex, Inc. filed a complaint in the United States District Court for the Central District of California, naming Elysium Health, Inc. (together with Elysium Health, LLC, “Elysium”) as defendant (the “Complaint”). On January 25, 2017, Elysium filed an answer and counterclaims in response to the Complaint (together with the Complaint, the “California Action”). Over the course of the California Action, the parties have each filed amended pleadings several times and have each engaged in several rounds of motions to dismiss and one round of motion for judgment on the pleadings with respect to various claims. Most recently, on November 27, 2018, ChromaDex, Inc. filed a fifth amended complaint that added an individual, Mark Morris, as a defendant. Elysium and Morris (“the Defendants”) moved to dismiss on December 21, 2018. The court denied Defendants’ motion on February 4, 2019. Defendants filed their answer to ChromaDex, Inc.'s fifth amended complaint on February 19, 2019. ChromaDex, Inc. filed an answer to Elysium’s restated counterclaims on March 5, 2019. Discovery closed on August 9, 2019.

On August 16, 2019, the parties filed motions for partial summary judgment as to certain claims and counterclaims. The parties filed opposition briefs on August 28, 2019, and reply briefs on September 4, 2019. On October 9, 2019, among other things, the court vacated the previously scheduled trial date, ordered supplemental briefing with respect to certain issues related to summary judgment. Elysium filed its opening supplemental brief on October 30, 2019, ChromaDex filed its opening supplemental brief on November 18, 2019, and Elysium filed a reply brief on November 27, 2019, and the court heard argument on January 13, 2020. On January 16, 2020, the court granted both parties’ motions for summary judgment in part and denied both in part. On ChromaDex’s motion, the court granted summary judgment in favor of ChromaDex on Elysium’s counterclaims for (i) breach of contract related to manufacturing NIAGEN® according to the defined standard, selling NIAGEN and ingredients that are substantially similar to pterostilbene to other customers, distributing the NIAGEN® product specifications, and failing to provide information concerning the quality and identity of NIAGEN®, and (ii) breach of the implied covenant of good faith and fair dealing. The court denied summary judgment on Elysium’s counterclaims for (i) fraudulent inducement of the Trademark License and Royalty Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium (the “License Agreement”), (ii) patent misuse, and (iii) unjust enrichment. On Elysium’s motion, the court granted summary judgment in favor of Elysium on ChromaDex’s claim for damages related to $110,000in avoided costs arising from documents that Elysium used in violation of the Supply Agreement, dated February 3, 2014, by and between ChromaDex, Inc. and Elysium, as amended (the “NIAGEN® Supply Agreement”). The court denied summary judgment on Elysium’s counterclaim for breach of contract related to certain refunds or credits to Elysium. The court also denied summary judgment on ChromaDex’s breach of contract claim against Morris and claims for disgorgement of $8.3 million in Elysium’s resale profits, $600,000 for a price discount received by Elysium, and $684,781 in Morris’s compensation.

Following the court’s January 16, 2020 order, the claims that ChromaDex, Inc. presently asserts in the California Action, among other allegations, are that (i) Elysium breached the Supply Agreement, dated June 26, 2014, by and between ChromaDex, Inc. and Elysium (the “pTeroPure® Supply Agreement”), by failing to make payments to ChromaDex, Inc. for purchases of pTeroPure® and by improper disclosure of confidential ChromaDex, Inc. information pursuant to the pTeroPure® Supply Agreement, (ii) Elysium breached the NIAGEN® Supply Agreement, by failing to make payments to ChromaDex, Inc. for purchases of NIAGEN®, (iii) Defendants willfully and maliciously misappropriated ChromaDex, Inc. trade secrets concerning its ingredient sales business under both the California Uniform Trade Secrets Act and the Federal Defend Trade Secrets Act, (iv) Morris breached two confidentiality agreements he signed by improperly stealing confidential ChromaDex, Inc. documents and information, (v) Morris breached his fiduciary duty to ChromaDex, Inc. by lying to and competing with ChromaDex, Inc. while still employed there, and (vi) Elysium aided and abetted Morris’s breach of fiduciary duty. ChromaDex, Inc. is seeking damages and interest for Elysium’s alleged breaches of the NIAGEN® Supply Agreement and pTeroPure® Supply Agreement and Morris’s alleged breaches of his confidentiality agreements, compensatory damages and interest, punitive damages, injunctive relief, and attorney’s fees for Defendants’ alleged willful and malicious misappropriation of ChromaDex, Inc.’s trade secrets, and compensatory damages and interest, disgorgement of all benefits received, and punitive damages for Morris’s alleged breach of his fiduciary duty and Elysium’s aiding and abetting of that alleged breach.

 

The claims that Elysium presently alleges in the California Action are that (i) ChromaDex, Inc. breached the NIAGEN® Supply Agreement by not issuing certain refunds or credits to Elysium, (ii) ChromaDex, Inc. fraudulently induced Elysium into entering into the License Agreement, (iv) ChromaDex, Inc.’s conduct constitutes misuse of its patent rights, and (v) ChromaDex, Inc. was unjustly enriched by the royalties Elysium paid pursuant to the License Agreement. Elysium is seeking damages for ChromaDex, Inc.’s alleged breaches of the NIAGEN® Supply Agreement, and compensatory damages, punitive damages, and/or rescission of the License Agreement and restitution of any royalty payments conveyed by Elysium pursuant to the License Agreement, and a declaratory judgment that ChromaDex, Inc. has engaged in patent misuse.

 

On January 17, 2020, Elysium moved to substitute its counsel. The same day, the court ordered hearing on that motion for January 21, 2020, and granted Elysium’s motion at the hearing. On January 23, 2020, the court issued a scheduling order that, among other things, set trial on the remaining claims to begin on May 12, 2020. On March 19, 2020, in light of the global COVID-19 pandemic and ongoing private mediation efforts, the parties jointly stipulated to adjourn the trial date. The Court vacated the trial date on March 20, 2020. The Court held a telephonic status conference on June 9, 2020, during which the Court indicated that it will reschedule the jury trial as soon as conditions permit.

 

(B) Patent Office Proceedings

 

On July 17, 2017, Elysium filed petitions with the U.S. Patent and Trademark Office for inter partes review of U.S. Patents 8,197,807 (the “’807 Patent”) and 8,383,086 (the “’086 Patent”), patents to which ChromaDex, Inc. is the exclusive licensee. The Patent Trial and Appeal Board (“PTAB”) denied institution of the inter partes review for the ’807 Patent on January 18, 2018. On January 29, 2018, the PTAB granted institution of the inter partes review as to claims 1 and 3-5 and denied institution as to claim 2 of the ’086 Patent. Based upon a recent U.S. Supreme Court decision, and solely on a procedural basis, the PTAB was required to include claim 2 in the trial of the inter partes review. The matter was heard on October 2, 2018. The PTAB issued its written decision on January 16, 2019, upholding claim 2 of the ’086 Patent which relates to the use of isolated NR in a pharmaceutical composition as valid. Elysium is now prevented from raising invalidity arguments against the ’086 Patent in the ongoing patent litigation in Delaware that it brought or could have brought before the PTAB in its inter partes review. Elysium appealed the PTAB’s decision with respect to claim 2 on March 6, 2019. A cross-appeal with respect to claims 1 and 3–5 was filed on March 20, 2019. Elysium filed its opening brief on June 17, 2019. Dartmouth moved to voluntarily dismiss its cross-appeal on August 14, 2019. The motion was granted on August 18, 2019. Dartmouth’s response brief was filed on August 28, 2019. Elysium’s reply brief was filed on October 9, 2019. Oral argument on Elysium’s appeal was heard on March 5, 2020. On March 6, 2020, the United States Court of Appeals for the Federal Circuit affirmed the PTAB’s decision, rejecting Elysium's attempt to invalidate claim 2 of the '086 patent.

 

(C) Southern District of New York Action

On September 27, 2017, Elysium Health Inc. ("Elysium Health") filed a complaint in the United States District Court for the Southern District of New York, against ChromaDex, Inc. (the “Elysium SDNY Complaint”). Elysium Health alleges in the Elysium SDNY Complaint that ChromaDex, Inc. made false and misleading statements in a citizen petition to the Food and Drug Administration it filed on or about August 18, 2017. Among other allegations, Elysium Health avers that the citizen petition made Elysium Health’s product appear dangerous, while casting ChromaDex, Inc.’s own product as safe. The Elysium SDNY Complaint asserts four claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. § 1125(a); (ii) trade libel; (iii) deceptive business practices under New York General Business Law § 349; and (iv) tortious interference with prospective economic relations. ChromaDex, Inc. denies the claims in the Elysium SDNY Complaint and intends to defend against them vigorously. On October 26, 2017, ChromaDex, Inc. moved to dismiss the Elysium SDNY Complaint on the grounds that, inter alia, its statements in the citizen petition are immune from liability under the Noerr-Pennington Doctrine, the litigation privilege, and New York’s Anti-SLAPP statute, and that the Elysium SDNY Complaint failed to state a claim. Elysium Health opposed the motion on November 2, 2017. ChromaDex, Inc. filed its reply on November 9, 2017.

On October 26, 2017, ChromaDex, Inc. filed a complaint in the United States District Court for the Southern District of New York against Elysium Health (the “ChromaDex SDNY Complaint”). ChromaDex, Inc. alleges that Elysium Health made material false and misleading statements to consumers in the promotion, marketing, and sale of its health supplement product, Basis, and asserts five claims for relief: (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); (iii) deceptive practices under New York General Business Law § 349; (iv) deceptive practices under New York General Business Law § 350; and (v) tortious interference with prospective economic advantage. On November 16, 2017, Elysium Health moved to dismiss for failure to state a claim. ChromaDex, Inc. opposed the motion on November 30, 2017 and Elysium Health filed a reply on December 7, 2017.

 

On November 3, 2017, the Court consolidated the Elysium SDNY Complaint and the ChromaDex SDNY Complaint actions under the caption In re Elysium Health-ChromaDex Litigation, 17-cv-7394, and stayed discovery in the consolidated action pending a Court-ordered mediation. The mediation was unsuccessful. On September 27, 2018, the Court issued a combined ruling on both parties’ motions to dismiss. For ChromaDex’s motion to dismiss, the Court converted the part of the motion on the issue of whether the citizen petition is immune under the Noerr-Pennington Doctrine into a motion for summary judgment, and requested supplemental evidence from both parties, which were submitted on October 29, 2018. The Court otherwise denied the motion to dismiss. On January 3, 2019, the Court granted ChromaDex, Inc.’s motion for summary judgment under the Noerr-Pennington Doctrine and dismissed all claims in the Elysium SDNY Complaint. Elysium moved for reconsideration on January 17, 2019. The Court denied Elysium’s motion for reconsideration on February 6, 2019, and issued an amended final order granting ChromaDex, Inc.’s motion for summary judgment on February 7, 2019.

 

The Court granted in part and denied in part Elysium’s motion to dismiss, sustaining three grounds for ChromaDex’s Lanham Act claims while dismissing two others, sustaining the claim under New York General Business Law § 349, and dismissing the claims under New York General Business Law § 350 and for tortious interference. Elysium filed an answer and counterclaims on October 10, 2018, alleging claims for (i) false advertising under the Lanham Act, 15 U.S.C. §1125(a); (ii) unfair competition under 15 U.S.C. § 1125(a); and (iii) deceptive practices under New York General Business Law § 349. ChromaDex answered Elysium’s counterclaims on November 2, 2018.

 

ChromaDex, Inc. filed an amended complaint on March 27, 2019, adding new claims against Elysium Health for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On April 10, 2019, Elysium Health answered the amended complaint and filed amended counterclaims, also adding new claims against ChromaDex, Inc. for false advertising and unfair competition under the Lanham Act, 15 U.S.C. § 1125(a). On July 1, 2019, Elysium Health filed further amended counterclaims, adding new claims under the Copyright Act §§ 106 & 501. On February 9, 2020, ChromaDex, Inc. filed a motion for leave to amend its complaint to add additional claims against Elysium Health for false advertising and unfair competition. On February 10, 2020, Elysium Health filed a motion for leave to amend its counterclaims to identify allegedly false and misleading statements in ChromaDex’s advertising. Those motions were both granted after respective stipulations. On March 12, 2020, Elysium Health answered the second amended complaint. On March 13, 2020, ChromaDex, Inc. filed an answer and objection to Elysium Health’s third amended counterclaims.

 

The Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to the legal proceedings discussed herein. As of June 30, 2020, ChromaDex, Inc. did not accrue a potential loss for the California Action or the Elysium SDNY Complaint because ChromaDex, Inc. believes that the allegations are without merit and thus it is not probable that a liability has been incurred.

 

(D) Delaware – Patent Infringement Action

On September 17, 2018, ChromaDex, Inc. and Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. The complaint alleges that Elysium’s BASIS® dietary supplement violates U.S. Patents 8,197,807 (the “’807 Patent”) and 8,383,086 (the “’086 Patent”) that comprise compositions containing isolated nicotinamide riboside held by Dartmouth and licensed exclusively to ChromaDex, Inc. On October 23, 2018, Elysium filed an answer to the complaint. The answer asserts various affirmative defenses and denies that Plaintiffs are entitled to any relief.

On November 7, 2018, Elysium filed a motion to stay the patent infringement proceedings pending resolution of (1) the inter partes review of the ’807 Patent and the ’086 Patent before the Patent Trial and Appeal Board (“PTAB”) and (2) the outcome of the litigation in the California Action. ChromaDex, Inc. filed an opposition brief on November 21, 2018 detailing the issues with Elysium’s motion to stay. In particular, ChromaDex, Inc. argued that given claim 2 of the ’086 Patent was only included in the PTAB’s inter partes review for procedural reasons the PTAB was unlikely to invalidate claim 2 and therefore litigation in Delaware would continue regardless. In addition, ChromaDex, Inc. argued that the litigation in the California Action is unlikely to have a significant effect on the ongoing patent litigation. After the PTAB released its written decision upholding claim 2 of the ’086 Patent, proving right ChromaDex, Inc.’s prediction, ChromaDex, Inc. informed the Delaware court of the PTAB’s decision on January 17, 2019. On June 19, 2019, the Delaware court granted in part and denied in part Elysium’s motion, ordering that the case was stayed pending the resolution of Elysium’s patent misuse counterclaim in the California Action.

 

On November 1, 2019, ChromaDex, Inc. filed a motion to lift the stay due to changed circumstances in the California Action, among other reasons. Briefing on the motion was completed on November 22, 2019. On January 6, 2020, the Delaware court issued an oral order instructing the parties to submit a joint status report after the January 13, 2020 motions hearing in the California Action. The joint status report was submitted on January 30, 2020. On February 4, 2020, the Delaware court issued an order granting ChromaDex, Inc.’s motion to lift the stay and setting a scheduling conference for March 10, 2020. On March 19, 2020, the Delaware court entered a scheduling order, which, among other things, set the claim-construction hearing for December 17, 2020 and trial for the week of September 27, 2021. On April 17, 2020, ChromaDex, Inc. served infringement contentions. On April 24, 2020, ChromaDex, Inc. moved for leave to amend the complaint to add Healthspan Research, LLC as a plaintiff. On May 5, 2020, Elysium filed its opposition to ChromaDex, Inc.’s motion for leave to amend and moved to dismiss ChromaDex, Inc. for alleged lack of standing. ChromaDex, Inc. filed its opposition to Elysium’s motion to dismiss and reply in support of its motion to amend on May 19, 2020. Elysium filed its reply in support of its motion to dismiss on May 26, 2020. Elysium filed a Second Amended Answer on July 10, 2020. On July 22, 2020 the parties filed a Joint Claim Construction Chart and respective motions for claim construction. The parties’ Joint Claim Construction Brief is due on November 5, 2020. The Court will hold a Markman hearing on claim-construction issues on December 17, 2020.

 

From time to time we are involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.

 

Contingencies

In September 2019, the Company received a letter from a licensor stating that the Company owed the licensor $1.6 million plus interest of sublicense fees as a result of the Company entering into the supply agreement with a customer. After reviewing the relevant facts and circumstances, the Company believes that the Company does not owe any sublicense fees to the licensor and has corresponded with the licensor to resolve the matter. The Company does not believe that the ultimate resolution of this matter will be material to the Company’s results of operations, financial condition or cash flows.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events
6 Months Ended
Jun. 30, 2020
Subsequent Events  
13. Subsequent events Note 13. Subsequent Event

 

Subsequent to the period ended June 30, 2020, the Company entered into a lease amendment to lease additional space located in Longmont, Colorado. The lease amendment also extends the expiration of the lease period from February 2024 to December 2025. Pursuant to the lease amendment, the Company will make additional total lease payments of approximately $1.1 million during the term of the lease.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2020
Significant Accounting Policies  
Basis of presentation

Basis of presentation:The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on December 31.

Recent accounting standards

Recent accounting standards: In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the expected credit losses estimate will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit loss impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company can elect to defer compliance effective for fiscal years beginning after December 15, 2022. We are currently evaluating the impact of our pending adoption of ASU 2016-13 on our consolidated financial statements.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share Applicable to Common Stockholders (Tables)
6 Months Ended
Jun. 30, 2020
Earnings Per Share Applicable to Common Stockholders  
Schedule of loss per share amounts applicable to common stockholders

The following table sets forth the computations of earnings per share amounts applicable to common stockholders for the three and the six months ended June 30, 2020 and June 30, 2019:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands, except per share data)

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(3,711)

 

$(7,755)

 

$(9,613)

 

$(16,092)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per common share

 

$(0.06)

 

$(0.14)

 

$(0.16)

 

$(0.29)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted weighted average common shares outstanding (1):

 

 

60,906

 

 

 

55,539

 

 

 

60,344

 

 

 

55,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potentially dilutive securities (2):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Stock options

 

 

11,457

 

 

 

10,174

 

 

 

11,457

 

 

 

10,174

 

  Warrants

 

 

-

 

 

 

140

 

 

 

-

 

 

 

140

 

  Convertible notes

 

 

-

 

 

 

2,192

 

 

 

-

 

 

 

2,192

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2020
Related Party Transactions  
Schedule of net amount of assets and liabilities acquired

 

Net sales
Three months ended
Jun. 30, 2020

Net sales
Three months ended
Jun. 30, 2019

Net sales
Six months ended
Jun. 30, 2020

Net sales
Six months ended
Jun. 30, 2019

Trade receivable at
Jun. 30, 2020

Trade receivable at
Dec. 31, 2019

A.S. Watson Group

$1.3 million

$1.9 million

$3.1 million

$3.2 million

$1.0 million

$0.8 million

Horizon Ventures(1)

$1.6 million

-

$1.6 million

-

$0.1million

-

Total

$2.9 million

$1.9 million

$4.7 million

$3.2 million

$1.1 million

$0.8 million

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Tables)
6 Months Ended
Jun. 30, 2020
Inventories  
Schedule of inventories

(In thousands)

 

Jun. 30, 2020

 

 

Dec. 31, 2019

 

Consumer Products - Finished Goods

 

$

7,994

 

 

 

4,877

 

Consumer Products - Work in Process

 

 

2,996

 

 

 

4,659

 

Bulk ingredients

 

 

684

 

 

$

1,364

 

Reference standards

 

 

664

 

 

 

635

 

 

 

$

12,338

 

 

$

11,535

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Tables)
6 Months Ended
Jun. 30, 2020
Leases  
Schedule of operating leases expenses

 

 

For the Three Months Ended Jun. 30, 2020

 

 

For the Three Months Ended Jun. 30, 2019

 

 

For the Six Months Ended Jun. 30, 2020

 

 

For the Six Months Ended Jun. 30, 2019

 

(In thousands)

 

 

 

 

Operating leases

 

 

 

 

 

 

 

 

 

 

 

 

   Operating lease expense

 

$120

 

 

$180

 

 

$240

 

 

$360

 

   Variable lease expense

 

 

65

 

 

 

66

 

 

 

134

 

 

 

121

 

Operating lease expense

 

 

185

 

 

 

246

 

 

 

374

 

 

 

481

 

Short-term lease rent expense

 

 

64

 

 

 

1

 

 

 

127

 

 

 

3

 

Total expense

 

$249

 

 

$247

 

 

$501

 

 

$484

 

Schedule of operating lease additional lease information

 

Weighted-average remaining lease term (years) – operating leases

 

1.6

 

Weighted-average discount rate – operating leases

 

 

8.0%
Schedule of minimum future lease payments under operating leases

 

 

 

 

Six months ending December 31, 2020

 

$347

 

Year Ending December 31, 2021

 

 

614

 

Year Ending December 31, 2022

 

 

138

 

Year Ending December 31, 2023

 

 

143

 

Year Ending December 31, 2024

 

 

25

 

Total

 

 

1,267

 

Less present value discount

 

 

113

 

Operating lease liabilities

 

 

1,154

 

Long-term obligations under operating leases

 

$522

 

Schedule of finance lease expenses

 

 

At Jun. 30, 2020

 

Weighted-average remaining lease term (years) finance leases

 

 

1.1

 

Weighted-average discount rate finance leases

 

 

7.9%
Schedule of finance lease additional lease information

(In thousands)

 

 

 

Six Months Ending December 31, 2020

 

$115

 

Year Ending December 31, 2021

 

 

32

 

Year Ending December 31, 2022

 

 

21

 

Total

 

 

168

 

Less present value discount

 

 

7

 

Finance lease liabilities

 

 

161

 

Less current portion

 

 

134

 

Long-term obligations under finance leases

 

$27

 

Schedule of minimum future lease payments under finance leases

 

 

For the Three Months Ended Jun. 30, 2020

 

 

For the Three Months Ended Jun. 30, 2019

 

 

For the Six Months Ended Jun. 30, 2020

 

 

For the Six Months Ended Jun. 30, 2019

 

(In thousands)

 

 

 

 

 

 

 

 

Finance leases

 

 

 

 

 

 

 

 

 

 

 

 

   Amortization of equipment assets

 

$29

 

 

$15

 

 

$57

 

 

$37

 

   Interest on lease liabilities

 

 

3

 

 

 

10

 

 

 

9

 

 

 

17

 

Total expenses

 

$32

 

 

$25

 

 

$66

 

 

$54

 

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation (Tables)
6 Months Ended
Jun. 30, 2020
ShareBased Compensation  
Schedule of weighted average assumptions of stock options granted

Six months Ended June 30, 2020

 

 

Expected term

 

6 years

 

Expected volatility

 

 

66%

Risk-free rate

 

 

1%

Expected dividends

 

 

0%
Schedule of stock option activity

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Fair

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

 

Value

 

Outstanding at Dec. 31, 2019

 

 

9,509

 

 

$3.86

 

 

 

6.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

2,133

 

 

 

3.62

 

 

 

10.0

 

 

$2.13

 

 

 

 

Options Exercised

 

 

(592)

 

 

3.77

 

 

 

 

 

 

 

 

 

 

$719

 

Options Expired

 

 

(239)

 

 

4.70

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Forfeited

 

 

(518)

 

 

3.44

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at Jun. 30, 2020

 

 

10,293

 

 

$3.82

 

 

 

7.1

 

 

 

 

 

 

$9,322*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at Jun. 30, 2020

 

 

6,126

 

 

$3.76

 

 

 

5.7

 

 

 

 

 

 

$6,252*

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Fair

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term (Years)

 

 

Value

 

 

Value

 

Outstanding at Dec. 31, 2019

 

 

42

 

 

$1.89

 

 

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

164

 

 

 

4.34

 

 

 

4.0

 

 

$2.26

 

 

 

 

Options Exercised

 

 

(42)

 

 

1.89

 

 

 

 

 

 

 

 

 

 

$100

 

Options Forfeited

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at Jun. 30, 2020

 

 

164

 

 

$4.34

 

 

 

3.6

 

 

 

 

 

 

$41*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at Jun. 30, 2020

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

Schedule of share-based compensation

 

 

Three months ending

 

 

Six months ending

 

(In thousands)

 

June 30, 2020

 

 

June 30, 2019

 

 

June 30, 2020

 

 

June 30, 2019

 

Share-based compensation expense

 

 

 

 

 

 

 

 

 

 

  Cost of sales

 

$42

 

 

$34

 

 

$75

 

 

$60

 

  Sales and marketing

 

 

242

 

 

 

144

 

 

 

474

 

 

 

263

 

  Research and development

 

 

134

 

 

 

127

 

 

 

272

 

 

 

250

 

  General and administrative

 

 

1,293

 

 

 

1,454

 

 

 

2,763

 

 

 

3,215

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Total

 

$1,711

 

 

$1,759

 

 

$3,584

 

 

$3,788

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segments (Tables)
6 Months Ended
Jun. 30, 2020
Business Segments  
Schedule of business segmentation

Three months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$11,720

 

 

$2,850

 

 

$717

 

 

$-

 

 

$15,287

 

Cost of sales

 

 

4,339

 

 

 

1,135

 

 

 

725

 

 

 

-

 

 

 

6,199

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

7,381

 

 

 

1,715

 

 

 

(8)

 

 

-

 

 

 

9,088

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,743

 

 

 

76

 

 

 

140

 

 

 

-

 

 

 

4,959

 

Research and development

 

 

805

 

 

 

137

 

 

 

-

 

 

 

-

 

 

 

942

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6,874

 

 

 

6,874

 

Operating expenses

 

 

5,548

 

 

 

213

 

 

 

140

 

 

 

6,874

 

 

 

12,775

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$1,833

 

 

$1,502

 

 

$(148)

 

$(6,874)

 

$(3,687)

  

Three months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$8,744

 

 

$1,387

 

 

$970

 

 

$-

 

 

$11,101

 

Cost of sales

 

 

3,519

 

 

 

641

 

 

 

687

 

 

 

-

 

 

 

4,847

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

5,225

 

 

 

746

 

 

 

283

 

 

 

-

 

 

 

6,254

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

4,072

 

 

 

79

 

 

 

157

 

 

 

-

 

 

 

4,308

 

Research and development

 

 

875

 

 

 

194

 

 

 

-

 

 

 

-

 

 

 

1,069

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

7,932

 

 

 

7,932

 

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

125

 

 

 

125

 

Operating expenses

 

 

4,947

 

 

 

273

 

 

 

157

 

 

 

8,057

 

 

 

13,434

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$278

 

 

$473

 

 

$126

 

 

$(8,057)

 

$(7,180)

Six months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$22,864

 

 

$5,325

 

 

$1,443

 

 

$-

 

 

$29,632

 

Cost of sales

 

 

8,641

 

 

 

2,191

 

 

 

1,401

 

 

 

-

 

 

 

12,233

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

14,223

 

 

 

3,134

 

 

 

42

 

 

 

-

 

 

 

17,399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

9,152

 

 

 

(8)

 

 

262

 

 

 

-

 

 

 

9,406

 

Research and development

 

 

1,587

 

 

 

274

 

 

 

-

 

 

 

-

 

 

 

1,861

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

15,709

 

 

 

15,709

 

Operating expenses

 

 

10,739

 

 

 

266

 

 

 

262

 

 

 

15,709

 

 

 

26,976

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$3,484

 

 

$2,868

 

 

$(220)

 

$(15,709)

 

$(9,577)

  

Six months ended

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

June 30, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$16,198

 

 

$2,881

 

 

$2,070

 

 

$-

 

 

$21,149

 

Cost of sales

 

 

6,590

 

 

 

1,454

 

 

 

1,550

 

 

 

-

 

 

 

9,594

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

9,608

 

 

 

1,427

 

 

 

520

 

 

 

-

 

 

 

11,555

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

7,989

 

 

 

191

 

 

 

302

 

 

 

-

 

 

 

8,482

 

Research and development

 

 

1,844

 

 

 

393

 

 

 

-

 

 

 

-

 

 

 

2,237

 

General and administrative

 

 

-

 

 

 

-

 

 

 

-

 

 

 

16,263

 

 

 

16,263

 

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

125

 

 

 

125

 

Operating expenses

 

 

9,833

 

 

 

584

 

 

 

302

 

 

 

16,388

 

 

 

27,107

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$(225)

 

$843

 

 

$218

 

 

$(16,388)

 

$(15,552)

 

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

At June 30, 2020

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$14,392

 

 

$2,280

 

 

$950

 

 

$24,370

 

 

$41,992

 

  

 

 

Consumer

 

 

 

 

 

Analytical Reference

 

 

 

 

 

 

 

At December 31, 2019

 

Products

 

 

Ingredients

 

 

Standards and

 

 

Corporate

 

 

 

 

(In thousands)

 

segment

 

 

segment

 

 

Services segment

 

 

and other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

$12,137

 

 

$2,135

 

 

$918

 

 

$25,057

 

 

$40,247

 

Schedule of disaggregation of revenue

Three Months Ended June 30, 2020
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$11,720

 

 

$-

 

 

$-

 

 

$11,720

 

NIAGEN® Ingredient

 

 

-

 

 

 

1,995

 

 

 

-

 

 

 

1,995

 

Subtotal NIAGEN Related

 

$11,720

 

 

$1,995

 

 

$-

 

 

$13,715

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

855

 

 

 

-

 

 

 

855

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

686

 

 

 

686

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

31

 

 

 

31

 

Subtotal Other Goods and Services

 

$-

 

 

$855

 

 

$717

 

 

$1,572

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$11,720

 

 

$2,850

 

 

$717

 

 

$15,287

 

Three Months Ended June 30, 2019
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN , Consumer Product

 

$8,744

 

 

$-

 

 

$-

 

 

$8,744

 

NIAGEN Ingredient

 

 

-

 

 

 

1,080

 

 

 

-

 

 

 

1,080

 

Subtotal NIAGEN Related

 

$8,744

 

 

$1,080

 

 

$-

 

 

$9,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

307

 

 

 

-

 

 

 

307

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

717

 

 

 

717

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

253

 

 

 

253

 

Subtotal Other Goods and Services

 

$-

 

 

$307

 

 

$970

 

 

$1,277

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$8,744

 

 

$1,387

 

 

$970

 

 

$11,101

 

 

Six Months Ended June 30, 2020
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$22,864

 

 

$-

 

 

$-

 

 

$22,864

 

NIAGEN® Ingredient

 

 

-

 

 

 

3,956

 

 

 

-

 

 

 

3,956

 

Subtotal NIAGEN Related

 

$22,864

 

 

$3,956

 

 

$-

 

 

$26,820

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

1,369

 

 

 

-

 

 

 

1,369

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

1,359

 

 

 

1,359

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

84

 

 

 

84

 

Subtotal Other Goods and Services

 

$-

 

 

$1,369

 

 

$1,443

 

 

$2,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$22,864

 

 

$5,325

 

 

$1,443

 

 

$29,632

 

Six Months Ended June 30, 2019
(In thousands)

 

Consumer
Products
Segment

 

 

Ingredients
Segment

 

 

Analytical Reference Standards
and Services
Segment

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TRU NIAGEN®, Consumer Product

 

$16,198

 

 

$-

 

 

$-

 

 

$16,198

 

NIAGEN® Ingredient

 

 

-

 

 

 

2,190

 

 

 

-

 

 

 

2,190

 

Subtotal NIAGEN Related

 

$16,198

 

 

$2,190

 

 

$-

 

 

$18,388

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Ingredients

 

 

-

 

 

 

691

 

 

 

-

 

 

 

691

 

Reference Standards

 

 

-

 

 

 

-

 

 

 

1,547

 

 

 

1,547

 

Consulting and Other

 

 

-

 

 

 

-

 

 

 

523

 

 

 

523

 

Subtotal Other Goods and Services

 

$-

 

 

$691

 

 

$2,070

 

 

$2,761

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales

 

$16,198

 

 

$2,881

 

 

$2,070

 

 

$21,149

 

Schedule of disclosure of major customers

 

 

Three months ended

 

 

Six months ended

 

Major Customers

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

Jun. 30, 2020

 

 

Jun. 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Horizon Ventures - Related Party

 

 

10.2%

 

*

 

 

*

 

 

*

 

A.S. Watson Group - Related Party

 

*

 

 

 

17.2%

 

 

10.6%

 

 

15.1%

 

Major accounts which had more than 10% of the Company’s total trade receivables were as follows:

  

 

 

Percentage of the Company's Total Trade Receivables

 

Major Accounts

 

At June 30, 2020

 

 

At December 31, 2019

 

 

 

 

 

 

 

 

A.S. Watson Group - Related Party (1)

 

 

26.7%

 

 

39.0%

Dr. Loges

 

 

15.4%

 

*

 

Thorne Research

 

 

12.1%

 

*

 

Life Extension

 

 

10.1%

 

 

27.4%

Amazon Marketplaces

 

*

 

 

 

10.3%

_____________________

 

 

 

 

 

 

 

 

* Represents less than 10%.

 

 

 

 

 

 

 

 

(1) Includes approximately $0.1 million trade receivables from Horizon Ventures.

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2020
Commitments and Contingencies  
Schedule of inventory purchase obligations

Six Months Ending December 31, 2020

 

$7.3

 

 

Million

Six Months Ending June 30, 2021

 

$4.3

 

 

Million

Total

 

$11.6

 

 

Million

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Liquidity (Details Narrative) - USD ($)
$ in Millions
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Cash and cash equivalents $ 18.9    
Restricted cash 0.2 $ 0.2 $ 0.2
Western Alliance Bank [Member]      
Line of credit, maximum borrowing capacity $ 7.0    
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share Applicable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Net loss $ (3,711) $ (7,755) $ (9,613) $ (16,092)
Basic and diluted loss per common share $ (0.06) $ (0.14) $ (0.16) $ (0.29)
Basic and diluted weighted average common shares outstanding 60,906 55,539 60,344 55,433
Stock Option [Member]        
Potentially dilutive securities (in thousands) 11,457,000 10,174,000 11,457,000 10,174,000
Warrant [Member]        
Potentially dilutive securities (in thousands) 0 140,000 0 140,000
Convertible notes [Member]        
Potentially dilutive securities (in thousands) 0 2,192,000 0 2,192,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Net sales $ 2,900,000 $ 1,900,000 $ 4,700,000 $ 3,200,000  
Trade receivable 1,100,000   1,100,000   $ 800,000
A.S. Watson Group [Member]          
Net sales 1,300,000 1,900,000 3,100,000 3,200,000  
Trade receivable 1,000,000.0   1,000,000.0   800,000
Horizon Ventures [Member]          
Net sales 1,600,000 $ 0 1,600,000 $ 0  
Trade receivable $ 100,000   $ 100,000   $ 0
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Inventories    
Consumer products - finished goods $ 7,994 $ 4,877
Consumer Products - work in process 2,996 4,659
Bulk ingredients 684 1,364
Reference standards 664 635
Inventories $ 12,338 $ 11,535
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Stock Issuance (Details Narrative) - USD ($)
$ / shares in Units, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended
May 07, 2020
Apr. 27, 2020
Jun. 30, 2020
Jun. 30, 2020
Jun. 30, 2019
Shares issued to related parties, amount     $ 4,856,000 $ 4,856,000  
Proceeds from issuance of stock       $ 4,856,000 $ 0
Securities Purchase Agreement [Member]          
Shares issued to related parties, shares   1.2      
Shares issued to related parties, amount   $ 5,000,000.0      
Shares issued price per share   $ 4.08      
Proceeds from issuance of stock $ 4,900,000        
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating leases        
Operating lease expense $ 120 $ 180 $ 240 $ 360
Variable lease expense 65 66 134 121
Operating lease expense 185 246 374 481
Short-term lease rent expense 64 1 127 3
Total expense $ 249 $ 247 $ 501 $ 484
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details 1)
Jun. 30, 2020
Leases  
Weighted-average remaining lease term (years) - operating leases 1 year 7 months 6 days
Weighted-average discount rate - operating leases 80.00%
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details 2) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Leases    
Six months ending December 31, 2020 $ 347  
Year ending December 31, 2021 614  
Year ending December 31, 2022 138  
Year ending December 31, 2023 143  
Year ending December 31, 2024 25  
Total 1,267  
Less present value discount 113  
Operating lease liabilities 1,154  
Long-term obligations under operating leases $ 522 $ 848
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details 3) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Finance leases        
Amotization of equipment assets $ 29 $ 15 $ 57 $ 37
Interest on lease liabilities 3 10 9 17
Total expenses $ 32 $ 25 $ 66 $ 54
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details 4)
Jun. 30, 2020
Leases  
Weighted-average remaining lease term (years) - finance leases 1 year 1 month 6 days
Weighted-average discount rate - finance leases 79.00%
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details 5) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Leases    
Six months ending December 31, 2020 $ 115  
Year ending December 31, 2021 32  
Year ending December 31, 2022 21  
Total 168  
Less present value discount 7  
Finance lease liabilities 161  
Less current portion 134 $ 258
Long-term obligations under finance leases $ 27 $ 18
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Details Narrative)
$ in Millions
Jun. 30, 2020
USD ($)
Leases  
Operating lease - right of use assets $ 0.7
Operating lease liability 1.2
Finance lease - right of use assets 0.4
Finance lease liability $ 0.2
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation (Details)
6 Months Ended
Jun. 30, 2020
ShareBased Compensation  
Expected term 6 years
Expected volatility 6600.00%
Risk-free rate 100.00%
Expected dividends 0.00%
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation (Details 1) - Service Period Based Stock Options [Member]
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2020
USD ($)
$ / shares
shares
Number of shares, Outstanding, Beginning | shares 9,509
Number of shares, Options Granted | shares 2,133
Number of shares, Options Exercised | shares (592)
Number of shares, Options Expired | shares (239)
Number of shares, Outstanding, Ending | shares (518)
Number of shares, Options Forfeited | shares 10,293
Number of shares, Exercisable | shares 6,126
Weighted Average Exercise price  
Exercise price, Outstanding, Beginning $ 3.86
Exercise price, Options Granted 3.62
Exercise price, Options Exercised 3.77
Exercise price, Options Expired 4.70
Exercise price, Options Forfeited 3.44
Exercise price, Outstanding, Ending 3.82
Exercise price, Exercisable $ 3.76
Weighted Average Remaining Contatual Term (Years)  
Weighted Average Remaining Contatual Term, Outstanding, Beginning 6 years 10 months 24 days
Weighted Average Remaining Contatual Term, Options Granted 10 years
Weighted Average Remaining Contatual Term, Outstanding, Ending 7 years 1 month 6 days
Weighted Average Remaining Contatual Term, Exercisable 5 years 8 months 12 days
Fair Value  
Fair Value, Options Granted $ 2.13
Aggregate Intrinsic Value  
Aggregate Intrinsic Value, Options Exercised | $ $ 719
Aggregate Intrinsic Value, Outstanding | $ 9,322
Aggregate Intrinsic Value, , Exercisable | $ $ 6,252
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation (Details 2) - Performance Based Stock Options [Member]
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2020
USD ($)
$ / shares
shares
Number of shares, Outstanding, Beginning | shares 42,000
Number of shares, Options Granted | shares 164,000
Number of shares, Options Exercised | shares (42,000)
Number of shares, Exercisable | shares 164
Weighted Average Exercise price  
Exercise price, Outstanding, Beginning $ 1.89
Exercise price, Options Granted 4.34
Exercise price, Options Exercised 1.89
Exercise price, Outstanding, Ending 4.34
Exercise price, Exercisable, Ending $ 0
Weighted Average Remaining Contatual Term (Years)  
Weighted Average Remaining Contatual Term, Outstanding, Beginning 3 years 1 month 6 days
Weighted Average Remaining Contatual Term, Options Granted 4 years
Weighted Average Remaining Contatual Term, Outstanding, Ending 3 years 7 months 6 days
Fair Value  
Fair Value, Options Granted $ 2.26
Aggregate Intrinsic Value  
Aggregate Intrinsic Value, , Exercisable | $ $ 100
Aggregate Intrinsic Value, Outstanding | $ $ 41
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation (Details 3) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Share-based compensation $ 1,711 $ 1,759 $ 3,584 $ 3,788
Cost of Sales [Member]        
Share-based compensation 42 34 75 60
Sales and Marketing [Member]        
Share-based compensation 242 144 474 263
Research and Development [Member]        
Share-based compensation 134 127 272 250
General and Administrative [Member]        
Share-based compensation $ 1,293 $ 1,454 $ 2,763 $ 3,215
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.20.2
ShareBased Compensation (Details Narrative) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 6 Months Ended
Jun. 20, 2017
Jun. 30, 2020
Share price   $ 4.59
Unrecognized compensation expense   $ 8.4
Unrecognized compensation expense recognition period   2 years
2017 Equity Incentive Plan [Member]    
Equity incentive plan, description under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the 2007 Plan, (iii) any returning shares from the 2007 Plan or the 2017 Plan, such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 6.9 million shares at June 30, 2020.  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segments (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Net sales $ 15,287,000 $ 11,101,000 $ 29,632,000 $ 21,149,000  
Cost of sales 6,199,000 4,847,000 12,233,000 9,594,000  
Gross profit 9,088,000 6,254,000 17,399,000 11,555,000  
Operating expenses:          
Sales and marketing 4,959,000 4,308,000 9,406,000 8,482,000  
Research and development 942,000 1,069,000 1,861,000 2,237,000  
General and administrative 6,874,000 7,932,000 15,709,000 16,263,000  
Other 0 125,000 0 125,000  
Operating expenses 12,775,000 13,434,000 26,976,000 27,107,000  
Operating income (loss) (3,687,000) (7,180,000) (9,577,000) (15,552,000)  
Total assets 41,992,000   41,992,000   $ 40,247,000
Consumer Products Segment [Member]          
Net sales 11,720,000 8,744,000 22,864,000 16,198,000  
Cost of sales 4,339,000 3,519,000 8,641,000 6,590,000  
Gross profit 7,381,000 5,225,000 14,223,000 9,608,000  
Operating expenses:          
Sales and marketing 4,743,000 4,072,000 9,152,000 7,989,000  
Research and development 805,000 875,000 1,587,000 1,844,000  
General and administrative 0 0 0 0  
Other       0  
Operating expenses 5,548,000 4,947,000 10,739,000 9,833,000  
Operating income (loss) 1,833,000 278,000 3,484,000 (225,000)  
Total assets 14,392,000   14,392,000   12,137,000
Ingredients Segment [Member]          
Net sales 2,850,000 1,387,000 5,325,000 2,881,000  
Cost of sales 1,135,000 641,000 2,191,000 1,454,000  
Gross profit 1,715,000 746,000 3,134,000 1,427,000  
Operating expenses:          
Sales and marketing 76,000 79,000 8,000 191,000  
Research and development 137,000 194,000 274,000 393,000  
General and administrative 0   0 0  
Other   0   0  
Operating expenses 213,000 273,000 266,000 584,000  
Operating income (loss) 1,502,000 473,000 2,868,000 843,000  
Total assets 2,280,000   2,280,000   2,135,000
Analytical Reference Standards and Services Segment [Member]          
Net sales 717,000 970,000 1,443,000 2,070,000  
Cost of sales 725,000 687,000 1,401,000 1,550,000  
Gross profit (8,000) 283,000 42,000 520,000  
Operating expenses:          
Sales and marketing 140,000 157,000 262,000 302,000  
Research and development 0 0 0 0  
General and administrative 0 0 0 0  
Other       0  
Operating expenses 140,000 157,000 262,000 302,000  
Operating income (loss) (148,000) 126,000 (220,000) 218,000  
Total assets 950,000   950,000   918,000
Corporate and Other Segment [Member]          
Net sales 0 0 0 0  
Cost of sales 0   0 0  
Gross profit 0 0 0 0  
Operating expenses:          
Sales and marketing 0 0 0 0  
Research and development 0 0 0 0  
General and administrative 6,874,000 7,932,000 15,709,000 16,263,000  
Other   125,000   125,000  
Operating expenses 6,874,000 8,057,000 15,709,000 16,388,000  
Operating income (loss) (6,874,000) $ (8,057,000) (15,709,000) $ (16,388,000)  
Total assets $ 24,370,000   $ 24,370,000   $ 25,057,000
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segments (Details 1) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Net sales $ 15,287,000 $ 11,101,000 $ 29,632,000 $ 21,149,000
TRU NIAGEN Consumer Product        
Net sales 11,720,000 8,744,000 22,864,000 16,198,000
NIAGEN Ingredient        
Net sales 1,995,000 1,080,000 3,956,000 2,190,000
NIAGEN Related        
Net sales 13,715,000 9,824,000 26,820,000 18,388,000
Other Ingredients        
Net sales 855,000 307,000 1,369,000 691,000
Reference Standards        
Net sales 686,000 717,000 1,359,000 1,547,000
Consulting and Other        
Net sales 31,000 253,000 84,000 523,000
Other Goods and Services        
Net sales 1,572,000 1,277,000 2,812,000 2,761,000
Consumer Products Segment [Member]        
Net sales 11,720,000 8,744,000 22,864,000 16,198,000
Consumer Products Segment [Member] | TRU NIAGEN Consumer Product        
Net sales 11,720,000 8,744,000 22,864,000 16,198,000
Consumer Products Segment [Member] | NIAGEN Ingredient        
Net sales 0 0 0 0
Consumer Products Segment [Member] | NIAGEN Related        
Net sales 11,720,000 8,744,000 22,864,000 16,198,000
Consumer Products Segment [Member] | Other Ingredients        
Net sales 0 0 0 0
Consumer Products Segment [Member] | Reference Standards        
Net sales 0 0 0 0
Consumer Products Segment [Member] | Consulting and Other        
Net sales 0 0 0 0
Consumer Products Segment [Member] | Other Goods and Services        
Net sales 0 0 0 0
Ingredients Segment [Member]        
Net sales 2,850,000 1,387,000 5,325,000 2,881,000
Ingredients Segment [Member] | TRU NIAGEN Consumer Product        
Net sales 0 0 0  
Ingredients Segment [Member] | NIAGEN Ingredient        
Net sales 1,995,000 1,080,000 3,956,000 2,190,000
Ingredients Segment [Member] | NIAGEN Related        
Net sales 1,995,000 1,080,000 3,956,000 2,190,000
Ingredients Segment [Member] | Other Ingredients        
Net sales 855,000 307,000 1,369,000 691,000
Ingredients Segment [Member] | Reference Standards        
Net sales 0 0 0 0
Ingredients Segment [Member] | Consulting and Other        
Net sales 0 0 0 0
Ingredients Segment [Member] | Other Goods and Services        
Net sales 855,000 307,000 1,369,000 691,000
Analytical Reference Standards and Services Segment [Member]        
Net sales 717,000 970,000 1,443,000 2,070,000
Analytical Reference Standards and Services Segment [Member] | TRU NIAGEN Consumer Product        
Net sales 0 0 0  
Analytical Reference Standards and Services Segment [Member] | NIAGEN Ingredient        
Net sales 0 0 0  
Analytical Reference Standards and Services Segment [Member] | NIAGEN Related        
Net sales 0 0 0  
Analytical Reference Standards and Services Segment [Member] | Other Ingredients        
Net sales 0 0   0
Analytical Reference Standards and Services Segment [Member] | Reference Standards        
Net sales 686,000 717,000 1,359,000 1,547,000
Analytical Reference Standards and Services Segment [Member] | Consulting and Other        
Net sales 31,000 253,000 84,000 523,000
Analytical Reference Standards and Services Segment [Member] | Other Goods and Services        
Net sales $ 717,000 $ 970,000 $ 1,443,000 $ 2,070,000
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Business Segments (Details 2)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Sales Revenue, Net | A.S. Watson Group          
Customer concentration risk   172.00% 106.00% 151.00%  
Sales Revenue, Net | Horizon ventures          
Customer concentration risk 102.00%        
Trade Receivables | A.S. Watson Group          
Customer concentration risk     267.00%   390.00%
Trade Receivables | Horizon ventures          
Customer concentration risk     101.00%   274.00%
Trade Receivables | Dr. Loges          
Customer concentration risk     154.00%    
Trade Receivables | Thorne Research          
Customer concentration risk     121.00%    
Trade Receivables | Amazon Marketplaces          
Customer concentration risk         103.00%
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Details)
$ in Millions
Jun. 30, 2020
USD ($)
Business Segments  
Six Months Ending December 31, 2020 $ 7.3
Six Months Ending June 30, 2021 4.3
Remaining purchase obligation $ 11.6
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended
Dec. 29, 2016
Jun. 30, 2020
Invetory purchase obligation   $ 11,600,000
Elysium Health, Inc.    
Breach of contract, damages sought $ 110,000  
Court judgement, description The court also denied summary judgment on ChromaDex’s breach of contract claim against Morris and claims for disgorgement of $8.3 million in Elysium’s resale profits, $600,000 for a price discount received by Elysium, and $684,781 in Morris’s compensation.  
Manufacturing And Supply Agreement    
Invetory purchase obligation   $ 17,400,000
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events (Details Narrative) - Subsequent Event [Member] - Leasing amendment agreement [Member]
$ in Millions
6 Months Ended
Jun. 30, 2020
USD ($)
Description for the amendment to expiration dates from February 2024 to December 2025
Amount of additional lease payable during lease term $ 1.1
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 248 291 1 false 39 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://chromadex.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 7 false false R8.htm 0000008 - Disclosure - Interim Financial Statements Sheet http://chromadex.com/role/InterimFinancialStatements Interim Financial Statements Notes 8 false false R9.htm 0000009 - Disclosure - Nature of Business Sheet http://chromadex.com/role/NatureOfBusiness Nature of Business Notes 9 false false R10.htm 000010 - Disclosure - Liquidity Sheet http://chromadex.com/role/Liquidity Liquidity Notes 10 false false R11.htm 000011 - Disclosure - Significant Accounting Policies Sheet http://chromadex.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 11 false false R12.htm 000012 - Disclosure - Earnings Per Share Applicable to Common Stockholders Sheet http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholders Earnings Per Share Applicable to Common Stockholders Notes 12 false false R13.htm 000013 - Disclosure - Related Party Transactions Sheet http://chromadex.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 000014 - Disclosure - Inventories Sheet http://chromadex.com/role/Inventories Inventories Notes 14 false false R15.htm 000015 - Disclosure - Stock Issuance Sheet http://chromadex.com/role/StockIssuance Stock Issuance Notes 15 false false R16.htm 000016 - Disclosure - Leases Sheet http://chromadex.com/role/Leases Leases Notes 16 false false R17.htm 000017 - Disclosure - ShareBased Compensation Sheet http://chromadex.com/role/SharebasedCompensation ShareBased Compensation Notes 17 false false R18.htm 000018 - Disclosure - Business Segments Sheet http://chromadex.com/role/BusinessSegments Business Segments Notes 18 false false R19.htm 000019 - Disclosure - Commitments and Contingencies Sheet http://chromadex.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 000020 - Disclosure - Subsequent Events Sheet http://chromadex.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 000021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://chromadex.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://chromadex.com/role/SignificantAccountingPolicies 21 false false R22.htm 000022 - Disclosure - Earnings Per Share Applicable to Common Stockholders (Tables) Sheet http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersTables Earnings Per Share Applicable to Common Stockholders (Tables) Tables http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholders 22 false false R23.htm 000023 - Disclosure - Related Party Transactions (Tables) Sheet http://chromadex.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://chromadex.com/role/RelatedPartyTransactions 23 false false R24.htm 000024 - Disclosure - Inventories (Tables) Sheet http://chromadex.com/role/InventoriesTables Inventories (Tables) Tables http://chromadex.com/role/Inventories 24 false false R25.htm 000025 - Disclosure - Leases (Tables) Sheet http://chromadex.com/role/LeasesTables Leases (Tables) Tables http://chromadex.com/role/Leases 25 false false R26.htm 000026 - Disclosure - ShareBased Compensation (Tables) Sheet http://chromadex.com/role/SharebasedCompensationTables ShareBased Compensation (Tables) Tables http://chromadex.com/role/SharebasedCompensation 26 false false R27.htm 000027 - Disclosure - Business Segments (Tables) Sheet http://chromadex.com/role/BusinessSegmentsTables Business Segments (Tables) Tables http://chromadex.com/role/BusinessSegments 27 false false R28.htm 000028 - Disclosure - Commitments and Contingencies (Tables) Sheet http://chromadex.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://chromadex.com/role/CommitmentsAndContingencies 28 false false R29.htm 000029 - Disclosure - Liquidity (Details Narrative) Sheet http://chromadex.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://chromadex.com/role/Liquidity 29 false false R30.htm 000030 - Disclosure - Earnings Per Share Applicable to Common Stockholders (Details) Sheet http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails Earnings Per Share Applicable to Common Stockholders (Details) Details http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersTables 30 false false R31.htm 000031 - Disclosure - Related Party Transactions (Details) Sheet http://chromadex.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://chromadex.com/role/RelatedPartyTransactionsTables 31 false false R32.htm 000032 - Disclosure - Inventories (Details) Sheet http://chromadex.com/role/InventoriesDetails Inventories (Details) Details http://chromadex.com/role/InventoriesTables 32 false false R33.htm 000033 - Disclosure - Stock Issuance (Details Narrative) Sheet http://chromadex.com/role/StockIssuanceDetailsNarrative Stock Issuance (Details Narrative) Details http://chromadex.com/role/StockIssuance 33 false false R34.htm 000034 - Disclosure - Leases (Details) Sheet http://chromadex.com/role/LeasesDetails Leases (Details) Details http://chromadex.com/role/LeasesTables 34 false false R35.htm 000035 - Disclosure - Leases (Details 1) Sheet http://chromadex.com/role/LeasesDetails1 Leases (Details 1) Details http://chromadex.com/role/LeasesTables 35 false false R36.htm 000036 - Disclosure - Leases (Details 2) Sheet http://chromadex.com/role/LeasesDetails2 Leases (Details 2) Details http://chromadex.com/role/LeasesTables 36 false false R37.htm 000037 - Disclosure - Leases (Details 3) Sheet http://chromadex.com/role/LeasesDetails3 Leases (Details 3) Details http://chromadex.com/role/LeasesTables 37 false false R38.htm 000038 - Disclosure - Leases (Details 4) Sheet http://chromadex.com/role/LeasesDetails4 Leases (Details 4) Details http://chromadex.com/role/LeasesTables 38 false false R39.htm 000039 - Disclosure - Leases (Details 5) Sheet http://chromadex.com/role/LeasesDetails5 Leases (Details 5) Details http://chromadex.com/role/LeasesTables 39 false false R40.htm 000040 - Disclosure - Leases (Details Narrative) Sheet http://chromadex.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://chromadex.com/role/LeasesTables 40 false false R41.htm 000041 - Disclosure - ShareBased Compensation (Details) Sheet http://chromadex.com/role/SharebasedCompensationDetails ShareBased Compensation (Details) Details http://chromadex.com/role/SharebasedCompensationTables 41 false false R42.htm 000042 - Disclosure - ShareBased Compensation (Details 1) Sheet http://chromadex.com/role/SharebasedCompensationDetails1 ShareBased Compensation (Details 1) Details http://chromadex.com/role/SharebasedCompensationTables 42 false false R43.htm 000043 - Disclosure - ShareBased Compensation (Details 2) Sheet http://chromadex.com/role/SharebasedCompensationDetails2 ShareBased Compensation (Details 2) Details http://chromadex.com/role/SharebasedCompensationTables 43 false false R44.htm 000044 - Disclosure - ShareBased Compensation (Details 3) Sheet http://chromadex.com/role/SharebasedCompensationDetails3 ShareBased Compensation (Details 3) Details http://chromadex.com/role/SharebasedCompensationTables 44 false false R45.htm 000045 - Disclosure - ShareBased Compensation (Details Narrative) Sheet http://chromadex.com/role/SharebasedCompensationDetailsNarrative ShareBased Compensation (Details Narrative) Details http://chromadex.com/role/SharebasedCompensationTables 45 false false R46.htm 000046 - Disclosure - Business Segments (Details) Sheet http://chromadex.com/role/BusinessSegmentsDetails Business Segments (Details) Details http://chromadex.com/role/BusinessSegmentsTables 46 false false R47.htm 000047 - Disclosure - Business Segments (Details 1) Sheet http://chromadex.com/role/BusinessSegmentsDetails1 Business Segments (Details 1) Details http://chromadex.com/role/BusinessSegmentsTables 47 false false R48.htm 000048 - Disclosure - Business Segments (Details 2) Sheet http://chromadex.com/role/BusinessSegmentsDetails2 Business Segments (Details 2) Details http://chromadex.com/role/BusinessSegmentsTables 48 false false R49.htm 000049 - Disclosure - Commitments and Contingencies (Details) Sheet http://chromadex.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://chromadex.com/role/CommitmentsAndContingenciesTables 49 false false R50.htm 000050 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://chromadex.com/role/CommitmentsAndContingenciesTables 50 false false R51.htm 000051 - Disclosure - Subsequent Events (Details Narrative) Sheet http://chromadex.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://chromadex.com/role/SubsequentEvents 51 false false All Reports Book All Reports cdxc_10q.htm cdxc-20200630.xsd cdxc-20200630_cal.xml cdxc-20200630_def.xml cdxc-20200630_lab.xml cdxc-20200630_pre.xml cdxc_ex311.htm cdxc_ex312.htm cdxc_ex321.htm http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cdxc_10q.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 248, "dts": { "calculationLink": { "local": [ "cdxc-20200630_cal.xml" ] }, "definitionLink": { "local": [ "cdxc-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "cdxc_10q.htm" ] }, "labelLink": { "local": [ "cdxc-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cdxc-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cdxc-20200630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 332, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 4, "http://xbrl.sec.gov/dei/2019-01-31": 7, "total": 11 }, "keyCustom": 28, "keyStandard": 263, "memberCustom": 28, "memberStandard": 11, "nsprefix": "cdxc", "nsuri": "http://chromadex.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "strong", "p", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://chromadex.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "strong", "p", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Liquidity", "role": "http://chromadex.com/role/Liquidity", "shortName": "Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Significant Accounting Policies", "role": "http://chromadex.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Earnings Per Share Applicable to Common Stockholders", "role": "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholders", "shortName": "Earnings Per Share Applicable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Related Party Transactions", "role": "http://chromadex.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Inventories", "role": "http://chromadex.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "cdxc:StockIssuanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Stock Issuance", "role": "http://chromadex.com/role/StockIssuance", "shortName": "Stock Issuance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "cdxc:StockIssuanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Leases", "role": "http://chromadex.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - ShareBased Compensation", "role": "http://chromadex.com/role/SharebasedCompensation", "shortName": "ShareBased Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Business Segments", "role": "http://chromadex.com/role/BusinessSegments", "shortName": "Business Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Commitments and Contingencies", "role": "http://chromadex.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Subsequent Events", "role": "http://chromadex.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://chromadex.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Earnings Per Share Applicable to Common Stockholders (Tables)", "role": "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersTables", "shortName": "Earnings Per Share Applicable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Related Party Transactions (Tables)", "role": "http://chromadex.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Inventories (Tables)", "role": "http://chromadex.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Leases (Tables)", "role": "http://chromadex.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - ShareBased Compensation (Tables)", "role": "http://chromadex.com/role/SharebasedCompensationTables", "shortName": "ShareBased Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Business Segments (Tables)", "role": "http://chromadex.com/role/BusinessSegmentsTables", "shortName": "Business Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "cdxc:ScheduleOfInventoryPurchaseObligations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://chromadex.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "cdxc:ScheduleOfInventoryPurchaseObligations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Liquidity (Details Narrative)", "role": "http://chromadex.com/role/LiquidityDetailsNarrative", "shortName": "Liquidity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "lang": null, "name": "us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Earnings Per Share Applicable to Common Stockholders (Details)", "role": "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails", "shortName": "Earnings Per Share Applicable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30_us-gaap_StockOptionMember", "decimals": "-3", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Related Party Transactions (Details)", "role": "http://chromadex.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "strong", "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Inventories (Details)", "role": "http://chromadex.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "strong", "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Stock Issuance (Details Narrative)", "role": "http://chromadex.com/role/StockIssuanceDetailsNarrative", "shortName": "Stock Issuance (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "cdxc:StockIssuanceTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-04-27_cdxc_SecuritiesPurchaseAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Leases (Details)", "role": "http://chromadex.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfOperaingLeaseAdditionalLeaseInformationTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Leases (Details 1)", "role": "http://chromadex.com/role/LeasesDetails1", "shortName": "Leases (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfOperaingLeaseAdditionalLeaseInformationTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Leases (Details 2)", "role": "http://chromadex.com/role/LeasesDetails2", "shortName": "Leases (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfLeasedAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Leases (Details 3)", "role": "http://chromadex.com/role/LeasesDetails3", "shortName": "Leases (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfLeasedAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfFinanceLeaseExpensesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Leases (Details 4)", "role": "http://chromadex.com/role/LeasesDetails4", "shortName": "Leases (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfFinanceLeaseExpensesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfFinanceLeaseAdditionalLeaseInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Leases (Details 5)", "role": "http://chromadex.com/role/LeasesDetails5", "shortName": "Leases (Details 5)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfFinanceLeaseAdditionalLeaseInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "cdxc:OperatingLeaseRightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - Leases (Details Narrative)", "role": "http://chromadex.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "cdxc:OperatingLeaseRightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - ShareBased Compensation (Details)", "role": "http://chromadex.com/role/SharebasedCompensationDetails", "shortName": "ShareBased Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2019-12-31_cdxc_ServicePeriodBasedStockOptionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - ShareBased Compensation (Details 1)", "role": "http://chromadex.com/role/SharebasedCompensationDetails1", "shortName": "ShareBased Compensation (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2019-12-31_cdxc_ServicePeriodBasedStockOptionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2019-12-31_cdxc_PerformanceBasedStockOptionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - ShareBased Compensation (Details 2)", "role": "http://chromadex.com/role/SharebasedCompensationDetails2", "shortName": "ShareBased Compensation (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2019-12-31_cdxc_PerformanceBasedStockOptionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - ShareBased Compensation (Details 3)", "role": "http://chromadex.com/role/SharebasedCompensationDetails3", "shortName": "ShareBased Compensation (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - ShareBased Compensation (Details Narrative)", "role": "http://chromadex.com/role/SharebasedCompensationDetailsNarrative", "shortName": "ShareBased Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - Business Segments (Details)", "role": "http://chromadex.com/role/BusinessSegmentsDetails", "shortName": "Business Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30_cdxc_ConsumerProductsSegmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - Business Segments (Details 1)", "role": "http://chromadex.com/role/BusinessSegmentsDetails1", "shortName": "Business Segments (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-04-01to2020-06-30_cdxc_TruniagenConsumerProductMember", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2019-04-01to2019-06-30_us-gaap_SalesRevenueNetMember_cdxc_ASWatsonGroupMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - Business Segments (Details 2)", "role": "http://chromadex.com/role/BusinessSegmentsDetails2", "shortName": "Business Segments (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2019-04-01to2019-06-30_us-gaap_SalesRevenueNetMember_cdxc_ASWatsonGroupMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfInventoryPurchaseObligations", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - Commitments and Contingencies (Details)", "role": "http://chromadex.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cdxc:ScheduleOfInventoryPurchaseObligations", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "role": "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "cdxc:ScheduleOfInventoryPurchaseObligations", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2016-12-01to2016-12-29_cdxc_ElysiumHealthIncMember", "decimals": "0", "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_cdxc_LeaseAmendmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://chromadex.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_cdxc_LeaseAmendmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "AsOf2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "cdxc:InterimFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Interim Financial Statements", "role": "http://chromadex.com/role/InterimFinancialStatements", "shortName": "Interim Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "cdxc:InterimFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Nature of Business", "role": "http://chromadex.com/role/NatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdxc_10q.htm", "contextRef": "From2020-01-01to2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 39, "tag": { "cdxc_ASWatsonGroupMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "A.S. Watson Group [Member]", "verboseLabel": "A.S. Watson Group" } } }, "localname": "ASWatsonGroupMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2", "http://chromadex.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cdxc_AggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Aggregate Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValueAbstract", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "cdxc_AggregateIntrinsicValueExercisable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "Aggregate Intrinsic Value, , Exercisable", "verboseLabel": "Aggregate Intrinsic Value, , Exercisable" } } }, "localname": "AggregateIntrinsicValueExercisable", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "monetaryItemType" }, "cdxc_AggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "Aggregate Intrinsic Value, Outstanding", "verboseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "AggregateIntrinsicValueOutstanding", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "monetaryItemType" }, "cdxc_AmazonMarketplacesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amazon Marketplaces" } } }, "localname": "AmazonMarketplacesMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "cdxc_AmountOfAdditionalLeasePayableDuringLeaseTerm": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "Amount of additional lease payable during lease term" } } }, "localname": "AmountOfAdditionalLeasePayableDuringLeaseTerm", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cdxc_AnalyticalReferenceStandardsAndServicesSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Analytical Reference Standards and Services Segment [Member]" } } }, "localname": "AnalyticalReferenceStandardsAndServicesSegmentMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_ConsultingAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consulting and Other" } } }, "localname": "ConsultingAndOtherMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_ConsumerProductsSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consumer Products Segment [Member]" } } }, "localname": "ConsumerProductsSegmentMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Convertible notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "cdxc_CourtJudgementDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Court judgement, description" } } }, "localname": "CourtJudgementDescription", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "cdxc_CumulativeTranslationAdjustmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cumulative Translation Adjustments" } } }, "localname": "CumulativeTranslationAdjustmentsMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "cdxc_DrLogesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dr. Loges" } } }, "localname": "DrLogesMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "cdxc_ElysiumHealthIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Elysium Health, Inc." } } }, "localname": "ElysiumHealthIncMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cdxc_ExercisePriceExercisable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Exercise price, Exercisable" } } }, "localname": "ExercisePriceExercisable", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "cdxc_ExercisePriceExercisableEnding": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Exercise price, Exercisable, Ending" } } }, "localname": "ExercisePriceExercisableEnding", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "cdxc_FairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value", "verboseLabel": "Fair Value" } } }, "localname": "FairValueAbstract", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "cdxc_FairValueOptionsGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value, Options Granted", "verboseLabel": "Fair Value, Options Granted" } } }, "localname": "FairValueOptionsGranted", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "cdxc_FinanceLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Finance lease liability" } } }, "localname": "FinanceLeaseLiabilities", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cdxc_FinanceLeasesRentExpenseNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "Total expenses" } } }, "localname": "FinanceLeasesRentExpenseNet", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "cdxc_FinancingLeaseObligationIncurredForPrepaymentOfLicensingFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Financing lease obligation incurred for prepayment of licensing fees" } } }, "localname": "FinancingLeaseObligationIncurredForPrepaymentOfLicensingFees", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cdxc_FinancingLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Financing lease obligation incurred for purchase of computer equipment and software" } } }, "localname": "FinancingLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cdxc_HorizonVenturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Horizon Ventures [Member]" } } }, "localname": "HorizonVenturesMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cdxc_IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "Principal payments on operating leases" } } }, "localname": "IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cdxc_IngredientsSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ingredients Segment [Member]" } } }, "localname": "IngredientsSegmentMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_InterimFinancialStatementsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1. Interim Financial Statements" } } }, "localname": "InterimFinancialStatementsTextBlock", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/InterimFinancialStatements" ], "xbrltype": "textBlockItemType" }, "cdxc_LeaseAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leasing amendment agreement [Member]" } } }, "localname": "LeaseAmendmentMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cdxc_LifeExtensionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Horizon ventures" } } }, "localname": "LifeExtensionMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "cdxc_ManufacturingAndSupplyAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Manufacturing And Supply Agreement" } } }, "localname": "ManufacturingAndSupplyAgreementMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cdxc_NiagenIngredientMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NIAGEN Ingredient" } } }, "localname": "NiagenIngredientMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_NiagenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NIAGEN Related" } } }, "localname": "NiagenMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_NumberOfSharesExercisable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Number of shares, Exercisable", "verboseLabel": "Number of shares, Exercisable" } } }, "localname": "NumberOfSharesExercisable", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "cdxc_OperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilities", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cdxc_OperatingLeaseObligationIncurredForTenantImprovementCreditReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "Operating lease obligation incurred for tenant improvement credit received" } } }, "localname": "OperatingLeaseObligationIncurredForTenantImprovementCreditReceived", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cdxc_OperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "Operating lease - right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAssets", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cdxc_OperatingLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "label": "Less present value discount" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "cdxc_OtherGoodsAndServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Goods and Services" } } }, "localname": "OtherGoodsAndServicesMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_OtherIngredientsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Ingredients" } } }, "localname": "OtherIngredientsMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_OtherSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Corporate and Other Segment [Member]" } } }, "localname": "OtherSegmentMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails" ], "xbrltype": "domainItemType" }, "cdxc_PerformanceBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Performance Based Stock Options [Member]" } } }, "localname": "PerformanceBasedStockOptionsMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "cdxc_ProceedsFromSaleOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "Proceeds from sale of convertible notes" } } }, "localname": "ProceedsFromSaleOfConvertibleNotes", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cdxc_ReferenceStandardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reference Standards" } } }, "localname": "ReferenceStandardsMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_SalesAndMarketingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sales and Marketing [Member]" } } }, "localname": "SalesAndMarketingMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "cdxc_ScheduleOfFinanceLeaseAdditionalLeaseInformationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Schedule of finance lease additional lease information" } } }, "localname": "ScheduleOfFinanceLeaseAdditionalLeaseInformationTextBlock", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cdxc_ScheduleOfFinanceLeaseExpensesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Schedule of finance lease expenses" } } }, "localname": "ScheduleOfFinanceLeaseExpensesTextBlock", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cdxc_ScheduleOfInventoryPurchaseObligations": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Schedule of inventory purchase obligations" } } }, "localname": "ScheduleOfInventoryPurchaseObligations", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "cdxc_ScheduleOfOperaingLeaseAdditionalLeaseInformationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Schedule of operating lease additional lease information" } } }, "localname": "ScheduleOfOperaingLeaseAdditionalLeaseInformationTextBlock", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cdxc_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "cdxc_ServicePeriodBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Service Period Based Stock Options [Member]" } } }, "localname": "ServicePeriodBasedStockOptionsMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "cdxc_StockIssuanceTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "8. Stock Issuance" } } }, "localname": "StockIssuanceTextBlock", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/StockIssuance" ], "xbrltype": "textBlockItemType" }, "cdxc_ThorneResearchMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Thorne Research" } } }, "localname": "ThorneResearchMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "cdxc_TotalOperatingLeaseExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "[Operating lease expense]", "verboseLabel": "Operating lease expense" } } }, "localname": "TotalOperatingLeaseExpense", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "cdxc_TruniagenConsumerProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TRU NIAGEN Consumer Product" } } }, "localname": "TruniagenConsumerProductMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "cdxc_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "2017 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "cdxc_WeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Exercise price", "verboseLabel": "Weighted Average Exercise price" } } }, "localname": "WeightedAverageExercisePriceAbstract", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "cdxc_WeightedAverageRemainingContatualTermOptionsGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Remaining Contatual Term, Options Granted", "verboseLabel": "Weighted Average Remaining Contatual Term, Options Granted" } } }, "localname": "WeightedAverageRemainingContatualTermOptionsGranted", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "durationItemType" }, "cdxc_WeightedAverageRemainingContatualTermOutstandingBeginning": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Remaining Contatual Term, Outstanding, Beginning", "verboseLabel": "Weighted Average Remaining Contatual Term, Outstanding, Beginning" } } }, "localname": "WeightedAverageRemainingContatualTermOutstandingBeginning", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "durationItemType" }, "cdxc_WeightedAverageRemainingContatualTermOutstandingEnding": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Remaining Contatual Term, Outstanding, Ending", "verboseLabel": "Weighted Average Remaining Contatual Term, Outstanding, Ending" } } }, "localname": "WeightedAverageRemainingContatualTermOutstandingEnding", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "durationItemType" }, "cdxc_WeightedAverageRemainingContatualTermYearsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Remaining Contatual Term (Years)", "verboseLabel": "Weighted Average Remaining Contatual Term (Years)" } } }, "localname": "WeightedAverageRemainingContatualTermYearsAbstract", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "cdxc_WesternAllianceBankMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Western Alliance Bank [Member]" } } }, "localname": "WesternAllianceBankMember", "nsuri": "http://chromadex.com/20200630", "presentation": [ "http://chromadex.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://chromadex.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r96", "r193" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://chromadex.com/role/LiquidityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://chromadex.com/role/LiquidityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r31", "r69", "r191", "r194", "r195" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Trade receivables, net of allowances of $0.0 million and $2.8 million, respectively; Receivables from Related Party: $1.1 million and $0.8 million, respectively" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r12" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r17", "r97", "r99" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Receivables from related party, Allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation allowance for receivables classified as other, due within one year or the normal operating cycle, if longer.", "label": "Trade receivables, allowances" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r47", "r64", "r168" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of convertible notes issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r64", "r114", "r116" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfLeasedAsset": { "auth_ref": [ "r64", "r173" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.", "label": "Amotization of equipment assets" } } }, "localname": "AmortizationOfLeasedAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potentially dilutive securities (in thousands)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r89", "r213", "r217" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets", "verboseLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r38" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.", "label": "Schedule of net amount of assets and liabilities acquired" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases.", "label": "[Capital Leases, Future Minimum Payments Due]", "verboseLabel": "Total" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Capital Leases, Future Minimum Payments Due, Next Twelve Months]", "verboseLabel": "Six months ending December 31, 2020" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Capital Leases, Future Minimum Payments Due in Three Years]", "verboseLabel": "Year ending December 31, 2022" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Capital Leases, Future Minimum Payments Due in Two Years]", "verboseLabel": "Year ending December 31, 2021" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.", "label": "[Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments]", "verboseLabel": "Less present value discount" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesOfLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance leases" } } }, "localname": "CapitalLeasesOfLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r22", "r227", "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r22", "r66" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash, including restricted cash of $0.2 million and $0.2 million, respectively", "periodEndLabel": "Cash Ending of Period, including restricted cash $0.2 million for both 2020 and 2019", "periodStartLabel": "Cash Beginning of Period, including restricted cash of $0.2 million for both 2020 and 2019" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "12. Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in thousands)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares, issued (in thousands)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r127" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares, outstanding (in thousands)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r11" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.001 par value; authorized 150,000 shares; issued and outstanding June 30, 2020 61,421 shares and December 31, 2019 59,562 shares" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r81", "r82", "r162", "r163", "r226" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type Axis" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r81", "r82", "r162", "r163" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Customer concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r81", "r82", "r162", "r163" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r50" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerAdvancesAndDeposits": { "auth_ref": [ "r222" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Refundable consideration, usually cash, held by the entity pending satisfactory completion of the entity's obligations or pending the closing of a contract.", "label": "Customer deposits" } } }, "localname": "CustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized." } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r129", "r130", "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r64", "r117" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation of leasehold improvements and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "10. Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stock Issuance" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r135", "r153" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Schedule of share-based compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share Applicable to Common Stockholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r73" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted loss per common share", "verboseLabel": "Basic and diluted loss per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "5. Earnings Per Share Applicable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized compensation expense recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Interim Financial Statements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r178", "r181", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r177", "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r177" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current maturities of finance lease obligations", "verboseLabel": "Less current portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r177" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Obligations, Less Current Maturities", "verboseLabel": "Long-term obligations under finance leases" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://chromadex.com/role/LeasesDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r180", "r184" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "[Finance Lease, Principal Payments]", "negatedLabel": "Principal payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance lease - right of use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r178", "r181", "r189" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of right of use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r186", "r189" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails4" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r185", "r189" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (years) - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails4" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r100", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r109" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r49" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit", "verboseLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statements of Operations (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r119" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location Axis" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerDeposits": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.", "label": "Customer deposits and other" } } }, "localname": "IncreaseDecreaseInCustomerDeposits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "verboseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Trade receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]", "verboseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r113", "r115" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r42", "r88", "r167", "r168", "r216" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r59", "r61", "r67" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash payments for interest on finance leases" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "7. Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Consumer products - finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r36", "r110" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "[Inventory, Net]", "terseLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://chromadex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Bulk ingredients" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Reference standards" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Consumer Products - work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Schedule of operating leases expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "9. Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating leases" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeaseDescription": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "Description of lessor's operating lease.", "label": "Description for the amendment to expiration dates" } } }, "localname": "LessorOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r214", "r220" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r124", "r125", "r126" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Breach of contract, damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r79", "r84" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "2. Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/NatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 30.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 29.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r62", "r65" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 28.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r40", "r41", "r44", "r65", "r76", "r215", "r223" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent accounting standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Schedule of Noncash Operating Activity" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "[Nonoperating Income (Expense)]", "totalLabel": "Nonoperating expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating expense:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Operating expenses", "verboseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating expenses:", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss", "verboseLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r177" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current maturities of operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r177" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Obligations, Less Current Maturities", "verboseLabel": "Long-term obligations under operating leases" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r176" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of Use Assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r186", "r189" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r185", "r189" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (years) - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r169", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "[Operating Leases, Future Minimum Payments Due]", "verboseLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r169", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Six months ending December 31, 2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r169", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Year ending December 31, 2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r169", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Year ending December 31, 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r169", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Year ending December 31, 2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r169", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Year ending December 31, 2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Total expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Long-term Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r159", "r160", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r52", "r224" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other", "verboseLabel": "Other" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Non-cash financing costs" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Schedule of Noncash Investing Activity" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Trade receivable" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r58" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "[Payment of Financing and Stock Issuance Costs]", "negatedLabel": "Payment of convertible notes issuance costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r57" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "[Payments of Debt Issuance Costs]", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r54" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "[Payments to Acquire Intangible Assets]", "negatedLabel": "Purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r55" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "[Payments to Acquire Investments]", "negatedLabel": "Investment in other long-term assets" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r54" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchases of leasehold improvements and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment." } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r135", "r153" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r56" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock, net", "verboseLabel": "Proceeds from issuance of stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r56", "r154" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r118", "r221" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Leasehold Improvements and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r46", "r101" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "[Accounts Receivable, Credit Loss Expense (Reversal)]", "negatedLabel": "Allowance for doubtful trade receivables" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Remaining purchase obligation", "verboseLabel": "Invetory purchase obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetails", "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Six Months Ending June 30, 2021" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the remainder of the fiscal year following the latest fiscal year ended. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Six Months Ending December 31, 2020" } } }, "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r91", "r93" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Schedule of disaggregation of revenue" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2", "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://chromadex.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r131", "r192", "r194", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2", "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://chromadex.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "6. Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r157", "r230" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r68", "r212", "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://chromadex.com/role/LiquidityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r13", "r128", "r219" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r48", "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Net sales" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r43", "r86", "r87", "r94" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Sales, net", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "auth_ref": [ "r71", "r72", "r74", "r77" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.", "label": "Schedule of loss per share amounts applicable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of minimum future lease payments under finance leases" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of minimum future lease payments under operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r19", "r20", "r21" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r85", "r89", "r90", "r92", "r112" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of business segmentation" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r137", "r143", "r146" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of weighted average assumptions of stock options granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r80", "r81", "r82", "r83", "r162", "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedule of disclosure of major customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1", "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Segments" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "11. Business Segments" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing", "verboseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r63" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://chromadex.com/role/SharebasedCompensationDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ShareBased Compensation" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r133", "r136" ], "lang": { "en-US": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Equity incentive plan, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r145" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Aggregate Intrinsic Value, Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Number of shares, Options Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of shares, Options Forfeited", "verboseLabel": "Number of shares, Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of shares, Options Granted", "verboseLabel": "Number of shares, Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r139", "r153" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of shares, Outstanding, Ending", "periodStartLabel": "Number of shares, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Exercise price, Outstanding, Ending", "periodStartLabel": "Exercise price, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercise price, Options Exercised", "verboseLabel": "Exercise price, Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Exercise price, Options Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Exercise price, Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Exercise price, Options Granted", "verboseLabel": "Exercise price, Options Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r148", "r155" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contatual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r182", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease rent expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "4. Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r89", "r112", "r120", "r121", "r122", "r225" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Statement Business Segments Axis" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1", "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r29", "r127" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1", "http://chromadex.com/role/BusinessSegmentsDetails2", "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails", "http://chromadex.com/role/LiquidityDetailsNarrative", "http://chromadex.com/role/RelatedPartyTransactionsDetails", "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2", "http://chromadex.com/role/SharebasedCompensationDetails3", "http://chromadex.com/role/SharebasedCompensationDetailsNarrative", "http://chromadex.com/role/StockIssuanceDetailsNarrative", "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Balance Sheets (Unaudited)" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statement of Stockholders' Equity (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails", "http://chromadex.com/role/BusinessSegmentsDetails1", "http://chromadex.com/role/BusinessSegmentsDetails2", "http://chromadex.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails", "http://chromadex.com/role/LiquidityDetailsNarrative", "http://chromadex.com/role/RelatedPartyTransactionsDetails", "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2", "http://chromadex.com/role/SharebasedCompensationDetails3", "http://chromadex.com/role/SharebasedCompensationDetailsNarrative", "http://chromadex.com/role/StockIssuanceDetailsNarrative", "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r10", "r11", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock, net of offering costs of $0.1 million, shares", "verboseLabel": "Shares issued to related parties, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r10", "r11", "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Share-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r10", "r11", "r127", "r128", "r140" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of stock options, shares", "terseLabel": "Number of shares, Options Exercised", "verboseLabel": "Number of shares, Options Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r10", "r11", "r127", "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock, net of offering costs of $0.1 million, amount", "verboseLabel": "Shares issued to related parties, amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited", "http://chromadex.com/role/StockIssuanceDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r10", "r11", "r128", "r134", "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Share-based compensation, amount" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r29", "r127", "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of stock options, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r11", "r14", "r15", "r98" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://chromadex.com/role/CondensedConsolidatedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments Axis" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "13. Subsequent events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "3. Liquidity" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Disclosures of Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAccountsReceivableMember": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.", "label": "Trade Receivables" } } }, "localname": "TradeAccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/BusinessSegmentsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/SharebasedCompensationDetails1", "http://chromadex.com/role/SharebasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax": { "auth_ref": [ "r39", "r165", "r166" ], "calculation": { "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative translation gain (loss), after tax, from translating foreign currency financial statements into the reporting currency.", "label": "Cumulative translation adjustments" } } }, "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r183", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "common shares outstanding", "verboseLabel": "Basic and diluted weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://chromadex.com/role/EarningsPerShareApplicableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Basic and diluted weighted average" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://chromadex.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45031-112735" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r231": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r232": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r233": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r234": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r235": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r236": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(1),(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" } }, "version": "2.1" } ZIP 69 0001654954-20-008596-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-20-008596-xbrl.zip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�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end